PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 24949660-12 2014 In summary, VDR is expressed in skeletal muscle, and vitamin D regulates gene expression and modulates ligand-dependent uptake of 25-hydroxyvitamin D3 in primary myofibers. Calcifediol 130-150 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 12-15 24535953-1 2014 The potency of 25-hydroxyvitamin D3 (25(OH)D3) is increased by several fold through its metabolism into 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) by cytochrome P450 27B1 (CYP27B1). Calcifediol 15-35 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 156-176 24535953-1 2014 The potency of 25-hydroxyvitamin D3 (25(OH)D3) is increased by several fold through its metabolism into 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) by cytochrome P450 27B1 (CYP27B1). Calcifediol 15-35 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 178-185 23831447-0 2014 Epidemiologic study of the C-3 epimer of 25-hydroxyvitamin D(3) in a population-based sample. Calcifediol 41-63 complement C3 Homo sapiens 27-30 24931970-7 2014 Birds fed 25-hydroxycholecalciferol at 25 and 50 microg/kg and injected with LPS had approximately 7-fold and 3-fold less (P = 0.010) IL-1beta mRNA in the liver compared with those birds fed 6.25 microg/kg of 25-hydroxycholecalciferol and the cholecalciferol (250 IU/kg) group. Calcifediol 10-35 interleukin 1, beta Gallus gallus 134-142 24931970-9 2014 At 28 d of age, birds were fed 25-hydroxycholecalciferol and injected with LPS had 1.1-fold less (P < 0.01) IL-1beta mRNA in the liver than the cholecalciferol-fed group. Calcifediol 31-56 interleukin 1, beta Gallus gallus 111-119 24931970-11 2014 In conclusion, 25-hydroxycholecalciferol supplementation at higher doses improved growth performance and decreased inflammatory gene IL-1beta mRNA amounts in the liver post-LPS injection. Calcifediol 15-40 interleukin 1, beta Gallus gallus 133-141 25079458-1 2014 OBJECTIVE: To determine if GC (group-specific component globulin) and CYP2R1 genetic variants have an association with serum 25-OHD3 levels, BMD or bone turnover markers in a population of Chinese postmenopausal women. Calcifediol 125-132 GC vitamin D binding protein Homo sapiens 27-29 25079458-6 2014 The variants of rs2298849 (beta=0.105, P<0.001) in GC were significantly associated with serum 25-OHD3 levels. Calcifediol 98-105 GC vitamin D binding protein Homo sapiens 54-56 25176105-7 2014 CONCLUSION: Serum 25-(OH)D3 level is positively correlated with serum IL-6 level in KD children before IVIG treatment but not after the treatment,. Calcifediol 18-27 interleukin 6 Homo sapiens 70-74 24641623-0 2014 Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability. Calcifediol 34-54 UDP glucuronosyltransferase family 1 member A4 Homo sapiens 6-12 24641623-0 2014 Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability. Calcifediol 34-54 UDP glucuronosyltransferase family 1 member A3 Homo sapiens 17-23 24748388-12 2014 There was a significant interaction between calcidiol and FGF-23 levels (p = 0.025). Calcifediol 44-53 fibroblast growth factor 23 Homo sapiens 58-64 24748388-13 2014 When the population was divided according to FGF-23 levels, calcidiol still predicted the outcome independently in patients with FGF-23 levels higher than the median (HR = 0.50; 95% CI = 0.31-0.80; p = 0.003) but not in those with FGF-23 levels below this value (HR = 1.03; 95% CI = 0.62-1.71; p = 0.904). Calcifediol 60-69 fibroblast growth factor 23 Homo sapiens 45-51 24748388-13 2014 When the population was divided according to FGF-23 levels, calcidiol still predicted the outcome independently in patients with FGF-23 levels higher than the median (HR = 0.50; 95% CI = 0.31-0.80; p = 0.003) but not in those with FGF-23 levels below this value (HR = 1.03; 95% CI = 0.62-1.71; p = 0.904). Calcifediol 60-69 fibroblast growth factor 23 Homo sapiens 129-135 24748388-13 2014 When the population was divided according to FGF-23 levels, calcidiol still predicted the outcome independently in patients with FGF-23 levels higher than the median (HR = 0.50; 95% CI = 0.31-0.80; p = 0.003) but not in those with FGF-23 levels below this value (HR = 1.03; 95% CI = 0.62-1.71; p = 0.904). Calcifediol 60-69 fibroblast growth factor 23 Homo sapiens 129-135 24748388-15 2014 In this population, low calcidiol plasma levels predict an adverse prognosis in the presence of high FGF-23 levels. Calcifediol 24-33 fibroblast growth factor 23 Homo sapiens 101-107 24497297-3 2014 Cytochrome P450 2R1 (CYP2R1) is a microsomal vitamin D 25-hydroxylase which plays an important role in converting dietary vitamin D to active metabolite, 25-(OH)D3. Calcifediol 154-163 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 0-19 24613576-0 2014 Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1. Calcifediol 15-35 neurofibromin 1 Homo sapiens 79-103 24613576-2 2014 Serum 25-hydroxyvitamin D3 concentrations in NF1 adults are lower than in healthy controls in autumn respectively winter and are inversely correlated with the number of dermal neurofibromas. Calcifediol 6-26 neurofibromin 1 Homo sapiens 45-48 24613576-3 2014 We investigated 25-hydroxyvitamin D3 levels in children and adults with neurofibromatosis type 1 in winter and summer and compared them to healthy controls to get more pathogenic insights in vitamin D3 metabolism in NF1 patients. Calcifediol 16-36 neurofibromin 1 Homo sapiens 72-96 24613576-6 2014 25-Hydroxyvitamin D3 increased from winter to summer (mean: 21.0 to 46.5nmol/l) in NF1 adults. Calcifediol 0-20 neurofibromin 1 Homo sapiens 83-86 24576880-6 2014 The cell types tested, except HSF, are able to convert inactive 25-hydroxyvitamin D3 (25[OH]D3) into active 1,25-hydroxyvitamin D3 (1,25[OH]2D3). Calcifediol 64-84 interleukin 6 Homo sapiens 30-33 24132388-1 2014 UNLABELLED: Low serum 25-hydroxyvitamin D3 (25(OH)D) levels have been associated with insulin resistance and cardiovascular diseases. Calcifediol 22-42 insulin Homo sapiens 86-93 24613576-9 2014 CONCLUSIONS: Only adults with NF1 showed lower 25-hydroxyvitamin D3 levels in winter and summer, which are unlikely due to impaired UV-dependent dermal synthesis, but rather might be caused by an accelerated catabolism. Calcifediol 47-67 neurofibromin 1 Homo sapiens 30-33 24497297-3 2014 Cytochrome P450 2R1 (CYP2R1) is a microsomal vitamin D 25-hydroxylase which plays an important role in converting dietary vitamin D to active metabolite, 25-(OH)D3. Calcifediol 154-163 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 21-27 24471522-3 2014 The aim of the present study was to investigate the association of serum 25-hydroxyvitamin D3 (25(OH)D3) levels and B ultrasonography-detected carotid plaque and carotid intima-media thickness (C-IMT) in Chinese middle-aged and elderly men. Calcifediol 95-103 iodothyronine deiodinase 3 Homo sapiens 91-93 24497297-3 2014 Cytochrome P450 2R1 (CYP2R1) is a microsomal vitamin D 25-hydroxylase which plays an important role in converting dietary vitamin D to active metabolite, 25-(OH)D3. Calcifediol 154-163 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 45-69 24587317-4 2014 The aim of the present study was to examine the effects of 25(OH)D3, which is stable form of vitamin D3 in blood, and biologically active form 1,25(OH)2D3 on the production of interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) by cells of periodontal ligament. Calcifediol 59-67 interleukin 6 Mus musculus 191-195 24587317-9 2014 In primary hPdLCs, both 25(OH)D3 and 1,25(OH)2D3 inhibited the production of IL-8 and MCP-1 but have no significant effect on the IL-6 production. Calcifediol 24-32 C-X-C motif chemokine ligand 8 Homo sapiens 77-81 24587317-9 2014 In primary hPdLCs, both 25(OH)D3 and 1,25(OH)2D3 inhibited the production of IL-8 and MCP-1 but have no significant effect on the IL-6 production. Calcifediol 24-32 C-C motif chemokine ligand 2 Homo sapiens 86-91 24587317-10 2014 The effect of both 25(OH)D3 and 1,25(OH)2D3 was abolished by specific knockdown of vitamin D3 receptor by siRNA. Calcifediol 19-27 vitamin D receptor Homo sapiens 83-102 24910833-2 2013 VDDR type 1 (VDDR-I) is caused by an inborn error of vitamin D metabolism, which interferes with renal conversion of calcidiol (25OHD) to calcitriol (1,25(OH)2D) by the enzyme 1-alpha-hydroxylase. Calcifediol 117-126 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-4 24216092-5 2013 When compared to 25-hydroxyvitamin D3-DBP, the binding of some antibodies to the analogue-DBP complex of the 25-hydroxyvitamin D3 derivative 10 that posses an 8-aminoctyl alkyl chain is significantly reduced, but this analogue displaced [26,27-(3)H]-25-hydroxyvitamin D3 from DBP. Calcifediol 109-129 D-box binding PAR bZIP transcription factor Homo sapiens 38-41 24216092-5 2013 When compared to 25-hydroxyvitamin D3-DBP, the binding of some antibodies to the analogue-DBP complex of the 25-hydroxyvitamin D3 derivative 10 that posses an 8-aminoctyl alkyl chain is significantly reduced, but this analogue displaced [26,27-(3)H]-25-hydroxyvitamin D3 from DBP. Calcifediol 109-129 D-box binding PAR bZIP transcription factor Homo sapiens 90-93 24216092-5 2013 When compared to 25-hydroxyvitamin D3-DBP, the binding of some antibodies to the analogue-DBP complex of the 25-hydroxyvitamin D3 derivative 10 that posses an 8-aminoctyl alkyl chain is significantly reduced, but this analogue displaced [26,27-(3)H]-25-hydroxyvitamin D3 from DBP. Calcifediol 109-129 D-box binding PAR bZIP transcription factor Homo sapiens 90-93 25531016-8 2014 In a diabetic periodontitis-like environment, 25(OH)D3-loaded microspheres upregulated vitamin D receptor expression, and downregulated nuclear factor-kappaB expression and signal transducer and activator of transcription 3 phosphorylation in the BMSCs. Calcifediol 46-54 vitamin D receptor Rattus norvegicus 87-105 25531016-8 2014 In a diabetic periodontitis-like environment, 25(OH)D3-loaded microspheres upregulated vitamin D receptor expression, and downregulated nuclear factor-kappaB expression and signal transducer and activator of transcription 3 phosphorylation in the BMSCs. Calcifediol 46-54 signal transducer and activator of transcription 3 Rattus norvegicus 173-223 24216092-5 2013 When compared to 25-hydroxyvitamin D3-DBP, the binding of some antibodies to the analogue-DBP complex of the 25-hydroxyvitamin D3 derivative 10 that posses an 8-aminoctyl alkyl chain is significantly reduced, but this analogue displaced [26,27-(3)H]-25-hydroxyvitamin D3 from DBP. Calcifediol 17-37 D-box binding PAR bZIP transcription factor Homo sapiens 38-41 24216092-5 2013 When compared to 25-hydroxyvitamin D3-DBP, the binding of some antibodies to the analogue-DBP complex of the 25-hydroxyvitamin D3 derivative 10 that posses an 8-aminoctyl alkyl chain is significantly reduced, but this analogue displaced [26,27-(3)H]-25-hydroxyvitamin D3 from DBP. Calcifediol 17-37 D-box binding PAR bZIP transcription factor Homo sapiens 90-93 24216092-5 2013 When compared to 25-hydroxyvitamin D3-DBP, the binding of some antibodies to the analogue-DBP complex of the 25-hydroxyvitamin D3 derivative 10 that posses an 8-aminoctyl alkyl chain is significantly reduced, but this analogue displaced [26,27-(3)H]-25-hydroxyvitamin D3 from DBP. Calcifediol 17-37 D-box binding PAR bZIP transcription factor Homo sapiens 90-93 24910833-2 2013 VDDR type 1 (VDDR-I) is caused by an inborn error of vitamin D metabolism, which interferes with renal conversion of calcidiol (25OHD) to calcitriol (1,25(OH)2D) by the enzyme 1-alpha-hydroxylase. Calcifediol 117-126 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 13-17 23454830-3 2013 Based on their kcat/Km values, all CYP11A1-derived metabolites are poor substrates for CYP27B1 from both species compared with 25-hydroxyvitamin D3. Calcifediol 127-147 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 35-42 24098349-5 2013 In vitro experiments were conducted to assess the effects of pro-inflammatory cytokines, calcidiol, calcitriol and Ca2+ on CaSR expression in U937 cell line. Calcifediol 89-98 calcium sensing receptor Homo sapiens 123-127 24019477-9 2013 A double knockout of Cyp2r1 and Cyp27a1 maintained a similar circulating level of 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3. Calcifediol 82-102 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 21-27 24019477-9 2013 A double knockout of Cyp2r1 and Cyp27a1 maintained a similar circulating level of 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3. Calcifediol 82-102 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 32-39 23974111-1 2013 By means of an unbiased, automated fluorescence microscopy-based screen, we identified the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib as potent enhancers of the differentiation of HL-60 acute myeloid leukemia (AML) cells exposed to suboptimal concentrations of vitamin A (all-trans retinoic acid, ATRA) or vitamin D (1alpha,25-hydroxycholecalciferol, VD). Calcifediol 356-381 epidermal growth factor receptor Homo sapiens 91-123 23974111-1 2013 By means of an unbiased, automated fluorescence microscopy-based screen, we identified the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib as potent enhancers of the differentiation of HL-60 acute myeloid leukemia (AML) cells exposed to suboptimal concentrations of vitamin A (all-trans retinoic acid, ATRA) or vitamin D (1alpha,25-hydroxycholecalciferol, VD). Calcifediol 356-381 epidermal growth factor receptor Homo sapiens 125-129 22940288-2 2013 Calcitriol and its precursor calcidiol (25(OH)D3) are degraded by the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). Calcifediol 29-38 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 70-109 22940288-2 2013 Calcitriol and its precursor calcidiol (25(OH)D3) are degraded by the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). Calcifediol 29-38 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 111-118 22940288-2 2013 Calcitriol and its precursor calcidiol (25(OH)D3) are degraded by the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). Calcifediol 40-48 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 70-109 22940288-2 2013 Calcitriol and its precursor calcidiol (25(OH)D3) are degraded by the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). Calcifediol 40-48 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 111-118 22982627-7 2013 Second, 100nM 25(OH)D3 (p<0.01 vs. control, ANOVA) and 100nM PTH1-34 (p<0.05) significantly stimulated alkaline phosphatase (ALP) activity (a measure of osteoblastogenesis), with a synergistic effect when combined (p<0.001). Calcifediol 14-22 alkaline phosphatase, placental Homo sapiens 109-129 22982627-7 2013 Second, 100nM 25(OH)D3 (p<0.01 vs. control, ANOVA) and 100nM PTH1-34 (p<0.05) significantly stimulated alkaline phosphatase (ALP) activity (a measure of osteoblastogenesis), with a synergistic effect when combined (p<0.001). Calcifediol 14-22 alkaline phosphatase, placental Homo sapiens 131-134 24292029-8 2013 Maternal and neonatal serum 25(OH)D3 levels showed a positive correlation with serum Ca++ and negative correlation with serum PO4 and ALP. Calcifediol 28-36 alkaline phosphatase, placental Homo sapiens 134-137 23818972-6 2013 In scleroderma group the serum levels of 25(OH)D3 significantly correlated with PTH levels, BMD, stiffness index and bone turnover markers. Calcifediol 41-49 parathyroid hormone Homo sapiens 80-83 23021159-1 2013 OBJECTIVES: We have previously demonstrated reduced bone density and an increased incidence of 25-hydroxy vitamin D3 (25-OH D3) deficiency in adults with neurofibromatosis 1 (NF1) compared to healthy controls. Calcifediol 95-116 neurofibromin 1 Homo sapiens 154-173 23212742-0 2013 Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. Calcifediol 42-62 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 71-77 23021159-1 2013 OBJECTIVES: We have previously demonstrated reduced bone density and an increased incidence of 25-hydroxy vitamin D3 (25-OH D3) deficiency in adults with neurofibromatosis 1 (NF1) compared to healthy controls. Calcifediol 95-116 neurofibromin 1 Homo sapiens 175-178 23021159-1 2013 OBJECTIVES: We have previously demonstrated reduced bone density and an increased incidence of 25-hydroxy vitamin D3 (25-OH D3) deficiency in adults with neurofibromatosis 1 (NF1) compared to healthy controls. Calcifediol 118-126 neurofibromin 1 Homo sapiens 154-173 23021159-1 2013 OBJECTIVES: We have previously demonstrated reduced bone density and an increased incidence of 25-hydroxy vitamin D3 (25-OH D3) deficiency in adults with neurofibromatosis 1 (NF1) compared to healthy controls. Calcifediol 118-126 neurofibromin 1 Homo sapiens 175-178 23667735-8 2013 Maternal and neonatal serum 25(OH)D3 levels showed a positive correlation with serum Ca(++) and negative correlation with serum PO4 and ALP. Calcifediol 28-36 alkaline phosphatase, placental Homo sapiens 136-139 23333931-0 2013 25-Hydroxyvitamin D3 attenuates experimental periodontitis through downregulation of TLR4 and JAK1/STAT3 signaling in diabetic mice. Calcifediol 0-20 toll-like receptor 4 Mus musculus 85-89 23333931-0 2013 25-Hydroxyvitamin D3 attenuates experimental periodontitis through downregulation of TLR4 and JAK1/STAT3 signaling in diabetic mice. Calcifediol 0-20 Janus kinase 1 Mus musculus 94-98 23333931-0 2013 25-Hydroxyvitamin D3 attenuates experimental periodontitis through downregulation of TLR4 and JAK1/STAT3 signaling in diabetic mice. Calcifediol 0-20 signal transducer and activator of transcription 3 Mus musculus 99-104 23333931-3 2013 We showed that 25-OHD3 intraperitoneal injection attenuated diabetic periodontitis by reducing serum fasting blood glucose, glycosylated hemoglobin and TNF-alpha levels, which led to decreased alveolar bone loss. Calcifediol 15-22 tumor necrosis factor Mus musculus 152-161 23020803-1 2013 Vitamin D is a fat-soluble precursor of the circulating 25-hydroxyvitamin D3 (25(OH)D3)which can be converted by the 1alpha-hydroxylase (1alpha(OH)ase) enzyme into the bioactive hormonal metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), generally known to promote bone mineralization through its ability to enhance calcium absorption from the gut. Calcifediol 56-76 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 137-150 23020803-1 2013 Vitamin D is a fat-soluble precursor of the circulating 25-hydroxyvitamin D3 (25(OH)D3)which can be converted by the 1alpha-hydroxylase (1alpha(OH)ase) enzyme into the bioactive hormonal metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), generally known to promote bone mineralization through its ability to enhance calcium absorption from the gut. Calcifediol 78-86 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 137-150 23413917-1 2013 BACKGROUND: Serum 25-hydroxyvitamin D3 (Vitamin D) insufficiency and single-nucleotide polymorphisms (SNPs) on its receptor, Vitamin D receptor (VDR), have been reported to be involved in melanoma susceptibility in populations mostly from northern countries. Calcifediol 18-38 vitamin D receptor Homo sapiens 125-143 23413917-1 2013 BACKGROUND: Serum 25-hydroxyvitamin D3 (Vitamin D) insufficiency and single-nucleotide polymorphisms (SNPs) on its receptor, Vitamin D receptor (VDR), have been reported to be involved in melanoma susceptibility in populations mostly from northern countries. Calcifediol 18-38 vitamin D receptor Homo sapiens 145-148 23138030-4 2013 The intraperitoneal administration of 25(OH)D(3) to streptozotocin-induced diabetic mice reduced fasting glucose and serum TNF-alpha levels, leading to decreased alveolar bone loss. Calcifediol 38-48 tumor necrosis factor Mus musculus 123-132 23909735-1 2013 Megalin and disabled-2 (Dab2) are essential for uptake of the 25-hydroxycholecalciferol (25D3)-vitamin D binding protein (DBP) complex in tissues. Calcifediol 62-87 LDL receptor related protein 2 Homo sapiens 0-7 23364629-17 2013 Both treatment with paricalcitol and with calcifediol produced a significant decrease in levels of IL-8 (P<.001), a known inflammatory marker, drawing attention to a trend towards better response to erythropoiesis-stimulating agents (ESAs), possibly related to the decrease in inflammation. Calcifediol 42-53 C-X-C motif chemokine ligand 8 Homo sapiens 99-103 23302066-9 2013 Simple regression analysis showed that serum osteoprotegerin levels had significant positive correlations with age, systolic blood pressure and serum adiponectin levels, and significant negative correlations with BMI and serum 25-hydroxyvitamin D3. Calcifediol 227-247 TNF receptor superfamily member 11b Homo sapiens 45-60 24073717-8 2013 Serum 25(OH)D3 levels below 30 nmol/L were positively correlated with serum osteoprotegerin levels in this cohort. Calcifediol 6-14 TNF receptor superfamily member 11b Homo sapiens 76-91 23875809-3 2013 However, the possible link between circulating 25-hydroxycholecalciferol and apoproteins (Apo A1 and B) and the atherogenic lipoprotein (a) [Lp(a)] has not been documented to date. Calcifediol 47-72 apolipoprotein A1 Homo sapiens 90-102 23875809-3 2013 However, the possible link between circulating 25-hydroxycholecalciferol and apoproteins (Apo A1 and B) and the atherogenic lipoprotein (a) [Lp(a)] has not been documented to date. Calcifediol 47-72 lipoprotein(a) Homo sapiens 141-146 23909735-1 2013 Megalin and disabled-2 (Dab2) are essential for uptake of the 25-hydroxycholecalciferol (25D3)-vitamin D binding protein (DBP) complex in tissues. Calcifediol 62-87 DAB adaptor protein 2 Homo sapiens 12-22 23909735-1 2013 Megalin and disabled-2 (Dab2) are essential for uptake of the 25-hydroxycholecalciferol (25D3)-vitamin D binding protein (DBP) complex in tissues. Calcifediol 62-87 DAB adaptor protein 2 Homo sapiens 24-28 23909735-1 2013 Megalin and disabled-2 (Dab2) are essential for uptake of the 25-hydroxycholecalciferol (25D3)-vitamin D binding protein (DBP) complex in tissues. Calcifediol 62-87 GC vitamin D binding protein Homo sapiens 95-120 23909735-1 2013 Megalin and disabled-2 (Dab2) are essential for uptake of the 25-hydroxycholecalciferol (25D3)-vitamin D binding protein (DBP) complex in tissues. Calcifediol 62-87 D-box binding PAR bZIP transcription factor Homo sapiens 122-125 23043189-0 2012 Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate. Calcifediol 11-31 parathyroid hormone Homo sapiens 69-72 22753133-3 2012 We evaluated the hepatic expression of VDR along with that of vitamin D 25-hydroxylases in patients with nonalcoholic steatohepatitis (NASH) or chronic hepatitis C (CHC) and its relationship with hepatic histological features and serum 25(OH)D(3) levels. Calcifediol 236-246 vitamin D receptor Homo sapiens 39-42 22802085-12 2012 Serum myostatin levels were positively correlated with serum levels of 25-hydroxycholecalciferol (25OHD), even after adjustment for season. Calcifediol 71-96 myostatin Homo sapiens 6-15 22862690-1 2012 CYP27B1 is a mitochondrial cytochrome P450 that catalyses the hydroxylation of 25-hydroxyvitamin D3 at the C1alpha-position to give the hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3. Calcifediol 79-99 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-7 22210453-11 2012 Our study reports the highest k(cat) for the 25-hydroxylation of vitamin D3 by any human cytochrome P450 suggesting that CYP27A1 might be an important contributor to the synthesis of 25-hydroxyvitamin D3, particularly in tissues where it is highly expressed. Calcifediol 183-203 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 121-128 22862690-1 2012 CYP27B1 is a mitochondrial cytochrome P450 that catalyses the hydroxylation of 25-hydroxyvitamin D3 at the C1alpha-position to give the hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3. Calcifediol 79-99 endogenous retrovirus group K member 1 Homo sapiens 107-114 22862690-8 2012 Human CYP27B1 was also active on 25-hydroxyvitamin D(2) and on intermediates of the CYP24A1-mediated inactivation pathway, 24R,25-dihydroxyvitamin D3, 24-oxo-25-hydroxyvitamin D3 and 24-oxo-23,25-dihydroxyvitamin D3, with all these substrates showing comparable k(cat) values of 50-71 min(-1) , similar to 25-hydroxyvitamin D3. Calcifediol 159-179 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 6-13 22862690-8 2012 Human CYP27B1 was also active on 25-hydroxyvitamin D(2) and on intermediates of the CYP24A1-mediated inactivation pathway, 24R,25-dihydroxyvitamin D3, 24-oxo-25-hydroxyvitamin D3 and 24-oxo-23,25-dihydroxyvitamin D3, with all these substrates showing comparable k(cat) values of 50-71 min(-1) , similar to 25-hydroxyvitamin D3. Calcifediol 159-179 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 85-92 22344194-9 2012 CONCLUSIONS: Higher circulating 25(OH)D(3) was associated with cardioprotective levels of HDL-C, Apo-A1, and adiponectin in children. Calcifediol 32-42 apolipoprotein A1 Homo sapiens 97-103 22344194-9 2012 CONCLUSIONS: Higher circulating 25(OH)D(3) was associated with cardioprotective levels of HDL-C, Apo-A1, and adiponectin in children. Calcifediol 32-42 adiponectin, C1Q and collagen domain containing Homo sapiens 109-120 22042758-9 2012 An increasing trend in apoptosis in response to 25(OH)D(3), in both SaOS-2 and 143B cells was detected by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining. Calcifediol 48-58 DNA nucleotidylexotransferase Homo sapiens 106-143 22042758-9 2012 An increasing trend in apoptosis in response to 25(OH)D(3), in both SaOS-2 and 143B cells was detected by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining. Calcifediol 48-58 DNA nucleotidylexotransferase Homo sapiens 145-148 21944666-10 2012 By multivariable linear regression, higher baseline CAC score, history of cardiovascular event, use of a statin, and lower 25-hydroxyvitamin D(3) level were independent determinants of CAC progression. Calcifediol 123-145 carbonic anhydrase 2 Homo sapiens 185-188 22382217-11 2012 We found a significant positive correlation between serum 25(OH)D3 levels and serum IL-10, while there was a negative correlation between 25(OH)D3 levels and SIL-2R; this correlation was not significant. Calcifediol 58-66 interleukin 10 Homo sapiens 84-89 22382217-12 2012 Our findings suggest that 25(OH)D3 levels affect the immune state in patients through their effect on both limbs of immunity, the anti-inflammatory and the pro-inflammatory, but the effect was higher on the anti-inflammatory IL-10. Calcifediol 26-34 interleukin 10 Homo sapiens 225-230 21958677-2 2012 Increased urinary loss of vitamin D binding protein (VDBP), the main transporter of 25-hydroxyvitamin D(3) in the circulation, has been postulated to contribute to vitamin D deficiency in proteinuria. Calcifediol 84-106 GC vitamin D binding protein Homo sapiens 26-51 22213329-9 2012 In a recent study, our group demonstrated that calcidiol is an active hormone in CYP24 (24-hydroxylase) deficient cells. Calcifediol 47-56 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 81-86 22013102-0 2012 The C-3 epimer of 25-hydroxyvitamin D(3) is present in adult serum. Calcifediol 18-40 complement C3 Homo sapiens 4-7 21993384-13 2012 CONCLUSIONS: 25-hydroxyvitamin D3 correlated inversely and significantly with clinical SLE activity, anti-C1q and anti-dsDNA titers, but not with complement levels or damage scores. Calcifediol 13-33 complement C1q A chain Homo sapiens 106-109 22192194-10 2012 We postulate that the increased tissue responsiveness to parathyroid hormone induced by the low DCAD is crucial for the observed positive effects of the 25-OHD(3) treatment. Calcifediol 153-162 parathyroid hormone Bos taurus 57-76 21710586-1 2012 A dominant aptamer loop structure from a library of nearly 100 candidate aptamer sequences developed against immobilized 25-hydroxyvitamin D(3) (calcidiol) was converted into a 5"-TYE 665 and 3"-Iowa black-labelled aptamer beacon. Calcifediol 121-143 ubiquitin like 5 Homo sapiens 223-229 21710586-1 2012 A dominant aptamer loop structure from a library of nearly 100 candidate aptamer sequences developed against immobilized 25-hydroxyvitamin D(3) (calcidiol) was converted into a 5"-TYE 665 and 3"-Iowa black-labelled aptamer beacon. Calcifediol 145-154 ubiquitin like 5 Homo sapiens 223-229 21958677-2 2012 Increased urinary loss of vitamin D binding protein (VDBP), the main transporter of 25-hydroxyvitamin D(3) in the circulation, has been postulated to contribute to vitamin D deficiency in proteinuria. Calcifediol 84-106 GC vitamin D binding protein Homo sapiens 53-57 21256461-3 2011 Interestingly, the ratio of 25-OH-D3 to 1-25-(OH)-D3 (a surrogate for parathyroid hormone [PTH]) is the strongest predictor of cardiac iron. Calcifediol 28-36 parathyroid hormone Mus musculus 70-89 21753070-3 2011 METHODS: We determined serum 25(OH)D(3) concentrations in relation to MetS, its components (central obesity, hypertension, low high-density lipoprotein (HDL)-cholesterol, hypertriglyceridemia, glucose impairment, and/or insulin resistance (IR)), and impairment of flow-mediated vasodilatation (FMD) and increased carotid intima-media thickness (cIMT) - two markers of subclinical atherosclerosis. Calcifediol 29-39 ETS variant transcription factor 3 Homo sapiens 70-74 22338929-6 2011 The respective correlations between PTH and calcidiol, beta-CTx and PINP were -0.217, 0.640 and 0.393. Calcifediol 44-53 parathyroid hormone Homo sapiens 36-39 22365999-0 2012 [Effect of 25-hydroxyvitamin D(3) on vitamin D receptor expression and distribution in human bronchial epithelial cells in vitro]. Calcifediol 11-33 vitamin D receptor Homo sapiens 37-55 22365999-1 2012 OBJECTIVE: To evaluate the effect of 25-hydroxyvitamin D(3) on the expression and distribution of vitamin D receptor in normal human bronchial epithelial cells. Calcifediol 37-59 vitamin D receptor Homo sapiens 98-116 21613383-8 2012 Significant correlations were found between sclerostin and gender (R = 0.41), iPTH (R = -0.28), 25-hydroxy-cholecalciferol (R = 0.27) and calcium (R = 0.25). Calcifediol 96-122 sclerostin Homo sapiens 44-54 23166493-2 2012 We report here that TLR8 activation in human macrophages induces the expression of the human cathelicidin microbial peptide (CAMP), the vitamin D receptor (VDR) and cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1), which 1alpha-hydroxylates the inactive form of vitamin D, 25-hydroxycholecalciferol, into its biologically active metabolite. Calcifediol 289-314 toll like receptor 8 Homo sapiens 20-24 23166493-2 2012 We report here that TLR8 activation in human macrophages induces the expression of the human cathelicidin microbial peptide (CAMP), the vitamin D receptor (VDR) and cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1), which 1alpha-hydroxylates the inactive form of vitamin D, 25-hydroxycholecalciferol, into its biologically active metabolite. Calcifediol 289-314 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 165-219 22118750-6 2011 The link between 25-hydroxyvitamin D3 and HDL cholesterol (HDLc) and apo A-I is not as clear. Calcifediol 17-37 apolipoprotein A1 Homo sapiens 69-76 21998409-5 2011 In vitro supplementation of vitamin D-deficient serum with 25-hydroxyvitamin D3 restored IFN-gamma-induced antimicrobial peptide expression, autophagy, phagosome-lysosome fusion, and antimicrobial activity. Calcifediol 59-79 interferon gamma Homo sapiens 89-98 22074799-11 2011 In urban women, PTH and CTX were correlated while dietary calcium was inversely correlated with CTX and PTH with 25(OH)D3. Calcifediol 113-121 parathyroid hormone Homo sapiens 104-107 21701937-5 2011 The first calcidiol dose produced a significant reduction of serum PTH levels (P < 0.001), which then remained constant over time. Calcifediol 10-19 parathyroid hormone Homo sapiens 67-70 21610497-4 2011 RECENT FINDINGS: CYP24A1 is the cytochrome P450 enzyme that catalyzes the conversion of 25-hydroxyvitamin D3 (25-OHD3) and its hormonal form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], into 24-hydroxylated products targeted for excretion. Calcifediol 88-108 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 17-24 21610497-4 2011 RECENT FINDINGS: CYP24A1 is the cytochrome P450 enzyme that catalyzes the conversion of 25-hydroxyvitamin D3 (25-OHD3) and its hormonal form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], into 24-hydroxylated products targeted for excretion. Calcifediol 110-117 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 17-24 21752320-6 2011 Serum 25-(OH)D(3) levels were negatively correlated with serum total IgE levels in asthmatic children (r=-0.783, P<0.01). Calcifediol 6-17 immunoglobulin heavy constant epsilon Homo sapiens 69-72 21752320-9 2011 The increased serum 25-(OH)D(3) level may inhibit total IgE expression, suggesting that increasing serum 25-(OH)D(3) level might be a new option for the prevention and treatment of asthma. Calcifediol 20-31 immunoglobulin heavy constant epsilon Homo sapiens 56-59 21752320-9 2011 The increased serum 25-(OH)D(3) level may inhibit total IgE expression, suggesting that increasing serum 25-(OH)D(3) level might be a new option for the prevention and treatment of asthma. Calcifediol 105-116 immunoglobulin heavy constant epsilon Homo sapiens 56-59 21424825-4 2011 The expression and activity of CYP27B1 (the enzyme responsible for converting calcidiol to calcitriol) was measured. Calcifediol 78-87 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 31-38 21424825-6 2011 Calcitriol and calcidiol induced VDR expression in the presence of aldo with EC(50) at 0.3 and 7,952 nM, respectively. Calcifediol 15-24 vitamin D receptor Rattus norvegicus 33-36 21424825-7 2011 Calcitriol, paricalcitol and calcidiol stimulated CYP24A1 (EC(50) at 6.4, 4.5 and 992 nM, respectively) and suppressed NPPB expression (IC(50) at 1.9, 0.1 and 210 nM, respectively) in the presence of 1 muM aldo. Calcifediol 29-38 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 50-57 21424825-7 2011 Calcitriol, paricalcitol and calcidiol stimulated CYP24A1 (EC(50) at 6.4, 4.5 and 992 nM, respectively) and suppressed NPPB expression (IC(50) at 1.9, 0.1 and 210 nM, respectively) in the presence of 1 muM aldo. Calcifediol 29-38 natriuretic peptide B Rattus norvegicus 119-123 21764691-1 2011 OBJECTIVE: To observe the effect of 25-hydroxyvitamin D3 on the permeability and ZO-1 expression in normal human airway epithelial cells. Calcifediol 36-56 tight junction protein 1 Homo sapiens 81-85 21169421-0 2011 Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. Calcifediol 91-100 parathyroid hormone Mus musculus 22-25 21169421-0 2011 Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. Calcifediol 91-100 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 114-132 21143012-1 2011 BACKGROUND: Since the introduction of liquid chromatography-mass spectrometry (LC/MS) for assessing vitamin D status, it has been shown that the C-3 epimer can account for a significant proportion of circulating 25-hydroxyvitamin D3 (25OHD3) concentrations in infants. Calcifediol 212-232 complement C3 Homo sapiens 145-148 20596035-8 2011 In models that included MS (IDF) and PTH/25-OH-D3, the regression coefficients relating CIMT to PTH/25-OH-D3 ratio and MS were +51 microm (P = 0.013) and +19 microm (P = 0.45), respectively. Calcifediol 41-49 CIMT Homo sapiens 88-92 20596035-0 2011 The metabolic syndrome and carotid intima-media thickness in relation to the parathyroid hormone to 25-OH-D(3) ratio in a general population. Calcifediol 100-110 parathyroid hormone Homo sapiens 77-96 20596035-8 2011 In models that included MS (IDF) and PTH/25-OH-D3, the regression coefficients relating CIMT to PTH/25-OH-D3 ratio and MS were +51 microm (P = 0.013) and +19 microm (P = 0.45), respectively. Calcifediol 41-49 parathyroid hormone Homo sapiens 96-99 20596035-8 2011 In models that included MS (IDF) and PTH/25-OH-D3, the regression coefficients relating CIMT to PTH/25-OH-D3 ratio and MS were +51 microm (P = 0.013) and +19 microm (P = 0.45), respectively. Calcifediol 100-108 CIMT Homo sapiens 88-92 20596035-10 2011 CONCLUSIONS: MS prevalence and CIMT were positively associated with PTH/25-OH-D3. Calcifediol 72-80 CIMT Homo sapiens 31-35 20596035-10 2011 CONCLUSIONS: MS prevalence and CIMT were positively associated with PTH/25-OH-D3. Calcifediol 72-80 parathyroid hormone Homo sapiens 68-71 21071961-11 2011 CONCLUSION: Serum 25(OH)D(3) concentration is independently associated with erythropoietin responsiveness in CKD patients on maintenance HD. Calcifediol 18-28 erythropoietin Homo sapiens 76-90 22145480-2 2011 Vitamin D dependent rickets type 1 (VDDR-I) is caused by an inborn error of vitamin D metabolism, which interferes with renal conversion of calcidiol (25OHD) to calcitriol (1,25(OH)2D) by the enzyme 1alpha-hydroxylase. Calcifediol 140-149 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 36-40 20441671-5 2010 We measured serum 25-hydroxyvitamin D3 (S-25(OH)D3) by LC-MS/MS in 669 of the 713 subjects in whom sufficient serum was available. Calcifediol 18-38 ribosomal protein S25 Homo sapiens 40-50 20483384-6 2010 25-D3 was clearly converted into 1,25-D3 in the DC cultures and the process was accompanied by a reduced expression of CD80 (p<0.01), CD83 (p<0.01), CD86 (p=0.02), and HLA-DR (p=0.02). Calcifediol 0-5 CD80 molecule Homo sapiens 119-123 20595682-2 2010 CKD associates with a decrease in liver cytochrome P450 (CYP450) enzymes, and specific CYP450 isoforms mediate vitamin D(3) C-25-hydroxylation, which forms calcidiol. Calcifediol 156-165 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 40-55 20595682-2 2010 CKD associates with a decrease in liver cytochrome P450 (CYP450) enzymes, and specific CYP450 isoforms mediate vitamin D(3) C-25-hydroxylation, which forms calcidiol. Calcifediol 156-165 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 87-93 20595682-4 2010 Here, we evaluated the effects of PTH and uremia on liver CYP450 isoforms involved in calcidiol synthesis in rats. Calcifediol 86-95 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 58-64 20483384-6 2010 25-D3 was clearly converted into 1,25-D3 in the DC cultures and the process was accompanied by a reduced expression of CD80 (p<0.01), CD83 (p<0.01), CD86 (p=0.02), and HLA-DR (p=0.02). Calcifediol 0-5 CD83 molecule Homo sapiens 137-141 20483384-6 2010 25-D3 was clearly converted into 1,25-D3 in the DC cultures and the process was accompanied by a reduced expression of CD80 (p<0.01), CD83 (p<0.01), CD86 (p=0.02), and HLA-DR (p=0.02). Calcifediol 0-5 CD86 molecule Homo sapiens 155-159 20398757-0 2010 The role of cubilin gene polymorphisms and their influence on 25(OH)D3 and 1,25(OH)2D3 plasma levels in type 1 diabetes patients. Calcifediol 62-70 cubilin Homo sapiens 12-19 20227497-3 2010 Vitamin D also elicits numerous intracrine actions when circulating 25-hydroxyvitamin D3, the metabolite reflecting vitamin D status, is converted to 1,25D locally by extrarenal CYP27B1, and binds VDR to promote immunoregulation, antimicrobial defense, xenobiotic detoxification, anti-inflammatory/anticancer actions and cardiovascular benefits. Calcifediol 68-88 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 178-185 20227497-3 2010 Vitamin D also elicits numerous intracrine actions when circulating 25-hydroxyvitamin D3, the metabolite reflecting vitamin D status, is converted to 1,25D locally by extrarenal CYP27B1, and binds VDR to promote immunoregulation, antimicrobial defense, xenobiotic detoxification, anti-inflammatory/anticancer actions and cardiovascular benefits. Calcifediol 68-88 vitamin D receptor Homo sapiens 197-200 20435140-2 2010 Introduction of the 1alpha-hydroxyl group into 25-hydroxyvitamin D3 (2) to produce 1alpha,25-dihydroxyvitamin D3 (1) increases the VDR binding affinity by approximately 1000-fold. Calcifediol 47-67 vitamin D receptor Homo sapiens 131-134 20398757-2 2010 Once the complex is internalized, 25(OH)D3 is released and activated to 1,25(OH)2D3 the ligand for the vitamin D receptor (VDR). Calcifediol 34-42 vitamin D receptor Homo sapiens 103-121 20398757-2 2010 Once the complex is internalized, 25(OH)D3 is released and activated to 1,25(OH)2D3 the ligand for the vitamin D receptor (VDR). Calcifediol 34-42 vitamin D receptor Homo sapiens 123-126 20175051-7 2010 CONCLUSIONS: Treatment with oral calcitriol was associated with a decrease in the serum levels of ALP and 25(OH)D; treatment with oral calcidiol was associated with more physiological serum levels of 25(OH)D and with an increase in the serum levels of ALP and PTH: whether the statistically significant differences in the biochemical parameters achieved with the 2 treatments have a clinical relevance, remains a matter of debate. Calcifediol 135-144 alkaline phosphatase, placental Homo sapiens 252-255 20637153-0 2010 [Correlation between vitamin D receptor genetic polymorphism and 25-hydroxyvitamin D3 in vitamin D deficiency rickets]. Calcifediol 65-85 vitamin D receptor Homo sapiens 21-39 20362753-7 2010 RESULTS: On univariate analyses, low 25-hydroxyvitamin D(3) levels were inversely correlated with asymmetric dimethylarginine concentrations, high-sensitivity C-reactive protein levels, and body mass index. Calcifediol 37-59 C-reactive protein Homo sapiens 159-177 20193763-1 2010 CYP27B1 catalyzes the 1alpha-hydroxylation of 25-hydroxyvitamin D3 to 1alpha,25-dihydroxyvitamin D3, the hormonally active form of vitamin D3. Calcifediol 46-66 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 0-7 20193763-4 2010 CYP27B1 showed inhibition when substrate concentrations in the membrane were greater than 4 times K(m), more pronounced with 25-hydroxyvitamin D3 than 25-hydroxyvitamin D2. Calcifediol 125-145 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 0-7 20193763-7 2010 This study shows that CYP27B1 can hydroxylate 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 associated with phospholipid membranes with the highest activity yet reported for the enzyme. Calcifediol 71-91 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 22-29 20175051-7 2010 CONCLUSIONS: Treatment with oral calcitriol was associated with a decrease in the serum levels of ALP and 25(OH)D; treatment with oral calcidiol was associated with more physiological serum levels of 25(OH)D and with an increase in the serum levels of ALP and PTH: whether the statistically significant differences in the biochemical parameters achieved with the 2 treatments have a clinical relevance, remains a matter of debate. Calcifediol 135-144 parathyroid hormone Homo sapiens 260-263 19770375-7 2009 There was evidence of interaction between the vitamin D receptor (VDR) BsmI genotype and serum 25-hydroxyvitamin D(3) levels on RFS. Calcifediol 95-117 vitamin D receptor Homo sapiens 46-64 19944755-5 2010 25-Hydroxyvitamin D(3) action depends on the vitamin D receptor signalling supported by the unresponsiveness of the vitamin D receptor knockout cells. Calcifediol 0-22 vitamin D receptor Homo sapiens 45-63 19770375-7 2009 There was evidence of interaction between the vitamin D receptor (VDR) BsmI genotype and serum 25-hydroxyvitamin D(3) levels on RFS. Calcifediol 95-117 vitamin D receptor Homo sapiens 66-69 19221564-0 2009 [Correlation analysis between plasma levels of 25-hydroxy vitamin D3 and osteocalcin in patients with aggressive periodontitis]. Calcifediol 47-68 bone gamma-carboxyglutamate protein Homo sapiens 73-84 19667160-1 2009 Tissue-specific expression of 25-hydroxyvitamin D-1alpha-hydroxylase (1alpha-OHase) and vitamin D-hydroxylase (24-OHase) may act as the pivotal link between 25-hydroxyvitamin D3 (25(OH)D3) serum levels and the anticancer effects of 1,25-dihydoxyvitamin D3 (1,25(OH)2D3) and alternative splicing of the enzymes may regulate their biological function. Calcifediol 157-177 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 111-119 19338780-4 2009 PTH(1-34) stimulated the conversion of 25-OHD3 to 1,25-(OH)2D3, and PTH(7-84) dose-dependently inhibited this process. Calcifediol 39-46 parathyroid hormone Mus musculus 0-3 19667162-3 2009 There are two principal enzymes involved in the formation of circulating 1,25(OH)2D3 from vitamin D, the hepatic microsomal or mitochondrial vitamin D-25-hydroxylase (CYP27A1) and the renal mitochondrial 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) for vitamin D and 25(OH)D3 (calcidiol), respectively. Calcifediol 281-290 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 141-165 19667162-3 2009 There are two principal enzymes involved in the formation of circulating 1,25(OH)2D3 from vitamin D, the hepatic microsomal or mitochondrial vitamin D-25-hydroxylase (CYP27A1) and the renal mitochondrial 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) for vitamin D and 25(OH)D3 (calcidiol), respectively. Calcifediol 281-290 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 167-174 19221564-1 2009 OBJECTIVE: To explore the relationship between plasmatic 25-hydroxy vitamin D3 (25OHD3) level and plasmatic osteocalcin level in patients with aggressive periodontitis (AgP). Calcifediol 57-78 bone gamma-carboxyglutamate protein Homo sapiens 108-119 18981132-4 2008 Although both IL-15 and IL-4 triggered macrophage differentiation, only IL-15 was sufficient by itself to induce CYP27b1 and subsequent bioconversion of 25-hydroxyvitamin D3 (25D3) into bioactive 1,25D3, leading to VDR activation and induction of cathelicidin. Calcifediol 153-173 interleukin 15 Homo sapiens 72-77 18205042-7 2009 However, we also observed that clotrimazol (1alpha-hydroxylase inhibitor) enhanced 25(OH)D(3) -induced CYP24 expression in breast cancer cells. Calcifediol 83-93 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 103-108 18936726-3 2008 25(OH)D3 is metabolized by a renal 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) into the vitamin D hormone 1,25 dihydroxycholecalciferol (calcitriol), which generates a wide range of biological responses via both the regulation of gene transcription and nongenomic pathways. Calcifediol 0-8 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 75-82 17878529-1 2007 BACKGROUND: It is known that 25(OH)D3 can be metabolized to 1,25(OH)2 D3 by 1alpha-OHase in breast tissue. Calcifediol 29-37 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 76-88 18575896-6 2008 PTH for patients with 25(OH)D3 levels >30 ng/ml was 67.84 +/- 29.09 ng/ml and in the remaining patients was elevated, at 120.36 +/- 86.42 ng/ml (p = 0.05). Calcifediol 22-30 parathyroid hormone Homo sapiens 0-3 18567755-1 2008 The major circulating form of vitamin D, 25-hydroxycholecalciferol (25D3), circulates bound to vitamin D-binding protein (DBP). Calcifediol 41-66 GC vitamin D binding protein Homo sapiens 95-120 18567755-1 2008 The major circulating form of vitamin D, 25-hydroxycholecalciferol (25D3), circulates bound to vitamin D-binding protein (DBP). Calcifediol 41-66 D-box binding PAR bZIP transcription factor Homo sapiens 122-125 18487663-0 2008 Blood mineral, hormone, and osteocalcin responses of multiparous Jersey cows to an oral dose of 25-hydroxyvitamin D3 or vitamin D3 before parturition. Calcifediol 96-116 bone gamma-carboxyglutamate protein Bos taurus 28-39 17607662-2 2007 CYP2R1, a cytochrome P450 enzyme, catalyzes the formation of vitamin D3 to 25-hydroxyvitamin D3 (25(OH)D3), the main circulating vitamin D metabolite. Calcifediol 75-95 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 0-6 17607662-2 2007 CYP2R1, a cytochrome P450 enzyme, catalyzes the formation of vitamin D3 to 25-hydroxyvitamin D3 (25(OH)D3), the main circulating vitamin D metabolite. Calcifediol 97-105 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 0-6 18178294-2 2008 Herein, we report that murine DCs exposed to TLR3/TLR4 ligands upregulate their expression of 1 alpha-hydroxylase, the enzyme that converts circulating 25(OH)D3 to calcitriol, the active form of vitamin D3. Calcifediol 152-160 toll-like receptor 3 Mus musculus 45-49 18178294-2 2008 Herein, we report that murine DCs exposed to TLR3/TLR4 ligands upregulate their expression of 1 alpha-hydroxylase, the enzyme that converts circulating 25(OH)D3 to calcitriol, the active form of vitamin D3. Calcifediol 152-160 toll-like receptor 4 Mus musculus 50-54 18029472-1 2007 Mice lacking 25-hydroxycholecalciferol [25(OH)D]-1alpha-hydroxylase (CYP27B1) are growth retarded, hypocalcemic, and have poor bone mineralization. Calcifediol 13-38 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 69-76 17243190-3 2007 For this purpose, we studied whether VDR TaqI or FokI genotype are associated with serum 25-hydroxyvitamin D3 in 52 controls and 26 patients with colorectal cancer. Calcifediol 89-109 vitamin D receptor Homo sapiens 37-40 17286279-4 2007 We also demonstrate that WT145 cells express CYP27B1, the enzyme that converts 25-hydroxyvitamin D(3) (25D) to 1,25D, and that 25D inhibits growth of these cells but does not trigger apoptosis or induce CYP24 expression. Calcifediol 79-101 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 45-52 16690021-5 2006 The promoter activity was markedly suppressed by 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in presence of vitamin D receptor (VDR). Calcifediol 83-103 vitamin D receptor Homo sapiens 119-137 17426122-1 2007 The human 25-hydroxyvitamin D3 (25(OH)D3) 1alpha-hydroxylase, which is encoded by the CYP27B1 gene, catalyzes the metabolic activation of the 25(OH)D3 into 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the most biologically potent vitamin D3 metabolite. Calcifediol 32-40 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 86-93 16824767-0 2006 Dermal fibroblasts pretreated with a sterol Delta7-reductase inhibitor produce 25-hydroxyvitamin D3 upon UVB irradiation. Calcifediol 79-99 7-dehydrocholesterol reductase Homo sapiens 50-60 16886688-3 2006 MATERIALS AND METHODS: Vitamin D receptor (VDR)- positive MCF-7 cells in culture were stimulated with the vitamin D metabolites vitamin D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 for 24, 48; 72 and 96 hours in physiological and supraphysiological concentrations. Calcifediol 140-160 vitamin D receptor Homo sapiens 23-41 16886688-3 2006 MATERIALS AND METHODS: Vitamin D receptor (VDR)- positive MCF-7 cells in culture were stimulated with the vitamin D metabolites vitamin D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 for 24, 48; 72 and 96 hours in physiological and supraphysiological concentrations. Calcifediol 140-160 vitamin D receptor Homo sapiens 43-46 17292862-0 2007 Role of Gln 85 of human CYP27A1 in 25-hydroxyvitamin D(3)-binding and protein folding. Calcifediol 35-57 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 24-31 17388667-2 2007 Circulating 25-hydroxyvitamin D3 (25[OH]D), the most commonly used index of vitamin D status, is converted to the active hormone 1,25 dihydroxyvitamin D3 (1,25[OH]2D), which, operating through the vitamin D receptor (VDR), inhibits in vitro cell proliferation, induces differentiation and apoptosis, and may protect against prostate cancer. Calcifediol 12-32 vitamin D receptor Homo sapiens 197-215 17388667-2 2007 Circulating 25-hydroxyvitamin D3 (25[OH]D), the most commonly used index of vitamin D status, is converted to the active hormone 1,25 dihydroxyvitamin D3 (1,25[OH]2D), which, operating through the vitamin D receptor (VDR), inhibits in vitro cell proliferation, induces differentiation and apoptosis, and may protect against prostate cancer. Calcifediol 12-32 vitamin D receptor Homo sapiens 217-220 17250953-1 2007 CYP27B1 is a critical enzyme of Vitamin D biosynthesis that hydroxylates 25(OH)D(3) at the final step of the biosynthetic pathway. Calcifediol 73-83 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-7 18050015-7 2007 In stepwise backward regression, eGFR and 25-hydroxyvitamin D3 were associated with iPTH, as follows: iPTH = 24.91 -(0.06 x 25-hydroxyvitamin D3) - (0.16 x eGFR) (R2 = 0.14). Calcifediol 42-62 epidermal growth factor receptor Homo sapiens 156-160 18050015-7 2007 In stepwise backward regression, eGFR and 25-hydroxyvitamin D3 were associated with iPTH, as follows: iPTH = 24.91 -(0.06 x 25-hydroxyvitamin D3) - (0.16 x eGFR) (R2 = 0.14). Calcifediol 124-145 epidermal growth factor receptor Homo sapiens 33-37 17199789-9 2006 Anti-cubilin antibodies inhibit cellular uptake of DBP/25-(OH)D3 by up to 70%. Calcifediol 55-64 cubilin (intrinsic factor-cobalamin receptor) Mus musculus 5-12 17199789-12 2006 Specific forms of renal Fanconi syndrome are associated with endocytic pathway dysfunction with disruption of megalin-mediated uptake DBP/25-(OH)D3 complex, producing metabolic bone disease in affected individuals as a prominent clinical finding. Calcifediol 138-147 low density lipoprotein receptor-related protein 2 Mus musculus 110-117 17056796-0 2006 Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. Calcifediol 74-99 LDL receptor related protein 2 Homo sapiens 0-7 17056796-0 2006 Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. Calcifediol 74-99 GC vitamin D binding protein Homo sapiens 32-57 17056796-1 2006 The major circulating form of vitamin D is 25-hydroxycholecalciferol [25(OH)D3], which is delivered to target tissues in complex with the serum vitamin D binding protein (DBP). Calcifediol 43-68 GC vitamin D binding protein Homo sapiens 144-169 17056796-1 2006 The major circulating form of vitamin D is 25-hydroxycholecalciferol [25(OH)D3], which is delivered to target tissues in complex with the serum vitamin D binding protein (DBP). Calcifediol 43-68 D-box binding PAR bZIP transcription factor Homo sapiens 171-174 17056796-1 2006 The major circulating form of vitamin D is 25-hydroxycholecalciferol [25(OH)D3], which is delivered to target tissues in complex with the serum vitamin D binding protein (DBP). Calcifediol 70-78 GC vitamin D binding protein Homo sapiens 144-169 17056796-1 2006 The major circulating form of vitamin D is 25-hydroxycholecalciferol [25(OH)D3], which is delivered to target tissues in complex with the serum vitamin D binding protein (DBP). Calcifediol 70-78 D-box binding PAR bZIP transcription factor Homo sapiens 171-174 17056796-2 2006 We recently observed that mammary cells can metabolize 25(OH)D3 to 1,25-dihydroxycholecalciferol [1,25(OH)(2)D3], the vitamin D receptor (VDR) ligand, and the objective of our study was to elucidate the mechanisms by which the 25(OH)D3-DBP complex is internalized by mammary cells prior to metabolism. Calcifediol 55-63 vitamin D receptor Homo sapiens 118-136 17056796-2 2006 We recently observed that mammary cells can metabolize 25(OH)D3 to 1,25-dihydroxycholecalciferol [1,25(OH)(2)D3], the vitamin D receptor (VDR) ligand, and the objective of our study was to elucidate the mechanisms by which the 25(OH)D3-DBP complex is internalized by mammary cells prior to metabolism. Calcifediol 55-63 vitamin D receptor Homo sapiens 138-141 17056796-2 2006 We recently observed that mammary cells can metabolize 25(OH)D3 to 1,25-dihydroxycholecalciferol [1,25(OH)(2)D3], the vitamin D receptor (VDR) ligand, and the objective of our study was to elucidate the mechanisms by which the 25(OH)D3-DBP complex is internalized by mammary cells prior to metabolism. Calcifediol 55-63 D-box binding PAR bZIP transcription factor Homo sapiens 236-239 16807549-0 2006 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Calcifediol 0-22 parathyroid hormone Bos taurus 34-37 16886671-1 2006 BACKGROUND: The presence of extra-renal 25-hydroxyvitamin D3 [25(OH)D3]-1alpha-hydroxylase (1alpha-OHase) has been reported in several cell types including prostate and colon cancer cells. Calcifediol 40-60 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 92-104 16690021-5 2006 The promoter activity was markedly suppressed by 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in presence of vitamin D receptor (VDR). Calcifediol 83-103 vitamin D receptor Homo sapiens 139-142 16690021-6 2006 The data suggest that VDR-mediated inhibition of 25-hydroxylase(s) by vitamin D3 metabolites at the transcriptional level may play an important role in the regulation of 25-hydroxyvitamin D3 production in liver and other tissues. Calcifediol 170-190 vitamin D receptor Homo sapiens 22-25 16549446-2 2006 CYP27B1 is a cytochrome P450-containing hydroxylase expressed in kidney and other tissues that generates 1alpha,25(OH)2D3 from an inactive vitamin D precursor 25-hydroxycholecalciferol [25(OH)D3]. Calcifediol 159-184 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-7 16699104-11 2006 The LM of cows receiving 25-OH D3 with or without manipulated DCAD had greater concentrations of mu-calpain and m-calpain mRNA, whereas the reverse was observed for calpastatin mRNA. Calcifediol 25-33 calpain 1 Bos taurus 97-107 16699104-11 2006 The LM of cows receiving 25-OH D3 with or without manipulated DCAD had greater concentrations of mu-calpain and m-calpain mRNA, whereas the reverse was observed for calpastatin mRNA. Calcifediol 25-33 calpain 2 Bos taurus 112-121 16699104-14 2006 However, DCAD+25-OH D3 induced greater expressions of mu-calpain protein as well as mRNA. Calcifediol 14-22 calpain 1 Bos taurus 54-64 16600026-5 2006 At least one positive SNP with a TDT of p < 0.05 for asthma or total IgE and calcidiol or calcitriol was seen in IL10, GC, IL12B, CYP2R1, IL4R, and CYP24A1. Calcifediol 80-89 interleukin 10 Homo sapiens 116-120 16600026-5 2006 At least one positive SNP with a TDT of p < 0.05 for asthma or total IgE and calcidiol or calcitriol was seen in IL10, GC, IL12B, CYP2R1, IL4R, and CYP24A1. Calcifediol 80-89 interleukin 12B Homo sapiens 126-131 16600026-5 2006 At least one positive SNP with a TDT of p < 0.05 for asthma or total IgE and calcidiol or calcitriol was seen in IL10, GC, IL12B, CYP2R1, IL4R, and CYP24A1. Calcifediol 80-89 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 133-139 16600026-5 2006 At least one positive SNP with a TDT of p < 0.05 for asthma or total IgE and calcidiol or calcitriol was seen in IL10, GC, IL12B, CYP2R1, IL4R, and CYP24A1. Calcifediol 80-89 interleukin 4 receptor Homo sapiens 141-145 16600026-5 2006 At least one positive SNP with a TDT of p < 0.05 for asthma or total IgE and calcidiol or calcitriol was seen in IL10, GC, IL12B, CYP2R1, IL4R, and CYP24A1. Calcifediol 80-89 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 151-158 16600026-7 2006 Haplotype association were found only for CYP24A1, the main calcidiol degrading enzyme, where a frequent 5-point-haplotype was associated with asthma (p = 0.00063), total IgE (p = 0.0014), calcidiol (p = 0.0043) and calcitriol (p = 0.0046). Calcifediol 60-69 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 42-49 16600026-7 2006 Haplotype association were found only for CYP24A1, the main calcidiol degrading enzyme, where a frequent 5-point-haplotype was associated with asthma (p = 0.00063), total IgE (p = 0.0014), calcidiol (p = 0.0043) and calcitriol (p = 0.0046). Calcifediol 189-198 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 42-49 16700010-3 2006 This review describes these new pathways for uptake of 25-hydroxy-vitamin-D3 and the gonadal sex-steroids (17beta-estradiol and testosterone) bound to vitamin D-binding protein and sex hormone-binding globulin respectively. Calcifediol 55-76 sex hormone binding globulin Mus musculus 181-209 16549446-2 2006 CYP27B1 is a cytochrome P450-containing hydroxylase expressed in kidney and other tissues that generates 1alpha,25(OH)2D3 from an inactive vitamin D precursor 25-hydroxycholecalciferol [25(OH)D3]. Calcifediol 186-194 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-7 16289102-1 2005 25-Hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) is an important inactivating enzyme and its expression is induced by 25-hydroxyvitamin D3 (25OHD3) and 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) through action of heterodimers of vitamin D receptor (VDR) and retinoid X receptor (RXR). Calcifediol 124-144 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 23-37 16524720-1 2006 25-Hydroxyvitamin D3-24-hydroxylase (24-hydroxylase, CYP24) is an important inactivating enzyme controlling the concentrations of both active metabolites 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3. Calcifediol 154-174 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 53-58 16289102-1 2005 25-Hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) is an important inactivating enzyme and its expression is induced by 25-hydroxyvitamin D3 (25OHD3) and 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) through action of heterodimers of vitamin D receptor (VDR) and retinoid X receptor (RXR). Calcifediol 124-144 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 39-53 16289102-1 2005 25-Hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) is an important inactivating enzyme and its expression is induced by 25-hydroxyvitamin D3 (25OHD3) and 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) through action of heterodimers of vitamin D receptor (VDR) and retinoid X receptor (RXR). Calcifediol 124-144 vitamin D receptor Homo sapiens 242-260 16289102-1 2005 25-Hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) is an important inactivating enzyme and its expression is induced by 25-hydroxyvitamin D3 (25OHD3) and 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) through action of heterodimers of vitamin D receptor (VDR) and retinoid X receptor (RXR). Calcifediol 124-144 vitamin D receptor Homo sapiens 262-265 16289102-1 2005 25-Hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) is an important inactivating enzyme and its expression is induced by 25-hydroxyvitamin D3 (25OHD3) and 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) through action of heterodimers of vitamin D receptor (VDR) and retinoid X receptor (RXR). Calcifediol 124-144 retinoid X receptor alpha Homo sapiens 271-290 16289102-1 2005 25-Hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) is an important inactivating enzyme and its expression is induced by 25-hydroxyvitamin D3 (25OHD3) and 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) through action of heterodimers of vitamin D receptor (VDR) and retinoid X receptor (RXR). Calcifediol 124-144 retinoid X receptor alpha Homo sapiens 292-295 15972816-0 2005 Identification of the amino acid residue of CYP27B1 responsible for binding of 25-hydroxyvitamin D3 whose mutation causes vitamin D-dependent rickets type 1. Calcifediol 79-99 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 44-51 16214919-3 2005 Recent studies, however, suggest that colonic epithelial cells express 25-hydroxyvitamin D3-1alpha-hydroxylase, an enzyme that converts nontoxic pro-vitamin D, 25-hydroxycholecalciferol [25(OH)D3], to its bioactive form. Calcifediol 160-185 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 71-110 16141393-4 2005 Transient overexpression of an hsc70-green fluorescent protein chimeric construct in primate kidney cells resulted in a 6-fold increase in specific, extractable 25-hydroxyvitamin D(3) binding. Calcifediol 161-183 heat shock protein family A (Hsp70) member 8 Homo sapiens 31-36 15972816-2 2005 Using the three-dimensional model we studied the docking of the substrate, 25-hydroxyvitamin D3, into the substrate binding pocket of CYP27B1. Calcifediol 75-95 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 134-141 15972816-5 2005 In a mutation study of mouse CYP27B1 that included spectroscopic analysis, we concluded that in a 1alpha-hydroxylation process, Ser408 of mouse CYP27B1 corresponding to Thr409 of human CYP27B1 forms a hydrogen bond with the 25-hydroxyl group of 25-hydroxyvitamin D3. Calcifediol 245-265 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 29-36 15972816-5 2005 In a mutation study of mouse CYP27B1 that included spectroscopic analysis, we concluded that in a 1alpha-hydroxylation process, Ser408 of mouse CYP27B1 corresponding to Thr409 of human CYP27B1 forms a hydrogen bond with the 25-hydroxyl group of 25-hydroxyvitamin D3. Calcifediol 245-265 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 144-151 15972816-5 2005 In a mutation study of mouse CYP27B1 that included spectroscopic analysis, we concluded that in a 1alpha-hydroxylation process, Ser408 of mouse CYP27B1 corresponding to Thr409 of human CYP27B1 forms a hydrogen bond with the 25-hydroxyl group of 25-hydroxyvitamin D3. Calcifediol 245-265 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 144-151 14757768-0 2004 C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. Calcifediol 83-103 complement C3 Sus scrofa 0-3 16227152-10 2005 We found that 25-hydroxyvitamin D3 1alpha-hydroxylase, which metabolize 25-hydroxyvitamin D3 (inactive form) to 1,25(OH)(2)D was expressed in Th2-cytokine induced bone marrow-derived DC2 but not Th1-cytokine induced DC1. Calcifediol 14-34 heart and neural crest derivatives expressed 2 Mus musculus 142-145 16227152-10 2005 We found that 25-hydroxyvitamin D3 1alpha-hydroxylase, which metabolize 25-hydroxyvitamin D3 (inactive form) to 1,25(OH)(2)D was expressed in Th2-cytokine induced bone marrow-derived DC2 but not Th1-cytokine induced DC1. Calcifediol 14-34 negative elongation factor complex member C/D, Th1l Mus musculus 195-198 15574355-3 2005 Upon analyses of the metabolites of vitamin D3 by the reconstituted system, CYP27A1 surprisingly produced at least seven forms of minor metabolites including 1alpha,25(OH)2D3 in addition to the major metabolite 25(OH)D3. Calcifediol 211-219 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 76-83 15574355-9 2005 CYP24A1 expressed in E. coli showed a remarkable metabolic processes of 25(OH)D3 and 1alpha,25(OH)2D3. Calcifediol 72-80 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 0-7 15223133-8 2004 Equivalent activity in normal and cancer cells of Vitamin D 24-hydroxylase, a mitochondrial enzyme that also uses 25(OH)D(3) as a substrate, further ruled out lack of access to substrate as a basis for low activity of 1alpha(OH)ase in cancer cells. Calcifediol 114-124 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 50-74 14648070-7 2004 Although no clinical responses were observed, results of this pilot study demonstrated that treatment of HNSCC patients with 25-hydroxyvitamin D(3 )reduces the number of immune suppressive CD34(+) cells, increases HLA-DR expression, increases plasma IL-12 and IFN-gamma levels, and improves T-cell blastogenesis. Calcifediol 125-148 CD34 molecule Homo sapiens 189-193 14648070-7 2004 Although no clinical responses were observed, results of this pilot study demonstrated that treatment of HNSCC patients with 25-hydroxyvitamin D(3 )reduces the number of immune suppressive CD34(+) cells, increases HLA-DR expression, increases plasma IL-12 and IFN-gamma levels, and improves T-cell blastogenesis. Calcifediol 125-148 interferon gamma Homo sapiens 260-269 15498883-0 2005 Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Calcifediol 62-82 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 151-158 15498883-1 2005 The 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) plays an important role in regulating concentrations of both the precursor 25-hydroxyvitamin D3 [25(OH)D3] and the hormone 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)(2)D3]. Calcifediol 124-144 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 40-47 15585637-0 2004 Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Calcifediol 58-78 vitamin D receptor Homo sapiens 118-136 15225763-2 2004 Our studies focused on: (1) elucidating the role of CYP24 in 25-OH-D3 and 1alpha,25-(OH)2D3 metabolism; (2) exploring how DBP influences this process; (3) measuring 25-OH-D3 metabolism in CYP24-knockout (CYP24-XO) cells and; (4) comparing 1alpha-OH-D2 metabolism in the CYP24-XO mouse in vivo and in vitro. Calcifediol 61-69 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 52-57 15225763-4 2004 We found that CYP24 metabolizes 25-OH-D3 and 1alpha,25-(OH)2D3 at similar rates in vitro, but that for 25-OH-D3 but not 1alpha,25-(OH)2D3, this rate is strongly influenced by the concentration of DBP. Calcifediol 32-40 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 14-19 15225763-4 2004 We found that CYP24 metabolizes 25-OH-D3 and 1alpha,25-(OH)2D3 at similar rates in vitro, but that for 25-OH-D3 but not 1alpha,25-(OH)2D3, this rate is strongly influenced by the concentration of DBP. Calcifediol 103-111 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 14-19 15225763-5 2004 Unlike their wild type littermates, the administration of 25-OH-D3 to CYP24-XO mice results in no measurable 24,25-(OH)2D3 production. Calcifediol 58-66 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 70-75 14757768-0 2004 C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. Calcifediol 83-103 complement C3 Sus scrofa 70-73 14757768-0 2004 C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. Calcifediol 122-148 complement C3 Sus scrofa 0-3 14757768-0 2004 C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. Calcifediol 122-148 complement C3 Sus scrofa 70-73 14757768-4 2004 25(OH)D3 was at least as sensitive to C-3 epimerization as 1alpha, 25(OH)2D3 which has been reported as a substrate for the C-3 epimerization reaction. Calcifediol 0-8 complement C3 Sus scrofa 38-41 14757768-4 2004 25(OH)D3 was at least as sensitive to C-3 epimerization as 1alpha, 25(OH)2D3 which has been reported as a substrate for the C-3 epimerization reaction. Calcifediol 0-8 complement C3 Sus scrofa 124-127 14760115-4 2004 We induced CYP24 in seven esophageal cancer cell lines using 25-hydroxyvitamin D3 [25(OH)D3] and compared cell growth rate, measured using the 3-(4, 5-dimethylthiazol-2-y)-2, 5-diphenyltetrazolium bromide (MTT) assay system. Calcifediol 61-81 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 11-16 12162340-4 2002 In the other two experiments, 1,25-(OH)2D3, D3 and 1alpha-OHD3 were consistently effective in increasing phytate P utilization as measured by plasma Ca and P, incidence of P rickets, bone ash, and retention of Ca, P, and phytate P. Supplementation with 25-OHD3 in general gave smaller and more inconsistent responses to these criteria, indicating some inconsistency in its ability to improve phytate P utilization. Calcifediol 253-260 dopamine receptor D3 Gallus gallus 44-62 12782149-0 2003 Metabolism of 25-hydroxyvitamin D3 by microsomal and mitochondrial vitamin D3 25-hydroxylases (CYP2D25 and CYP27A1): a novel reaction by CYP27A1. Calcifediol 14-34 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 107-114 12782149-0 2003 Metabolism of 25-hydroxyvitamin D3 by microsomal and mitochondrial vitamin D3 25-hydroxylases (CYP2D25 and CYP27A1): a novel reaction by CYP27A1. Calcifediol 14-34 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 137-144 12782149-1 2003 The metabolism of 25-hydroxyvitamin D(3) was studied with a crude mitochondrial cytochrome P450 extract from pig kidney and with recombinant human CYP27A1 (mitochondrial vitamin D(3) 25-hydroxylase) and porcine CYP2D25 (microsomal vitamin D(3) 25-hydroxylase). Calcifediol 18-40 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 147-154 12782149-1 2003 The metabolism of 25-hydroxyvitamin D(3) was studied with a crude mitochondrial cytochrome P450 extract from pig kidney and with recombinant human CYP27A1 (mitochondrial vitamin D(3) 25-hydroxylase) and porcine CYP2D25 (microsomal vitamin D(3) 25-hydroxylase). Calcifediol 18-40 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 170-197 12782149-1 2003 The metabolism of 25-hydroxyvitamin D(3) was studied with a crude mitochondrial cytochrome P450 extract from pig kidney and with recombinant human CYP27A1 (mitochondrial vitamin D(3) 25-hydroxylase) and porcine CYP2D25 (microsomal vitamin D(3) 25-hydroxylase). Calcifediol 18-40 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 231-258 12782149-5 2003 A monoclonal antibody directed against purified pig liver CYP27A1 immunoprecipitated the 1alpha- and 27-hydroxylase activities towards 25-hydroxyvitamin D(3) as well as the formation of the unknown metabolite. Calcifediol 135-157 cytochrome P450 family 27 subfamily A member 1 Sus scrofa 58-65 12782149-6 2003 These results together with substrate inhibition experiments indicate that CYP27A1 is responsible for the formation of the unknown 25-hydroxyvitamin D(3) metabolite in kidney. Calcifediol 131-153 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 75-82 12782149-7 2003 Recombinant human CYP27A1 was found to convert 25-hydroxyvitamin D(3) into 1alpha,25-dihydroxyvitamin D(3), 25,27-dihydroxyvitamin D(3) and a major metabolite with the same retention time on HPLC as that formed by kidney mitochondrial cytochrome P450. Calcifediol 47-69 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 18-25 12594170-8 2003 Excreted albumin appeared to compete for the binding and reabsorption of the DBP-25-hydroxyvitamin D3 [25(OH)D3] complex with megalin, resulting in a loss of 25(OH)D3 into the urine and subsequent reduction of plasma 24,25(OH)2D3. Calcifediol 103-111 D-box binding PAR bZIP transcription factor Rattus norvegicus 77-80 12594170-8 2003 Excreted albumin appeared to compete for the binding and reabsorption of the DBP-25-hydroxyvitamin D3 [25(OH)D3] complex with megalin, resulting in a loss of 25(OH)D3 into the urine and subsequent reduction of plasma 24,25(OH)2D3. Calcifediol 103-111 LDL receptor related protein 2 Rattus norvegicus 126-133 12867411-6 2003 Thin layer chromatography and radioimmunoassays indicated that the secosteroid product of CYP2R1 was 25-hydroxyvitamin D3. Calcifediol 101-121 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 90-96 12496369-2 2002 1alpha-Hydroxylase catalyzes the conversion of 25-OHD(3) to 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)]. Calcifediol 47-56 interferon activated gene 205 Mus musculus 87-91 11814777-0 2002 The C(19) position of 25-hydroxyvitamin D(3) faces outward in the vitamin D sterol-binding pocket of vitamin D-binding protein. Calcifediol 22-44 GC vitamin D binding protein Homo sapiens 101-126 12051678-12 2002 In conclusion, we have provided data to suggest that although binding of 25-OH-D(3) to DBP might result in discrete conformational changes in the holo-protein to influence actin-binding, these binding processes are largely independent of each other in solution. Calcifediol 73-83 D-box binding PAR bZIP transcription factor Homo sapiens 87-90 11704292-5 2001 A phase IB clinical trial was initiated with HNSCC patients to determine if 25-hydroxyvitamin D(3) treatment could diminish CD34(+) cell levels and improve immune function. Calcifediol 76-98 CD34 molecule Homo sapiens 124-128 12027153-12 2002 A negative association between serum intact PTH and 25(OH)D3 levels was found in subjects who were 80 years or older (p<0.001) but not in subjects under the age of 80 years. Calcifediol 52-60 parathyroid hormone Homo sapiens 44-47 11799400-2 2002 Here we report the 2.3 A crystal structure of DBP in complex with 25-hydroxyvitamin D3, a vitamin D3 metabolite, which reveals the vitamin D-binding site in the N-terminal part of domain I. Calcifediol 66-86 D-box binding PAR bZIP transcription factor Homo sapiens 46-49 11704292-8 2001 Although no clinical responses were observed, results of these pilot studies showed that 25-hydroxyvitamin D(3) reduced the presence of immune suppressive CD34(+) cells and improved immune competence of HNSCC patients. Calcifediol 89-111 CD34 molecule Homo sapiens 155-159 11013342-2 2000 Synthesis of 1, 25(OH)(2)D(3) from the major circulating metabolite, 25-hydroxyvitamin D(3) (25(OH)D(3)), is catalysed by a mitochondrial cytochrome P450 enzyme, 25-hydroxyvitamin D-1alpha-hydroxylase (1alpha-OHase). Calcifediol 69-91 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 202-214 11012668-11 2000 Addition of 25(OH)D3 to the recombinant E. coli cell culture yielded most of the metabolites in both the C-23 and C-24 hydroxylation pathways. Calcifediol 12-20 nucleolin Homo sapiens 105-109 11350446-10 2001 Serum calcidiol level correlated inversely (P < 0.05) with serum iPTH and ALP, and parathyroid gland weight. Calcifediol 6-15 alkaline phosphatase, placental Homo sapiens 77-80 11172626-10 2001 Mitochondrial cytochrome P450, catalyzing 1alpha-hydroxylation and 27-hydroxylation but not 24-hydroxylation of 25-hydroxyvitamin D3, was partially purified from pig kidney. Calcifediol 112-132 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 14-29 11686044-5 2001 On rat CYP24, it was demonstrated that CYP24 catalyzed four-step monooxygenation towards 25-hydroxyvitamin D3. Calcifediol 89-109 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 7-12 11686044-5 2001 On rat CYP24, it was demonstrated that CYP24 catalyzed four-step monooxygenation towards 25-hydroxyvitamin D3. Calcifediol 89-109 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 39-44 11686044-7 2001 These results strongly suggest that CYP24 is highly responsible for the metabolism of both 25-hydroxyvitamin D3 and 1 alpha,25-dihydroxyvitamin D3. Calcifediol 91-111 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 36-41 10924511-4 2000 The present paper reports that the microsomal vitamin D(3) 25-hydroxylase, purified from pig liver, converted vitamin D(3) into 25-hydroxyvitamin D(3) in substrate concentrations which are within the physiological range (apparent K(m) = 0.1 microm). Calcifediol 128-150 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 46-73 10232681-1 1999 The 25-hydroxyvitamin D3 1alpha-hydroxylase, also referred to as CYP27B1, is a mitochondrial cytochrome P450 enzyme that catalyzes the biosynthesis of 1alpha, 25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) from 25-hydroxyvitamin D3 in renal proximal tubular cells. Calcifediol 4-24 cytochrome P450 family 27 subfamily B member 1 Sus scrofa 65-72 10902806-10 2000 The overall results of this study provide evidence for the presence of 1alpha-(OH)ase in the human placenta, suggesting that conversion of 25OHD(3) to 1,25-dihydroxyvitamin D3 in the trophoblast is most probably attributed to an enzymatic 1alpha-hydroxylation reaction. Calcifediol 139-147 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 71-85 10696983-11 2000 Polymorphisms in the VDR gene also contribute to susceptibility when considered in combination with 25-hydroxycholecalciferol deficiency. Calcifediol 100-125 vitamin D receptor Homo sapiens 21-24 10424766-7 1999 24R,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 at high doses (concentration: 10(-7) M) also induced beta-galactosidase activity in clone NK-31. Calcifediol 31-51 galactosidase, beta 1 Rattus norvegicus 105-123 10374186-3 1999 PATIENTS AND METHODS: We analyzed the Bsml RFLP at the eight introm of the VDR gene in a population sample (n = 204) of postmenopausal Spanish women aged 50-65 years being seen clinically and studied calcium intake (dietetic questionnaire) and biochemical parameters (PTH and calcidiol). Calcifediol 276-285 vitamin D receptor Homo sapiens 75-78 11148801-5 2000 Serum PTH was inversely related to BMD at both hip and lumbar spine in the total group, and at the hip with calcidiol levels lower than 37 nmol/l. Calcifediol 108-117 parathyroid hormone Homo sapiens 6-9 11148801-7 2000 Results of a stepwise multiple regression analysis showed that the single factor which affected BMD at the hip was calcidiol in the subgroup with serum calcidiol levels below 37 nmol/l, while in the subgroup with serum calcidiol levels above 37 nmol/l, the main factor affecting hip BMD was serum PTH. Calcifediol 115-124 parathyroid hormone Homo sapiens 297-300 10589684-1 1999 The biosynthesis of 1alpha, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3 is catalyzed by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in renal proximal tubules. Calcifediol 56-76 cytochrome P450 family 27 subfamily B member 1 Sus scrofa 93-132 10589684-1 1999 The biosynthesis of 1alpha, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3 is catalyzed by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in renal proximal tubules. Calcifediol 56-76 cytochrome P450 family 27 subfamily B member 1 Sus scrofa 134-141 10374186-11 1999 CONCLUSIONS: Our results indicate an effect of the VDR genotype on BMD proximal femur which is clearly influenced by calcium intake and calcidiol serum levels. Calcifediol 136-145 vitamin D receptor Homo sapiens 51-54 10231362-5 1999 In this study, we demonstrate further oxidation by CYP24 including four- and six-step monooxygenation towards 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3, respectively. Calcifediol 110-130 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 51-56 10231362-7 1999 These results indicate that CYP24 catalyses at least four-step monooxygenation toward 25-hydroxyvitamin D3. Calcifediol 86-106 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 28-33 10231362-9 1999 These results strongly suggest that CYP24 is largely responsible for the metabolism of both 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3. Calcifediol 92-112 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 36-41 10399884-0 1999 C-6 functionalized analogs of 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3: synthesis and binding analysis with vitamin D-binding protein and vitamin D receptor. Calcifediol 30-50 complement C6 Homo sapiens 0-3 10399884-0 1999 C-6 functionalized analogs of 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3: synthesis and binding analysis with vitamin D-binding protein and vitamin D receptor. Calcifediol 30-50 GC vitamin D binding protein Homo sapiens 122-147 10399884-0 1999 C-6 functionalized analogs of 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3: synthesis and binding analysis with vitamin D-binding protein and vitamin D receptor. Calcifediol 30-50 vitamin D receptor Homo sapiens 152-170 10399884-1 1999 In this article, we describe the development of a general synthetic strategy to functionalize the C-6 position of vitamin D3 and its biologically important metabolites, i.e. 25-hydroxyvitamin D3 (25-OH-D3) and 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3]. Calcifediol 174-194 complement C6 Homo sapiens 98-101 10399884-1 1999 In this article, we describe the development of a general synthetic strategy to functionalize the C-6 position of vitamin D3 and its biologically important metabolites, i.e. 25-hydroxyvitamin D3 (25-OH-D3) and 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3]. Calcifediol 196-204 complement C6 Homo sapiens 98-101 9914327-7 1999 When the aged rats were injected with 25(OH)D3, similar Ca2+ influx, cAMP, and PKA responses to in vitro stimulation with calcitriol were obtained. Calcifediol 38-46 cathelicidin antimicrobial peptide Rattus norvegicus 69-73 9622848-2 1998 Kidney mitochondrial 24-hydroxylase cytochrome P450 (CYP24) catalyses sequential hydroxylation at both C-24 and C-23 positions of calcidiol and calcitriol. Calcifediol 130-139 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 53-58 9720659-8 1998 Post-menopausal women had higher serum levels than pre-menopausal women of beta2m (1.76 +/- 0.22 mg/l vs. 1.35 +/- 0.2 mg/l, P < 0.01); PTH (61.5 +/- 7.5 ng/ml vs. 39 +/- 6 ng/ml, P < 0.001) and lower serum levels of 25-OHD3 (7.5 +/- 2.3 ng/ml vs. 18.2 +/- 2.5 ng/ml, P < 0.001). Calcifediol 223-230 beta-2-microglobulin Homo sapiens 75-81 9833978-1 1998 Cultured human keratinocytes have the property to hydroxylate exogenous 25-hydroxyvitamin D3 (25OHD3) at the C-1alpha position thus producing 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3). Calcifediol 72-92 endogenous retrovirus group K member 1 Homo sapiens 109-117 9705822-1 1998 25-Hydroxyvitamin D3 1 alpha-hydroxylase (1 alpha-hydroxylase) catalyzes hydroxylation, mainly in the kidney, of 25-hydroxyvitamin D3 [25(OH)D3] into 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3], a hormonal form of vitamin D, acting as a key enzyme of vitamin D biosynthesis. Calcifediol 113-133 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-40 9079669-5 1997 In the current studies 25-[3H]hydroxyvitamin D3 (25-OHD3) was used as a competitive ligand to investigate the ability of a number of small lipid molecules to interact with this intracellular vitamin D-binding protein (IDBP) in post-nuclear extracts of a prototypical lymphoblast cell line from the common marmoset, a vitamin D-resistant New World primate. Calcifediol 49-56 GC vitamin D binding protein Homo sapiens 191-216 9295274-1 1997 Renal 25-hydroxyvitamin D3 1alpha-hydroxylase [1alpha(OH)ase] catalyzes metabolic activation of 25-hydroxyvitamin D3 into 1alpha, 25-dihydroxyvitamin D3 [1alpha,25(OH)2D3], an active form of vitamin D, and is inhibited by 1alpha,25(OH)2D3. Calcifediol 6-26 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 47-60 9213008-5 1997 In primary culture of neonatal mouse renal tubules, in which 1,25-(OH)2D3 was produced from 25-OHD3 in response to PTH, SFO significantly inhibited PTH-induced production of 1,25-(OH)2D3 at 30 mumol/L, which is attainable in the urine of patients receiving a therapeutic intravenous dose of SFO. Calcifediol 92-99 parathyroid hormone Mus musculus 115-118 9213008-5 1997 In primary culture of neonatal mouse renal tubules, in which 1,25-(OH)2D3 was produced from 25-OHD3 in response to PTH, SFO significantly inhibited PTH-induced production of 1,25-(OH)2D3 at 30 mumol/L, which is attainable in the urine of patients receiving a therapeutic intravenous dose of SFO. Calcifediol 92-99 parathyroid hormone Mus musculus 148-151 9165006-1 1997 Vitamin D-24-hydroxylase (24-OHase) is a cytochrome P-450 enzyme that catalyzes the conversion of 25-hydroxyvitamin D3 (25OHD3) and 1alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] to 24,25-dihydroxyvitamin D3 and 1,24,25-trihydroxyvitamin D3, respectively. Calcifediol 98-118 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 26-34 9601149-8 1998 The concentration and binding properties of DBP to calcidiol were not markedly different from those of other mammals. Calcifediol 51-60 D-box binding PAR bZIP transcription factor Equus caballus 44-47 9459385-8 1998 Serum parathyroid hormone was inversely correlated with serum calcidiol (r = -0.33, P < 0.001) and the regression predicted that mean serum parathyroid hormone would be reduced in the elderly to concentrations considered normal in the young when serum calcidiol is 122 nmol/L (49 ng/mL); this would require a much higher recommended dietary allowance for vitamin D than 5 microg/d (200 IU/d). Calcifediol 62-71 parathyroid hormone Homo sapiens 6-25 9459385-8 1998 Serum parathyroid hormone was inversely correlated with serum calcidiol (r = -0.33, P < 0.001) and the regression predicted that mean serum parathyroid hormone would be reduced in the elderly to concentrations considered normal in the young when serum calcidiol is 122 nmol/L (49 ng/mL); this would require a much higher recommended dietary allowance for vitamin D than 5 microg/d (200 IU/d). Calcifediol 255-264 parathyroid hormone Homo sapiens 6-25 9459385-8 1998 Serum parathyroid hormone was inversely correlated with serum calcidiol (r = -0.33, P < 0.001) and the regression predicted that mean serum parathyroid hormone would be reduced in the elderly to concentrations considered normal in the young when serum calcidiol is 122 nmol/L (49 ng/mL); this would require a much higher recommended dietary allowance for vitamin D than 5 microg/d (200 IU/d). Calcifediol 255-264 parathyroid hormone Homo sapiens 143-162 9366495-3 1997 Importantly, when Caco-2 cells were incubated with tritium-labelled 25-hydroxyvitamin D3 (25(OH)D3) for up to 2 h they produced almost exclusively a metabolite, which was identified as 1alpha,25(OH)2D3 by co-chromatography with the synthetic standard in two different HPLC systems, and by a radioligand assay showing an identical binding affinity to the intestinal nuclear vitamin D receptor. Calcifediol 68-88 vitamin D receptor Homo sapiens 373-391 9366495-3 1997 Importantly, when Caco-2 cells were incubated with tritium-labelled 25-hydroxyvitamin D3 (25(OH)D3) for up to 2 h they produced almost exclusively a metabolite, which was identified as 1alpha,25(OH)2D3 by co-chromatography with the synthetic standard in two different HPLC systems, and by a radioligand assay showing an identical binding affinity to the intestinal nuclear vitamin D receptor. Calcifediol 90-98 vitamin D receptor Homo sapiens 373-391 7852330-0 1995 Trp-145 is essential for the binding of 25-hydroxyvitamin D3 to human serum vitamin D-binding protein. Calcifediol 40-60 GC vitamin D binding protein Homo sapiens 76-101 8768839-9 1996 These results suggest a selective modulation by vitamin D of the renal response to PTH; 1,25-(OH)2D3 facilitates PTH-induced calcium and sodium reabsorption, but does not influence PTH-induced cAMP excretion; phosphorus, potassium, and bicarbonate tubular transport, or 1 alpha-hydroxylation of 25-hydroxyvitamin D3. Calcifediol 295-315 parathyroid hormone Homo sapiens 83-86 8706816-5 1996 Taken together, the results from the purification and the experiments with CYP27 antibody, substrate inhibition, and recombinant expressed human liver CYP27 strongly indicate that CYP27 is able to catalyze 1 alpha-hydroxylation but not 24-hydroxylation of 25-hydroxyvitamin D3 in kidney. Calcifediol 256-276 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 75-80 8706816-5 1996 Taken together, the results from the purification and the experiments with CYP27 antibody, substrate inhibition, and recombinant expressed human liver CYP27 strongly indicate that CYP27 is able to catalyze 1 alpha-hydroxylation but not 24-hydroxylation of 25-hydroxyvitamin D3 in kidney. Calcifediol 256-276 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 151-156 8706816-5 1996 Taken together, the results from the purification and the experiments with CYP27 antibody, substrate inhibition, and recombinant expressed human liver CYP27 strongly indicate that CYP27 is able to catalyze 1 alpha-hydroxylation but not 24-hydroxylation of 25-hydroxyvitamin D3 in kidney. Calcifediol 256-276 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 151-156 8825582-9 1995 Increased levels of two to three orders of magnitude are required for 25-(OH)D3 to compete with 1,25-(OH)2D3 for binding on VDR. Calcifediol 70-79 vitamin D (1,25- dihydroxyvitamin D3) receptor Gallus gallus 124-127 7575580-2 1995 It was recently shown that liver mitochondrial sterol 27-hydroxylase CYP27, present also in kidney, catalyzes 1 alpha-hydroxylation of 25-hydroxyvitamin D3. Calcifediol 135-155 cytochrome P450, family 27, subfamily a, polypeptide 1 Rattus norvegicus 69-74 7603778-4 1995 Interestingly, serum osteocalcin level was not related to its major known regulators (1 alpha,25-dihydroxycholecalciferol, 25-hydroxycholecalciferol, and PTH) nor to stunting, but was related to serum transthyretin and thyroid hormones concentrations. Calcifediol 123-148 bone gamma-carboxyglutamate protein Homo sapiens 21-32 7852330-3 1995 We also evaluated the results of these modifications in the binding of 25-hydroxy[26(27)-3H]vitamin D3 ([3H]25-OH-D3) to hDBP. Calcifediol 108-116 D-box binding PAR bZIP transcription factor Homo sapiens 121-125 7852330-6 1995 Furthermore, loss of [3H]25-OH-D3-binding was protected by preincubation of hDBP samples with an excess of 25-hydroxyvitamin D3. Calcifediol 25-33 D-box binding PAR bZIP transcription factor Homo sapiens 76-80 7852330-6 1995 Furthermore, loss of [3H]25-OH-D3-binding was protected by preincubation of hDBP samples with an excess of 25-hydroxyvitamin D3. Calcifediol 107-127 D-box binding PAR bZIP transcription factor Homo sapiens 76-80 8980292-2 1997 Our results indicate that stimulation of HaCaT cells with epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha) within 16 h just prior to reaching confluence amplified the production of calcitriol when calcidiol (3H-25OHD3) was used as a substrate. Calcifediol 226-235 epidermal growth factor Homo sapiens 58-81 8980292-2 1997 Our results indicate that stimulation of HaCaT cells with epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha) within 16 h just prior to reaching confluence amplified the production of calcitriol when calcidiol (3H-25OHD3) was used as a substrate. Calcifediol 226-235 epidermal growth factor Homo sapiens 83-86 8980292-2 1997 Our results indicate that stimulation of HaCaT cells with epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha) within 16 h just prior to reaching confluence amplified the production of calcitriol when calcidiol (3H-25OHD3) was used as a substrate. Calcifediol 226-235 tumor necrosis factor Homo sapiens 91-123 8980292-2 1997 Our results indicate that stimulation of HaCaT cells with epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha) within 16 h just prior to reaching confluence amplified the production of calcitriol when calcidiol (3H-25OHD3) was used as a substrate. Calcifediol 226-235 transforming growth factor alpha Homo sapiens 125-134 8806764-5 1996 This labeling was largely prevented when incubations were carried out in the presence of an excess of 25-OH-D3, the natural ligand for rDBP. Calcifediol 102-110 D-box binding PAR bZIP transcription factor Rattus norvegicus 135-139 8806764-7 1996 Collectively, these results strongly suggested that 3H-25-OH-D3-epoxide and 3H-25-OH-D3-BE covalently modified the 25-OH-D3-binding site in rDBP. Calcifediol 55-63 D-box binding PAR bZIP transcription factor Rattus norvegicus 140-144 8806764-8 1996 The reagents described in this report could be important in mapping the 25-OH-D3-binding pocket in rDBP. Calcifediol 72-80 D-box binding PAR bZIP transcription factor Rattus norvegicus 99-103 7503080-5 1995 RESULTS: 25-Hydroxyvitamin D3 treatment significantly increased serum 25-hydroxyvitamin D and urinary calcium and reduced serum 1,25-dihydroxyvitamin D and urinary cyclic adenosine 3",5"-monophosphate, an index of function of parathyroid hormone. Calcifediol 9-29 parathyroid hormone Homo sapiens 226-245 7479923-4 1995 The effect of the hormone on the levels of p50 was demonstrable in the cytosolic and nuclear compartments; it required between 4 and 8 hr and was specific, as 25-hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 were ineffective. Calcifediol 159-179 nuclear factor kappa B subunit 1 Homo sapiens 43-46 7786034-4 1995 Competitive radioligand binding assays of 25-OH-D3-epoxide with hDBP demonstrated that the binding affinity of this analog was similar to that of 25-hydroxyvitamin D3 (25-OH-D3). Calcifediol 42-50 D-box binding PAR bZIP transcription factor Homo sapiens 64-68 7937829-0 1994 Liver mitochondrial cytochrome P450 CYP27 and recombinant-expressed human CYP27 catalyze 1 alpha-hydroxylation of 25-hydroxyvitamin D3. Calcifediol 114-134 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 36-41 7937829-0 1994 Liver mitochondrial cytochrome P450 CYP27 and recombinant-expressed human CYP27 catalyze 1 alpha-hydroxylation of 25-hydroxyvitamin D3. Calcifediol 114-134 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 74-79 7937829-8 1994 The purified recombinant-expressed CYP27 reconstituted with the electron-transferring system of adrenal mitochondria catalyzed 1 alpha-hydroxylation of 25-hydroxyvitamin D3. Calcifediol 152-172 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 35-40 7937829-9 1994 Expression of unmodified CYP27 cDNA in simian COS cells confirmed the 1 alpha-hydroxylase activity toward 25-hydroxyvitamin D3. Calcifediol 106-126 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 25-30 8370586-6 1993 Those of the DBP genetic forms to the vitamin D derivatives 25-OH-D3 and 1,25-(OH)2-D3 seem to be related to the isoelectric point of the proteins: a high affinity corresponding to a low isoelectric point. Calcifediol 60-68 D-box binding PAR bZIP transcription factor Homo sapiens 13-16 7938037-2 1994 1 alpha,25(OH)2D3 can be produced in keratinocytes from 25-hydroxyvitamin D3 by the enzyme 25-hydroxyvitamin D3-1 alpha-hydroxylase (1-OHase). Calcifediol 56-76 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 91-131 8302863-0 1994 Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. Calcifediol 58-67 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 69-105 8302863-1 1994 The calcidiol (25-hydroxyvitamin D3) 24-hydroxylase is one of the key enzymes in the metabolism of vitamin D. Calcifediol 4-13 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 15-51 8366134-5 1993 The biologically less potent metabolite of vitamin D3, 25 (OH) D3, also augmented 125I-interleukin 1 alpha binding but at steroid levels 2-3 log orders greater than 1,25 (OH)2 D3. Calcifediol 55-65 interleukin 1 alpha Mus musculus 87-106 8390483-10 1993 These findings indicate that endogenously synthesized vitamin D3 travels in plasma almost exclusively on DBP, providing for a slower hepatic delivery of the vitamin D and the more sustained increase in plasma 25-hydroxycholecalciferol observed after depot, parenteral administration of vitamin D. Calcifediol 209-234 D-box binding PAR bZIP transcription factor Homo sapiens 105-108 1550407-1 1992 Differential metabolism of 25-hydroxyvitamin D3 (25(OH)D3) has been shown for macrophages and fibroblast-like cells (possibly synoviocytes) cultured for two to 50 days after isolation from the synovial fluid of 12 patients with various forms of inflammatory arthritis. Calcifediol 49-57 iodothyronine deiodinase 3 Homo sapiens 45-47 1330237-6 1992 The potencies of dialkyl analogs in competing with 25-hydroxy-vitamin D3 for binding to rat serum vitamin D binding protein were much lower than that of 1,25(OH)2D3. Calcifediol 51-72 GC, vitamin D binding protein Rattus norvegicus 98-123 1512637-6 1992 The changes in serum osteocalcin were not correlated with serum 1,25-dihydroxycholecalciferol, whereas they could be related to serum 25-hydroxycholecalciferol concentrations. Calcifediol 134-159 bone gamma-carboxyglutamate protein Homo sapiens 21-32 1350464-1 1992 In a survey of cardiovascular risk factors in 185 men and 173 women of a Belgian population group, an independent and highly significant positive correlation was found between the serum concentrations of 25-hydroxyvitamin D3 and apolipoprotein A-I (p less than 0.001 in both sexes). Calcifediol 204-224 apolipoprotein A1 Homo sapiens 229-247 1350464-4 1992 Taking the biological variation of 25-hydroxyvitamin D3 levels (+/- 2 SD = 25 ng/ml) into account, these findings could explain variations in the levels of apolipoprotein A-I of 15 mg/100 ml and of high density lipoprotein cholesterol of 4 mg/100 ml. Calcifediol 35-55 apolipoprotein A1 Homo sapiens 156-174 1525046-1 1992 The affinity of purified human vitamin D-binding protein from serum (DBP) for 25-hydroxyvitamin D3 (25-OHD3) and 1 alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] was measured in the presence of free fatty acids (FFA), cholesterol, prostaglandins and several drugs. Calcifediol 78-98 GC vitamin D binding protein Homo sapiens 31-56 1525046-1 1992 The affinity of purified human vitamin D-binding protein from serum (DBP) for 25-hydroxyvitamin D3 (25-OHD3) and 1 alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] was measured in the presence of free fatty acids (FFA), cholesterol, prostaglandins and several drugs. Calcifediol 78-98 D-box binding PAR bZIP transcription factor Homo sapiens 69-72 1525046-1 1992 The affinity of purified human vitamin D-binding protein from serum (DBP) for 25-hydroxyvitamin D3 (25-OHD3) and 1 alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] was measured in the presence of free fatty acids (FFA), cholesterol, prostaglandins and several drugs. Calcifediol 100-107 GC vitamin D binding protein Homo sapiens 31-56 1525046-1 1992 The affinity of purified human vitamin D-binding protein from serum (DBP) for 25-hydroxyvitamin D3 (25-OHD3) and 1 alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] was measured in the presence of free fatty acids (FFA), cholesterol, prostaglandins and several drugs. Calcifediol 100-107 D-box binding PAR bZIP transcription factor Homo sapiens 69-72 1525046-2 1992 Mono- and polyunsaturated fatty acids markedly decreased the affinity of both 25-OHD3 and 1,25-(OH)2D3 for DBP, whereas saturated fatty acids (stearic and arachidic acid), cholesterol, cholesterol esters, retinol, retinoic acid and prostaglandins (A1 and E1) did not affect the apparent affinity. Calcifediol 78-85 D-box binding PAR bZIP transcription factor Homo sapiens 107-110 1525046-4 1992 The apparent affinity of DBP for both 25-OHD3 and 1,25-(OH)2D3 decreased 2.4- to 4.6-fold in the presence of 36 microM of linoleic or arachidonic acid, respectively. Calcifediol 38-45 D-box binding PAR bZIP transcription factor Homo sapiens 25-28 1525046-5 1992 Only a molar ratio of FFA:DBP higher than 10,000 was able to decrease the binding of 25-OHD3 to DBP by 20%. Calcifediol 85-92 D-box binding PAR bZIP transcription factor Homo sapiens 26-29 1525046-5 1992 Only a molar ratio of FFA:DBP higher than 10,000 was able to decrease the binding of 25-OHD3 to DBP by 20%. Calcifediol 85-92 D-box binding PAR bZIP transcription factor Homo sapiens 96-99 1644853-2 1992 These include the hepatic mitochondrial or microsomal vitamin D3-25-hydroxylase and the two renal mitochondrial enzymes which further hydroxylate 25-hydroxyvitamin-D3 (25-OH-D3) to form 24R,25-dihydroxyvitamin D3 (24,25(OH)2D3) and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the primary steroid hormonal derivative of vitamin D3. Calcifediol 146-166 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 54-79 1644853-2 1992 These include the hepatic mitochondrial or microsomal vitamin D3-25-hydroxylase and the two renal mitochondrial enzymes which further hydroxylate 25-hydroxyvitamin-D3 (25-OH-D3) to form 24R,25-dihydroxyvitamin D3 (24,25(OH)2D3) and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the primary steroid hormonal derivative of vitamin D3. Calcifediol 168-176 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 54-79 2049072-1 1991 The properties of cytochrome P-450 from pig kidney mitochondria, catalysing 26-hydroxylation of 25-hydroxyvitamin D3 and C27 steroids [Postlind & Wikvall (1989) Biochem. Calcifediol 96-116 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 18-34 1551697-6 1992 Incubation of the CD33+ cells with 1,25-(OH)2D3, 24-25-(OH)2D3 and 25-OHD3 resulted in dose-dependent inhibition of culture-enhanced HLA-DR paralleling the vitamin D3-receptor affinities of these compounds. Calcifediol 67-74 CD33 molecule Homo sapiens 18-22 1551697-6 1992 Incubation of the CD33+ cells with 1,25-(OH)2D3, 24-25-(OH)2D3 and 25-OHD3 resulted in dose-dependent inhibition of culture-enhanced HLA-DR paralleling the vitamin D3-receptor affinities of these compounds. Calcifediol 67-74 vitamin D receptor Homo sapiens 156-175 1854759-0 1991 Photoaffinity labeling of human serum vitamin D binding protein and chemical cleavages of the labeled protein: identification of an 11.5-kDa peptide containing the putative 25-hydroxyvitamin D3 binding site. Calcifediol 173-193 GC vitamin D binding protein Homo sapiens 38-63 1854759-2 1991 We have carried out studies to demonstrate that (1) 25-ANE competes with 25-OH-D3 for the binding site of the latter in hDBP and (2) 3H-25-ANE is capable of covalently labeling the hDBP molecule when exposed to UV light. Calcifediol 73-81 D-box binding PAR bZIP transcription factor Homo sapiens 120-124 1854759-2 1991 We have carried out studies to demonstrate that (1) 25-ANE competes with 25-OH-D3 for the binding site of the latter in hDBP and (2) 3H-25-ANE is capable of covalently labeling the hDBP molecule when exposed to UV light. Calcifediol 73-81 D-box binding PAR bZIP transcription factor Homo sapiens 181-185 1667458-1 1991 We have developed an assay to measure the affinity of serum vitamin D binding protein for 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3, and vitamin D3, using uniform diameter (6.4 microns) polystyrene beads coated with phosphatidylcholine and vitamin D metabolites as the vitamin D donor. Calcifediol 90-110 GC vitamin D binding protein Homo sapiens 60-85 2049072-11 1991 The cytochrome P-450 catalysed 26-hydroxylation of 25-hydroxyvitamin D3, cholesterol and 5 beta-cholestane-3 alpha, 7 alpha-diol at rates of 361, 1090 and 2065 pmol/min per nmol of cytochrome P-450. Calcifediol 51-71 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 4-20 2049072-11 1991 The cytochrome P-450 catalysed 26-hydroxylation of 25-hydroxyvitamin D3, cholesterol and 5 beta-cholestane-3 alpha, 7 alpha-diol at rates of 361, 1090 and 2065 pmol/min per nmol of cytochrome P-450. Calcifediol 51-71 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 181-197 2049072-15 1991 These results indicate that similar species of cytochrome P-450 catalyse 26-hydroxylation of 25-hydroxyvitamin D3 and C27 steroids in liver and kidney mitochondria. Calcifediol 93-113 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 47-63 2049072-16 1991 The results with the monoclonal antibody together with the finding that cholesterol competitively inhibits the 26-hydroxylation of 25-hydroxyvitamin D3 further indicate that 26-hydroxylation of 25-hydroxyvitamin D3 and cholesterol is catalysed by the same species of cytochrome P-450 in each tissue. Calcifediol 131-151 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 267-283 2049072-16 1991 The results with the monoclonal antibody together with the finding that cholesterol competitively inhibits the 26-hydroxylation of 25-hydroxyvitamin D3 further indicate that 26-hydroxylation of 25-hydroxyvitamin D3 and cholesterol is catalysed by the same species of cytochrome P-450 in each tissue. Calcifediol 194-214 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 267-283 2026586-0 1991 Isolation and characterization of a cytochrome P-450 from rat kidney mitochondria that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3. Calcifediol 121-141 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 36-52 2026586-1 1991 A cytochrome P-450 that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3 (P-450cc24: P-450cholecalciferol24) was purified to electrophoretic homogeneity from the kidney mitochondria of female rats treated with vitamin D3 (Ohyama, Y., Hayashi, S., and Okuda, K. (1989) FEBS Lett. Calcifediol 58-78 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 2-18 2026586-1 1991 A cytochrome P-450 that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3 (P-450cc24: P-450cholecalciferol24) was purified to electrophoretic homogeneity from the kidney mitochondria of female rats treated with vitamin D3 (Ohyama, Y., Hayashi, S., and Okuda, K. (1989) FEBS Lett. Calcifediol 58-78 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 80-89 1835718-3 1991 Opposite results were observed when the cells were incubated with vitamin D3 metabolites: the stimulation of fibronectin release was specific for 1,25-dihydroxyvitamin D3 relative to other vitamin D3 metabolites (1,25-dihydroxyvitamin D3 greater than 25-hydroxyvitamin D3 greater than 24,25-dihydroxyvitamin D3). Calcifediol 251-271 fibronectin 1 Homo sapiens 109-120 2029522-2 1991 Competitive binding assays of 25-OH-D3 and 25-ANE with rat serum demonstrated that 25-ANE competes for the 25-OH-D3 binding site in rat serum vitamin D binding protein (rDBP). Calcifediol 107-115 GC, vitamin D binding protein Rattus norvegicus 142-167 2029522-2 1991 Competitive binding assays of 25-OH-D3 and 25-ANE with rat serum demonstrated that 25-ANE competes for the 25-OH-D3 binding site in rat serum vitamin D binding protein (rDBP). Calcifediol 107-115 D-box binding PAR bZIP transcription factor Rattus norvegicus 169-173 2029522-5 1991 These results provide strong evidence for the covalent labeling of the 25-OH-D3 binding site in rDBP by 3H-25-ANE. Calcifediol 71-79 D-box binding PAR bZIP transcription factor Rattus norvegicus 96-100 2029522-0 1991 Synthesis of 25-hydroxyvitamin D3 3 beta-3"-[N-(4-azido-2-nitrophenyl)amino]propyl ether, a second-generation photoaffinity analogue of 25-hydroxyvitamin D3: photoaffinity labeling of rat serum vitamin D binding protein. Calcifediol 13-33 GC, vitamin D binding protein Rattus norvegicus 194-219 2029522-2 1991 Competitive binding assays of 25-OH-D3 and 25-ANE with rat serum demonstrated that 25-ANE competes for the 25-OH-D3 binding site in rat serum vitamin D binding protein (rDBP). Calcifediol 30-38 D-box binding PAR bZIP transcription factor Rattus norvegicus 169-173 2226314-4 1990 25-hydroxycholecalciferol (25(OH)D3) reproduced the effect of 1,25(OH)2D3 on [Ca2+]i, with equal potency and similar responses, whereas 24,25-dihydroxycholecalciferol, 1 alpha-hydroxycholecalciferol, and 22 oxa-1,25(OH)2D3 were not effective. Calcifediol 0-25 carbonic anhydrase 2 Rattus norvegicus 78-81 2173481-4 1990 The Bmax of plasma DBP for 25-OHD3 was 6.77 +/- 0.45 microM for PVDRI piglets and 7.30 +/- 0.41 microM for control piglets and showed no differences between the two groups. Calcifediol 27-34 D-box binding PAR bZIP transcription factor Homo sapiens 19-22 2229313-6 1990 A negative correlation existed between PTH and 25-hydroxy-cholecalciferol (r = -0.49; P less than 0.05), the main circulating metabolite of vitamin D. Calcifediol 47-73 parathyroid hormone Homo sapiens 39-42 2226314-4 1990 25-hydroxycholecalciferol (25(OH)D3) reproduced the effect of 1,25(OH)2D3 on [Ca2+]i, with equal potency and similar responses, whereas 24,25-dihydroxycholecalciferol, 1 alpha-hydroxycholecalciferol, and 22 oxa-1,25(OH)2D3 were not effective. Calcifediol 27-35 carbonic anhydrase 2 Rattus norvegicus 78-81 2078829-0 1990 Species differences in the binding kinetics of 25-hydroxyvitamin D3 to vitamin D binding protein. Calcifediol 47-67 GC vitamin D binding protein Homo sapiens 71-96 2078433-0 1990 25-Hydroxycholecalciferol and insulin-like growth factor I are determinants of serum concentration of osteocalcin in elderly subjects with and without spinal fractures. Calcifediol 0-25 bone gamma-carboxyglutamate protein Homo sapiens 102-113 2394211-0 1990 Interaction of the vitamin D-binding protein (group-specific component) and its ligand 25-hydroxy-vitamin D3: binding differences of the various genetic types disclosed by isoelectric focusing. Calcifediol 87-108 GC vitamin D binding protein Homo sapiens 19-44 2328005-3 1990 The present report demonstrates that different forms of cytochrome P-450 are involved in 1 alpha-, 24- and 26-hydroxylations of 25-hydroxyvitamin D3 and provides a basis for further purification and characterization of these enzymes. Calcifediol 128-148 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 56-72 2078433-4 1990 Significant correlation was found between osteocalcin and 25-OH-D3 level, as well as between osteocalcin and IGFI. Calcifediol 58-66 bone gamma-carboxyglutamate protein Homo sapiens 42-53 2078433-5 1990 The results show that IGFI and 25-OH-D3 are important determinants for serum concentration of osteocalcin in elderly subjects with and without spinal fractures. Calcifediol 31-39 bone gamma-carboxyglutamate protein Homo sapiens 94-105 34534339-4 2021 Uptake of 25(OH)D3 led to a significant upregulation of vitamin D metabolizing CYP24A1 mRNA levels, indicating that kidney organoids possess a feedback mechanism to control active vitamin D (1,25(OH)2D3) levels. Calcifediol 10-18 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 79-86 33767430-8 2021 While treating macrophages with 25-hydroxyvitamin D3 does not increase CRIg expression, added together with the toll like receptor 2 agonist, triacylated lipopeptide, Pam3CSK4, which promotes the conversion of 25-hydroxyvitamin D3 to 1,25D, leads to an increase in CRIg expression and increases in CYP27B1 mRNA. Calcifediol 210-230 toll like receptor 2 Homo sapiens 112-132 34637962-4 2022 Herein, for the first time, we propose a novel label-free impedimetric immunosensor for the detection and quantification of 25-hydroxyvitamin D3 (25(OH)D3) biomarker in serum samples based on the Au nanoparticles functionalized GCN-beta-CD nanocomposite. Calcifediol 124-144 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 232-239 34637962-4 2022 Herein, for the first time, we propose a novel label-free impedimetric immunosensor for the detection and quantification of 25-hydroxyvitamin D3 (25(OH)D3) biomarker in serum samples based on the Au nanoparticles functionalized GCN-beta-CD nanocomposite. Calcifediol 146-154 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 232-239 1965220-0 1990 25-Hydroxycholecalciferol and 1,25-dihydroxycholecalciferol enhances phosphaturia in rats with reduced renal mass: evidence for a PTH-dependent mechanism. Calcifediol 0-25 parathyroid hormone Rattus norvegicus 130-133 33775819-10 2021 Finally, energy intake influenced the vitamin D 25-hydroxylase through the 25-hydroxyvitamin D3/vitamin D3 ratio, which regulates the synthesis of the circulating form. Calcifediol 75-95 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 38-62 34959778-1 2021 Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Calcifediol 86-97 vitamin D receptor Homo sapiens 145-163 34959778-2 2021 Considering that itself may function as a VDR ligand, although with a lower affinity, respect than the active form of vitamin D, we have assumed that 25(OH)D3 by binding the VDR could have a vitamin"s D3 activity such as activating non-genomic pathways, and in particular we selected mesenchymal stem cells derived from human adipose tissue (hADMSCs) for the in vitro assessment of the intracellular Ca2+ mobilization in response to 25(OH)D3. Calcifediol 150-158 vitamin D receptor Homo sapiens 42-45 34959778-1 2021 Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Calcifediol 86-97 vitamin D receptor Homo sapiens 165-168 34959778-2 2021 Considering that itself may function as a VDR ligand, although with a lower affinity, respect than the active form of vitamin D, we have assumed that 25(OH)D3 by binding the VDR could have a vitamin"s D3 activity such as activating non-genomic pathways, and in particular we selected mesenchymal stem cells derived from human adipose tissue (hADMSCs) for the in vitro assessment of the intracellular Ca2+ mobilization in response to 25(OH)D3. Calcifediol 150-158 vitamin D receptor Homo sapiens 174-177 34959778-1 2021 Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Calcifediol 99-107 vitamin D receptor Homo sapiens 145-163 34959778-1 2021 Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Calcifediol 99-107 vitamin D receptor Homo sapiens 165-168 34836187-6 2021 As a secondary endpoint, we assessed the correlation between serum 25(OH)D3 levels and pro-inflammatory cytokine interleukin-6 (IL-6) in patients with extremely low serum 25(OH)D3 levels (<1 ng/mL) and in a subset supplemented with 1alpha,25(OH)2D3. Calcifediol 67-75 interleukin 6 Homo sapiens 113-126 34836187-6 2021 As a secondary endpoint, we assessed the correlation between serum 25(OH)D3 levels and pro-inflammatory cytokine interleukin-6 (IL-6) in patients with extremely low serum 25(OH)D3 levels (<1 ng/mL) and in a subset supplemented with 1alpha,25(OH)2D3. Calcifediol 67-75 interleukin 6 Homo sapiens 128-132 34727644-8 2022 Supplemental 25(OH)D3 improved water holding capacity and reduced drip loss of pork meat, increased serum 25(OH)D3 level, produced higher interleukin-1 and lower interleukin-6 concentrations in blood circulation, downregulated MSTN and upregulated MYOD and MYF5 gene expressions (p<0.05). Calcifediol 13-21 interleukin-6 Sus scrofa 162-175 34461573-3 2021 The aim of this study was to investigate the effects of vitamin D (25-hydroxy cholecalciferol (D3)) and estradiol on PAD2 gene expression level and its catalytic activity in rat C6 glioma cells. Calcifediol 67-93 peptidyl arginine deiminase 2 Homo sapiens 117-121 34448353-9 2021 CONCLUSION: Our findings suggest that diet-induced elevation of circulating cholesterol, glucose and insulin reduces serum 25(OH)D3 level through suppressing hepatic Cyp2r1 expression. Calcifediol 123-131 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 166-172 34717752-13 2021 Our data showed that leptin inhibited CMA activity of rBMMSCs by activating PI3K/AKT signal pathway; the ability of leptin to enhance 25(OH)D3 promoted osteoblast differentiation of rBMMSCs was weakened by the PI3K/AKT signal pathway inhibitor. Calcifediol 134-142 leptin Rattus norvegicus 21-27 34717752-13 2021 Our data showed that leptin inhibited CMA activity of rBMMSCs by activating PI3K/AKT signal pathway; the ability of leptin to enhance 25(OH)D3 promoted osteoblast differentiation of rBMMSCs was weakened by the PI3K/AKT signal pathway inhibitor. Calcifediol 134-142 leptin Rattus norvegicus 116-122 34727644-8 2022 Supplemental 25(OH)D3 improved water holding capacity and reduced drip loss of pork meat, increased serum 25(OH)D3 level, produced higher interleukin-1 and lower interleukin-6 concentrations in blood circulation, downregulated MSTN and upregulated MYOD and MYF5 gene expressions (p<0.05). Calcifediol 13-21 myostatin Sus scrofa 227-231 34717752-13 2021 Our data showed that leptin inhibited CMA activity of rBMMSCs by activating PI3K/AKT signal pathway; the ability of leptin to enhance 25(OH)D3 promoted osteoblast differentiation of rBMMSCs was weakened by the PI3K/AKT signal pathway inhibitor. Calcifediol 134-142 AKT serine/threonine kinase 1 Rattus norvegicus 215-218 34727644-8 2022 Supplemental 25(OH)D3 improved water holding capacity and reduced drip loss of pork meat, increased serum 25(OH)D3 level, produced higher interleukin-1 and lower interleukin-6 concentrations in blood circulation, downregulated MSTN and upregulated MYOD and MYF5 gene expressions (p<0.05). Calcifediol 13-21 myogenic differentiation 1 Sus scrofa 248-252 34727644-8 2022 Supplemental 25(OH)D3 improved water holding capacity and reduced drip loss of pork meat, increased serum 25(OH)D3 level, produced higher interleukin-1 and lower interleukin-6 concentrations in blood circulation, downregulated MSTN and upregulated MYOD and MYF5 gene expressions (p<0.05). Calcifediol 13-21 myogenic factor 5 Sus scrofa 257-261 34362362-10 2021 The RANKL:OPG ratio was downregulated by all concentrations (10 ng/ml, 40 ng/ml and 60 ng/ml) of 25(OH)D3 (mean = 0.96 +- 0.68, mean = 1.61 +- 0.66 and mean = 1.86 +- 0.78, respectively) in comparison to the control (mean 2.58 +- 1.16) (p < 0.05). Calcifediol 97-105 TNF superfamily member 11 Homo sapiens 4-9 34694941-9 2021 The combination of plasma 25OHD3 and total plasma cholesterol/high-density lipoprotein cholesterol was subsequently broken into low-risk, moderate-risk and high-risk groups; as the risk increased, the VDR quantity decreased (p = 0.04). Calcifediol 26-32 vitamin D receptor Homo sapiens 201-204 34679990-1 2021 The present study aimed to determine the effect of different times of supplementation of 25-hydroxycholecalciferol (25(OH)D3) in broiler chickens on the performance, carcass and cuts yield, bone resistance, plasma concentration of 25(OH)D3, and expression of the mTOR gene. Calcifediol 89-114 mechanistic target of rapamycin Gallus gallus 263-267 34679990-1 2021 The present study aimed to determine the effect of different times of supplementation of 25-hydroxycholecalciferol (25(OH)D3) in broiler chickens on the performance, carcass and cuts yield, bone resistance, plasma concentration of 25(OH)D3, and expression of the mTOR gene. Calcifediol 116-124 mechanistic target of rapamycin Gallus gallus 263-267 34679990-6 2021 The results also showed a positive linear correlation between mTOR expression and 25(OH)D3 plasma levels (r = 0.593; p < 0.05). Calcifediol 82-90 mechanistic target of rapamycin Gallus gallus 62-66 34620220-8 2021 Specifically, dietary 25-OH-D3 addition decreased abundance of B- and T-cells in blood, and the expression of inflammatory cytokines, especially TNF-alpha, in both the ileum and bone marrow, but did not alter the diversity and population or composition of major bacterial phyla. Calcifediol 22-30 tumor necrosis factor Homo sapiens 145-154 34620220-9 2021 With regard to bone remodeling, dietary 25-OH-D3 supplementation was linked to a decrease in serum C-terminal cross-linked telopeptide of type I collagen reflecting bone resorption and a concomitant decrement in osteoclast-specific marker genes expression (e.g. cathepsin K), whereas it did not apparently change serum bone formation markers during HS. Calcifediol 40-48 cathepsin K Homo sapiens 262-273 34593422-0 2021 Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D3 in LNCaP Cells. Calcifediol 76-96 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 14-21 34593422-0 2021 Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D3 in LNCaP Cells. Calcifediol 76-96 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 26-31 34593422-2 2021 The present study aimed to evaluate 25-hydroxyvitamin D3 (25(OH)D3) as a potential endocrine factor regulating proliferation and vitamin D receptor expression in LNCaP prostate cancer cells. Calcifediol 36-56 vitamin D receptor Homo sapiens 129-147 34593422-2 2021 The present study aimed to evaluate 25-hydroxyvitamin D3 (25(OH)D3) as a potential endocrine factor regulating proliferation and vitamin D receptor expression in LNCaP prostate cancer cells. Calcifediol 58-66 vitamin D receptor Homo sapiens 129-147 34593422-6 2021 The inhibitory effect of 25(OH)D3 on cell proliferation was potentiated after inhibition of CYP17B1 and CYP24 by genistein, preventing further metabolism of 25(OH)D3 to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3). Calcifediol 25-33 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 104-109 34593422-8 2021 CONCLUSION: 25(OH)D3 has a direct inhibitory effect on cell proliferation, which is enhanced and accelerated when the metabolism of 25(OH)D3 to 1,25(OH)2D3 and 24,25(OH)2D3 was inhibited by the CYP17B1 and CYP24 inhibitor genistein. Calcifediol 12-20 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 206-211 34593422-8 2021 CONCLUSION: 25(OH)D3 has a direct inhibitory effect on cell proliferation, which is enhanced and accelerated when the metabolism of 25(OH)D3 to 1,25(OH)2D3 and 24,25(OH)2D3 was inhibited by the CYP17B1 and CYP24 inhibitor genistein. Calcifediol 132-140 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 206-211 34626363-7 2022 Extended-release calcifediol increases circulating 25-OH vitamin D levels in a dose-dependent manner and lowers parathyroid hormone levels by a clinically relevant extent, comparable to what can be achieved by administering active vitamin D analogues, though with a lower risk of hypercalcaemia and hyperphosphataemia. Calcifediol 17-28 parathyroid hormone Homo sapiens 112-131 34588362-2 2021 There is limited evidence regarding the association between insulin response in diabetes in Asian populations and serum 25-hydroxyvitamin D3 (25(OH)D3) insufficiency. Calcifediol 120-140 insulin Homo sapiens 60-67 34588362-2 2021 There is limited evidence regarding the association between insulin response in diabetes in Asian populations and serum 25-hydroxyvitamin D3 (25(OH)D3) insufficiency. Calcifediol 142-150 insulin Homo sapiens 60-67 34621269-4 2021 However, vitamin D binding protein (DBP) strongly binds both 1,25(OH)2D3 and the precursor 25(OH)D3, leaving only a minor fraction of vitamin D in the free, bioavailable form. Calcifediol 91-99 GC vitamin D binding protein Homo sapiens 9-34 34621269-4 2021 However, vitamin D binding protein (DBP) strongly binds both 1,25(OH)2D3 and the precursor 25(OH)D3, leaving only a minor fraction of vitamin D in the free, bioavailable form. Calcifediol 91-99 D-box binding PAR bZIP transcription factor Homo sapiens 36-39 34621269-6 2021 In the present study, we show that pro-inflammatory, monocyte-derived M1 macrophages express very high levels of the 25(OH)D-1alpha-hydroxylase CYP27B1 that enables them to convert 25(OH)D3 into 1,25(OH)2D3 even in the presence of physiological concentrations of DBP. Calcifediol 181-189 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 117-143 34621269-6 2021 In the present study, we show that pro-inflammatory, monocyte-derived M1 macrophages express very high levels of the 25(OH)D-1alpha-hydroxylase CYP27B1 that enables them to convert 25(OH)D3 into 1,25(OH)2D3 even in the presence of physiological concentrations of DBP. Calcifediol 181-189 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 144-151 34458299-7 2021 Neither CD4+ nor CD8+ T cells responded to the circulating vitamin D precursor, 25-hydroxyvitamin D3 for induction of SERPINA1, suggesting that local generation of 1,25(OH)2D3 is required. Calcifediol 80-100 serpin family A member 1 Homo sapiens 118-126 34458299-12 2021 AAT levels in the airways of children with asthma and controls correlated with circulating 25(OH)D3. Calcifediol 91-99 serpin family A member 1 Homo sapiens 0-3 34362362-10 2021 The RANKL:OPG ratio was downregulated by all concentrations (10 ng/ml, 40 ng/ml and 60 ng/ml) of 25(OH)D3 (mean = 0.96 +- 0.68, mean = 1.61 +- 0.66 and mean = 1.86 +- 0.78, respectively) in comparison to the control (mean 2.58 +- 1.16) (p < 0.05). Calcifediol 97-105 TNF receptor superfamily member 11b Homo sapiens 10-13 34362362-11 2021 CYP2R1 gene expression was statistically modulated by the different 25(OH)D3 concentrations applied (p = 0.008). Calcifediol 68-76 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 0-6 34298790-3 2021 GBM incidence has been negatively correlated with the serum levels of 25-hydroxy-vitamin D3, while the low pH within tumors has been shown to promote the expression of the vitamin D3-degrading enzyme 24-hydroxylase, encoded by the CYP24A1 gene. Calcifediol 70-91 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 231-238 34370118-0 2022 Vitamin D Receptor Gene Polymorphisms and Risk of Knee Osteoarthritis: Possible Correlations with TNF-alpha, Macrophage Migration Inhibitory Factor, and 25-Hydroxycholecalciferol Status. Calcifediol 153-178 vitamin D receptor Homo sapiens 0-18 34272637-1 2021 CYP27B1, a cytochrome P450-containing hydroxylase enzyme, converts vitamin D precursor calcidiol (25-hydroxycholecalciferol) to its active form calcitriol (1alpha,25(OH)2D3). Calcifediol 87-96 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-7 34272637-1 2021 CYP27B1, a cytochrome P450-containing hydroxylase enzyme, converts vitamin D precursor calcidiol (25-hydroxycholecalciferol) to its active form calcitriol (1alpha,25(OH)2D3). Calcifediol 98-123 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-7 34337279-1 2021 Context: CYP24A1 encodes 24-hydroxylase, which converts 25(OH)D3 and 1,25(OH)2D3 to inactive metabolites. Calcifediol 56-64 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 9-16 34249156-9 2021 Combined intake estimates of calcidiol from the NF and calcidiol and vitamin D from the diet were below the tolerable upper intake level (UL) for vitamin D for subjects above 11 years of age. Calcifediol 29-38 neurofascin Homo sapiens 48-50 34337279-1 2021 Context: CYP24A1 encodes 24-hydroxylase, which converts 25(OH)D3 and 1,25(OH)2D3 to inactive metabolites. Calcifediol 56-64 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 25-39 34320495-6 2021 The serum was evaluated by liquid chromatography tandem-mass spectrometry for the ratio of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3, (25-OH-D3:24,25-(OH)2D3), an elevation pathognomonic for the loss of function of the CYP24A1 enzyme. Calcifediol 91-111 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 227-234 34062444-6 2021 Dietary 25-OH-D3 increased the villus height in duodenum and jejunum (P(25-OH-D3) < 0.05), decreased Chao 1 and ACE indexes in cecum (P(25-OH-D3) < 0.05), and it also up-regulated the mRNA expression of claudin-1, mucin-1 and mucin-2 (P(25-OH-D3) < 0.05). Calcifediol 8-16 angiotensin I converting enzyme Gallus gallus 112-115 34062444-6 2021 Dietary 25-OH-D3 increased the villus height in duodenum and jejunum (P(25-OH-D3) < 0.05), decreased Chao 1 and ACE indexes in cecum (P(25-OH-D3) < 0.05), and it also up-regulated the mRNA expression of claudin-1, mucin-1 and mucin-2 (P(25-OH-D3) < 0.05). Calcifediol 8-16 claudin 1 Gallus gallus 203-212 34062444-6 2021 Dietary 25-OH-D3 increased the villus height in duodenum and jejunum (P(25-OH-D3) < 0.05), decreased Chao 1 and ACE indexes in cecum (P(25-OH-D3) < 0.05), and it also up-regulated the mRNA expression of claudin-1, mucin-1 and mucin-2 (P(25-OH-D3) < 0.05). Calcifediol 8-16 mucin 2, oligomeric mucus/gel-forming Gallus gallus 226-233 34062444-7 2021 Layers treated with 25-OH-D3 led to an enhanced antioxidative enzyme activity of CAT (P(25-OH-D3) < 0.05). Calcifediol 20-28 catalase Gallus gallus 81-84 34062444-7 2021 Layers treated with 25-OH-D3 led to an enhanced antioxidative enzyme activity of CAT (P(25-OH-D3) < 0.05). Calcifediol 88-96 catalase Gallus gallus 81-84 34200930-4 2021 Supplemental 25-OH-D3 repressed IL-1beta secretion and respiratory burst of both cells mostly in R-hens, but promoted monocyte phagocytosis, chemotaxis, and bacterial killing activity in Ad-hens in accompany with relieved hyperglycemia, hyperlipidemia, and systemic inflammation. Calcifediol 13-21 interleukin 1, beta Gallus gallus 32-40 34071156-6 2021 The yield of milk (0.05 < p < 0.10), energy-corrected milk (p < 0.05), 3.5% fat-corrected milk (p < 0.05), and milk protein (p < 0.05) were significantly higher in 25-hydroxyvitamin D3-treated groups within 3 weeks of lactation than in vitamin D3-treated cows. Calcifediol 164-184 casein kappa Bos taurus 111-123 34071156-8 2021 Feeding 25-hydroxyvitamin D3 also showed a lower concentration of malondialdehyde (p < 0.05), interleukin 6 (p < 0.05), and tumor necrosis factor-alpha (TNF-alpha) (p < 0.05), as well as a higher concentration of alkaline phosphatase (p < 0.05), total antioxidant capacity (p < 0.05), and immunoglobulin G (p < 0.05) than vitamin D3. Calcifediol 8-28 interleukin 6 Bos taurus 94-107 34071156-8 2021 Feeding 25-hydroxyvitamin D3 also showed a lower concentration of malondialdehyde (p < 0.05), interleukin 6 (p < 0.05), and tumor necrosis factor-alpha (TNF-alpha) (p < 0.05), as well as a higher concentration of alkaline phosphatase (p < 0.05), total antioxidant capacity (p < 0.05), and immunoglobulin G (p < 0.05) than vitamin D3. Calcifediol 8-28 tumor necrosis factor Bos taurus 124-151 34071156-8 2021 Feeding 25-hydroxyvitamin D3 also showed a lower concentration of malondialdehyde (p < 0.05), interleukin 6 (p < 0.05), and tumor necrosis factor-alpha (TNF-alpha) (p < 0.05), as well as a higher concentration of alkaline phosphatase (p < 0.05), total antioxidant capacity (p < 0.05), and immunoglobulin G (p < 0.05) than vitamin D3. Calcifediol 8-28 tumor necrosis factor Bos taurus 153-162 34064175-11 2021 Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity >= 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate >= 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure <= 60 mm Hg, and age >= 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. Calcifediol 22-33 C-reactive protein Homo sapiens 419-437 34320495-6 2021 The serum was evaluated by liquid chromatography tandem-mass spectrometry for the ratio of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3, (25-OH-D3:24,25-(OH)2D3), an elevation pathognomonic for the loss of function of the CYP24A1 enzyme. Calcifediol 143-151 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 227-234 34320495-15 2021 The 25-OH-D3:24,25-(OH)2D3 ratio is an excellent tool for screening for biallelic pathogenic variants in CYP24A1. Calcifediol 4-12 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 105-112 35495908-8 2022 In addition, maternal liver VDR, FAT, and SR-BI increased significantly in the 25-OH-D3 group, but no changes were found in the placenta. Calcifediol 79-87 vitamin D receptor Rattus norvegicus 28-31 35609515-3 2022 OBJECTIVE: Our aim was to determine the relationship between plasma 25-hydroxyvitamin D3 (25(OH)D3) levels, the levels of the ligand of the vitamin D receptor (VDR) heterodimerization partner as well as the retinoid X receptor (RXR) and the active vitamin A5 derivative 9-cis-13,14-dihydroretinoic acid (9CDHRA) and AD severity. Calcifediol 90-98 vitamin D receptor Homo sapiens 140-158 35609515-3 2022 OBJECTIVE: Our aim was to determine the relationship between plasma 25-hydroxyvitamin D3 (25(OH)D3) levels, the levels of the ligand of the vitamin D receptor (VDR) heterodimerization partner as well as the retinoid X receptor (RXR) and the active vitamin A5 derivative 9-cis-13,14-dihydroretinoic acid (9CDHRA) and AD severity. Calcifediol 90-98 retinoid X receptor alpha Homo sapiens 207-226 35609515-3 2022 OBJECTIVE: Our aim was to determine the relationship between plasma 25-hydroxyvitamin D3 (25(OH)D3) levels, the levels of the ligand of the vitamin D receptor (VDR) heterodimerization partner as well as the retinoid X receptor (RXR) and the active vitamin A5 derivative 9-cis-13,14-dihydroretinoic acid (9CDHRA) and AD severity. Calcifediol 90-98 retinoid X receptor alpha Homo sapiens 228-231 35609515-5 2022 In our study, the frequently measured VDR ligand precursor 25(OH)D3 in addition to the VDR-ligand 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 9CDHRA displayed no different levels when compared with the plasma of AD patients and healthy volunteers. Calcifediol 59-67 vitamin D receptor Homo sapiens 38-41 35582969-11 2022 In such muscles, maternal VDD induced a compensatory increase in the content of calcitriol (two-fold; P < 0.05) and CYP27B1 (58%; P < 0.05), a metabolizing enzyme that converts calcidiol to calcitriol. Calcifediol 177-186 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 116-123 35507839-5 2022 Interaction (P<0.05) occurred with the highest parathyroid hormone (PTH) in laying hens that received dietary concentration of Ca (3.5%) with 25OHD3 (50 microg/kg), and Ca (4.0%) with 25OHD3 (50 microg/kg). Calcifediol 184-190 parathyroid hormone Gallus gallus 68-71 34515192-6 2021 RESULTS: The concentration of 25OHD3 in the serum of obese mice induced by HFD was significantly reduced, and these mice showed liver hypertrophy accompanied by abnormal liver injury, testicular hypertrophy, low testosterone levels, high leptin levels, and low sperm motility. Calcifediol 30-36 leptin Mus musculus 238-244 35351538-1 2022 In vitro studies indicate that 25-hydroxyvitamin D3 (25(OH)D3) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibits the synthesis of parathyroid hormone (PTH). Calcifediol 31-51 parathyroid hormone Homo sapiens 132-151 35351538-1 2022 In vitro studies indicate that 25-hydroxyvitamin D3 (25(OH)D3) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibits the synthesis of parathyroid hormone (PTH). Calcifediol 31-51 parathyroid hormone Homo sapiens 153-156 35351538-1 2022 In vitro studies indicate that 25-hydroxyvitamin D3 (25(OH)D3) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibits the synthesis of parathyroid hormone (PTH). Calcifediol 53-61 parathyroid hormone Homo sapiens 132-151 35351538-1 2022 In vitro studies indicate that 25-hydroxyvitamin D3 (25(OH)D3) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibits the synthesis of parathyroid hormone (PTH). Calcifediol 53-61 parathyroid hormone Homo sapiens 153-156 35582958-2 2022 The bioavailability of 25(OH)D3 is regulated by its main plasma carrier, vitamin D-binding protein (DBP). Calcifediol 23-31 GC vitamin D binding protein Homo sapiens 73-98 35582958-2 2022 The bioavailability of 25(OH)D3 is regulated by its main plasma carrier, vitamin D-binding protein (DBP). Calcifediol 23-31 D-box binding PAR bZIP transcription factor Homo sapiens 100-103 35582958-3 2022 Free 25(OH)D3 can be estimated by also measuring DBP concentration. Calcifediol 5-13 D-box binding PAR bZIP transcription factor Homo sapiens 49-52 35073416-0 2022 Physiological levels of 25-hydroxyvitamin D3 induce a suppressive CD4+ T cell phenotype not reflected in the epigenetic landscape. Calcifediol 24-44 CD4 molecule Homo sapiens 66-69 35073416-2 2022 Here we analyzed the influence of its precursor 25-hydroxyvitamin D3 (25(OH)D3 ) on the differentiation of human CD4+ T cells applying physiological concentrations in vitro. Calcifediol 48-68 CD4 molecule Homo sapiens 113-116 35495908-8 2022 In addition, maternal liver VDR, FAT, and SR-BI increased significantly in the 25-OH-D3 group, but no changes were found in the placenta. Calcifediol 79-87 CD36 molecule Rattus norvegicus 33-36 35495908-8 2022 In addition, maternal liver VDR, FAT, and SR-BI increased significantly in the 25-OH-D3 group, but no changes were found in the placenta. Calcifediol 79-87 scavenger receptor class B, member 1 Rattus norvegicus 42-47 35495908-9 2022 Interestingly, 25-OH-D3 decreased GAD67 expression in the fetal brain and it also tended to decrease VDR (P = 0.086). Calcifediol 15-23 glutamate decarboxylase 1 Rattus norvegicus 34-39 35495908-9 2022 Interestingly, 25-OH-D3 decreased GAD67 expression in the fetal brain and it also tended to decrease VDR (P = 0.086). Calcifediol 15-23 vitamin D receptor Rattus norvegicus 101-104 35495908-12 2022 The effects of 25-OH-D3 on the expression of VDR and GAD67 in fetal brain require further investigation. Calcifediol 15-23 vitamin D receptor Rattus norvegicus 45-48 35495908-12 2022 The effects of 25-OH-D3 on the expression of VDR and GAD67 in fetal brain require further investigation. Calcifediol 15-23 glutamate decarboxylase 1 Rattus norvegicus 53-58 35063189-8 2022 Calcidiol supplementation is credibly a promising adjuvant of combination anti-retroviral therapy (cART) for the treatment of HIV by increasing CD4 T-cells and lowering the viral load. Calcifediol 0-9 CD4 molecule Homo sapiens 144-147 35444957-9 2022 Moreover, calcitriol and calcifediol upregulated CAMP expression by nearly 5-fold and 3-fold, respectively. Calcifediol 25-36 cathelicidin antimicrobial peptide Homo sapiens 49-53 35115578-10 2022 The dimensions of response to the exercises observed through the changes in the concentration of 25(OH)D3, PTH, NEFA and glycerol were associated with the significant increases of IL-6 level. Calcifediol 97-105 interleukin 6 Homo sapiens 180-184 35058935-7 2021 ATG increased gene expression of CYP27B1, the enzyme responsible for the conversion of 25-hydroxyvitamin D3 into 1,25-dihydroxyvitamin D3, which was accompanied by higher 1,25-dihydroxyvitamin D3 levels in ATG-treated DC culture supernatants. Calcifediol 87-107 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 33-40 2560171-1 1989 Previous work from this laboratory has demonstrated that 25(OH) vitamin D3 [25(OH)D3] acutely suppresses the phosphaturic action of parathyroid hormone (PTH) and interferes with the PTH-induced activation of adenylate cyclase (AC). Calcifediol 76-84 parathyroid hormone Rattus norvegicus 132-151 2560171-3 1989 We have examined whether calmodulin antagonists affect the renal action of 25(OH)D3. Calcifediol 75-83 calmodulin 1 Rattus norvegicus 25-35 2560171-10 1989 These results suggest that the antiphosphaturic effect of 25(OH)D3 acting via the AC/cAMP system may be calmodulin dependent. Calcifediol 58-66 calmodulin 1 Rattus norvegicus 104-114 3281665-9 1988 A fraction solubilized from mitochondria by cholate became catalytically active in 1 alpha-hydroxylation of 25-hydroxyvitamin D3 after addition of ferredoxin and ferredoxin reductase. Calcifediol 108-128 NADPH:adrenodoxin oxidoreductase, mitochondrial Cavia porcellus 147-182 2489241-2 1989 D (25/OH/D = 6.8 +/- 3.0 ng/ml) during UVB stimulated skin synthesis of Vit.D the increment of Vit.D and 25-hydroxycholecalciferol (25/OH/D) depends on the starting values of Vit.D and 25/OH/D and is accompanied by significant increment of calciuria (delta mean UCa). Calcifediol 105-130 vitrin Homo sapiens 72-75 2505765-3 1989 Competition experiments showed that palmitic acid hardly competes with 25-hydroxycholecalciferol for binding to DBP. Calcifediol 71-96 D-box binding PAR bZIP transcription factor Bos taurus 112-115 2505765-5 1989 The great difference in competition of palmitic and arachidonic acids with 25-hydroxycholecalciferol may be related to changes in DBP conformation promoted by the binding of different ligands. Calcifediol 75-100 D-box binding PAR bZIP transcription factor Bos taurus 130-133 2910852-5 1989 The 25-hydroxyvitamin D3 and 1 alpha,25-dihydroxyvitamin D3 holo-sterol forms of hDBP bound actin in a manner indistinguishable from the apo-sterol hDBP. Calcifediol 4-24 D-box binding PAR bZIP transcription factor Homo sapiens 81-85 3364976-14 1988 A partially purified preparation of bovine proximal tubule mitochondrial cytochrome P-450, with purified renal ferredoxin, ferredoxin reductase, and NADPH, expressed both 1 alpha- and 24-hydroxylase activities toward 25-OH D3. Calcifediol 217-225 ferredoxin reductase Bos taurus 123-143 2488382-7 1989 Mass transfer (MT) of 25-OHD3 and DBP were respectively -10.4 +/- 8.3 nmol/24 h and -1.46 +/- 0.46 0.46 mumol/24 h. Peritoneal clearances of 25-OHD3 and DBP were low (0.40 +/- 0.37 mL/min and 0.18 +/- 0.06 mL/min, respectively. Calcifediol 141-148 GC vitamin D binding protein Homo sapiens 34-37 3477543-5 1987 The 1,25-(OH)2D3- and PTH-induced spikes were abolished by the prior addition of EGTA and Ca2+ entry blockers (verapamil, nifedipine, 1 microM) while the responses to 25-(OH)D3, 24,25-(OH)2D3, and PGE2 were unaffected. Calcifediol 167-176 parathyroid hormone Mus musculus 22-25 3693631-1 1987 Parathyroid hormone and 1,25-dihydroxyvitamin D3 had opposite effects on calf renal 25-hydroxyvitamin D3 24-, 23-, and 1 alpha-hydroxylase activities. Calcifediol 84-104 parathyroid hormone Bos taurus 0-19 2833907-9 1987 Furthermore, 1,25-dihydroxyvitamin D3 pretreatment of Hyp mice resulted in a 3.4-fold increase over basal metabolism of both 25-hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. Calcifediol 125-145 phosphate regulating endopeptidase homolog, X-linked Mus musculus 54-57 2833907-10 1987 These results demonstrate that (i) kidneys from normal and Hyp mice possess basal and 1,25-dihydroxyvitamin D3 inducible enzyme system(s) in the mitochondrial fraction, which catalyze the side-chain oxidation of 25-hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3, and (ii) the Hyp mutation appears to perturb the renal metabolism of both substrates only in the basal state. Calcifediol 212-232 phosphate regulating endopeptidase homolog, X-linked Mus musculus 59-62 2833907-10 1987 These results demonstrate that (i) kidneys from normal and Hyp mice possess basal and 1,25-dihydroxyvitamin D3 inducible enzyme system(s) in the mitochondrial fraction, which catalyze the side-chain oxidation of 25-hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3, and (ii) the Hyp mutation appears to perturb the renal metabolism of both substrates only in the basal state. Calcifediol 212-232 phosphate regulating endopeptidase homolog, X-linked Mus musculus 277-280 3152993-2 1988 Studies from our laboratory have demonstrated that Na(+)-dependent phosphate transport is significantly reduced in renal brush border membrane vesicles derived from Hyp mice and that the regulation of the renal mitochondrial enzymes which metabolize 25-hydroxyvitamin D3 (25-OH-D3) is impaired in the mutant strain. Calcifediol 250-270 phosphate regulating endopeptidase homolog, X-linked Mus musculus 165-168 3040297-2 1987 The binding protein for 25-hydroxycholecalciferol synthesized by HuH-7 cells was immunologically similar to vitamin D-binding protein in human serum and had an inter-alpha mobility. Calcifediol 24-49 GC vitamin D binding protein Homo sapiens 108-133 3113918-4 1987 1 X 10(-9) M 1,25-(OH)2D3 increased TRH (10(-9) M)-induced TSH release by 20% (P less than 0.05) but 10(-7) M and 10(-6) M 25-hydroxyvitamin D3 (25-OH D3) had no effect. Calcifediol 123-143 thyrotropin releasing hormone Rattus norvegicus 36-39 3113918-4 1987 1 X 10(-9) M 1,25-(OH)2D3 increased TRH (10(-9) M)-induced TSH release by 20% (P less than 0.05) but 10(-7) M and 10(-6) M 25-hydroxyvitamin D3 (25-OH D3) had no effect. Calcifediol 145-153 thyrotropin releasing hormone Rattus norvegicus 36-39 2821148-6 1987 Parathyroid hormone significantly increased the conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) by renal slices from young but not adult or old animals. Calcifediol 62-82 parathyroid hormone Rattus norvegicus 0-19 3112152-2 1987 Upon exposure to recombinant human interferon-gamma (IFN-gamma) both bone marrow-derived macrophages (BMM) and pulmonary alveolar macrophages (PAM) produced a polar 25-(OH)D3 metabolite which was purified from conditioned media and unequivocally identified as 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) by UV-absorbance spectrophotometry and mass spectrometry. Calcifediol 165-174 interferon gamma Homo sapiens 35-51 3112152-2 1987 Upon exposure to recombinant human interferon-gamma (IFN-gamma) both bone marrow-derived macrophages (BMM) and pulmonary alveolar macrophages (PAM) produced a polar 25-(OH)D3 metabolite which was purified from conditioned media and unequivocally identified as 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) by UV-absorbance spectrophotometry and mass spectrometry. Calcifediol 165-174 interferon gamma Homo sapiens 53-62 3651426-1 1987 3-Deoxy-3-azido-25-hydroxyvitamin D3 was covalently incorporated in the 25-hydroxyvitamin D3 binding site of purified human plasma vitamin D binding protein. Calcifediol 16-36 GC vitamin D binding protein Homo sapiens 131-156 3041108-8 1987 22-Hydroxyvitamin D3 and various vitamin D sterols were bound to vitamin D binding protein in the following order: 25-hydroxyvitamin D3. Calcifediol 115-135 GC vitamin D binding protein Gallus gallus 65-90 3651426-9 1987 When tritiated 3-deoxy-3-azido-25-hydroxyvitamin D3 was incubated with human plasma in the absence and presence of 25-hydroxyvitamin D3, 12% of the azido derivative was reversibly bound to vitamin D binding protein. Calcifediol 31-51 GC vitamin D binding protein Homo sapiens 189-214 3651426-10 1987 After ultraviolet irradiation, four plasma proteins covalently bound the azido label, but vitamin D binding protein was the only protein of the four that was unlabeled in the presence of 25-hydroxyvitamin D3. Calcifediol 187-207 GC vitamin D binding protein Homo sapiens 90-115 3777429-0 1986 Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography. Calcifediol 57-77 GC vitamin D binding protein Homo sapiens 28-53 3026790-8 1987 25-Hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 were effective but somewhat less potent inducers of CaBP, whereas vitamin D3 was without significant effect. Calcifediol 0-20 calcium-binding protein Gallus gallus 103-107 3777429-4 1986 The purified vitamin D-binding protein was fully active in regard to 25-hydroxyvitamin D3 and actin binding capabilities. Calcifediol 69-89 GC vitamin D binding protein Homo sapiens 13-38 3713442-6 1986 Vitamin D sterols, such as 25-hydroxyvitamin D3, 24,25-dihydroxyvitamin D3, and 25,26-dihydroxyvitamin D3, are bound with high affinity by a plasma alpha-globulin - VDBP, also known as group-specific component (Gc). Calcifediol 27-47 GC vitamin D binding protein Homo sapiens 165-169 3768308-3 1986 This analogue, 25-hydroxyvitamin D3 3 beta-[N-(4-azido-2-nitrophenyl)glycinate] (25-OH-D3-ANG), was recognized by the rat DBP and was about 10 times less active than 25-OH-D3 in terms of binding. Calcifediol 81-89 angiogenin Rattus norvegicus 90-93 3768308-3 1986 This analogue, 25-hydroxyvitamin D3 3 beta-[N-(4-azido-2-nitrophenyl)glycinate] (25-OH-D3-ANG), was recognized by the rat DBP and was about 10 times less active than 25-OH-D3 in terms of binding. Calcifediol 81-89 D-box binding PAR bZIP transcription factor Rattus norvegicus 122-125 3768308-4 1986 Incubation of [3H]25-OH-D3 or [3H]25-OH-D3-ANG with rat DBP revealed that both compounds were specifically bound to a protein with a sedimentation coefficient of 4.1 S. Each was displaced with a 500-fold excess of 25-OH-D3. Calcifediol 18-26 D-box binding PAR bZIP transcription factor Rattus norvegicus 56-59 3768308-4 1986 Incubation of [3H]25-OH-D3 or [3H]25-OH-D3-ANG with rat DBP revealed that both compounds were specifically bound to a protein with a sedimentation coefficient of 4.1 S. Each was displaced with a 500-fold excess of 25-OH-D3. Calcifediol 34-42 angiogenin Rattus norvegicus 43-46 3768308-4 1986 Incubation of [3H]25-OH-D3 or [3H]25-OH-D3-ANG with rat DBP revealed that both compounds were specifically bound to a protein with a sedimentation coefficient of 4.1 S. Each was displaced with a 500-fold excess of 25-OH-D3. Calcifediol 34-42 D-box binding PAR bZIP transcription factor Rattus norvegicus 56-59 3768308-4 1986 Incubation of [3H]25-OH-D3 or [3H]25-OH-D3-ANG with rat DBP revealed that both compounds were specifically bound to a protein with a sedimentation coefficient of 4.1 S. Each was displaced with a 500-fold excess of 25-OH-D3. Calcifediol 34-42 angiogenin Rattus norvegicus 43-46 3768308-4 1986 Incubation of [3H]25-OH-D3 or [3H]25-OH-D3-ANG with rat DBP revealed that both compounds were specifically bound to a protein with a sedimentation coefficient of 4.1 S. Each was displaced with a 500-fold excess of 25-OH-D3. Calcifediol 34-42 D-box binding PAR bZIP transcription factor Rattus norvegicus 56-59 3768308-5 1986 When [3H]25-OH-D3-ANG was exposed to UV radiation in the presence of rat DBP followed by the addition of a 500-fold excess of 25-OH-D3, there was no displacement of tritium from the 4.1S peak. Calcifediol 9-17 angiogenin Rattus norvegicus 18-21 3768308-6 1986 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis autoradiographic analysis of [3H]25-OH-D3-ANG exposed to UV radiation in the presence of rat DBP followed by the addition of a 500-fold excess of 25-OH-D3 revealed one major band with a molecular weight of 52 000. Calcifediol 91-99 angiogenin Rattus norvegicus 100-103 3084135-5 1986 The affinity constants of the high pressure liquid chromatography purified vitamin D binding protein for 25 hydroxycholecalciferol (25 OHD3) and 1,25 dihydroxycholecalciferol 1,25(OH)2D3 were 1.9 X 10(7) mol/l and 2.6 X 10(6) mol/l, respectively. Calcifediol 132-139 GC vitamin D binding protein Homo sapiens 75-100 3004922-0 1986 Human parathyroid hormone inhibits renal 24-hydroxylase activity of 25-hydroxyvitamin D3 by a mechanism involving adenosine 3",5"-monophosphate in rats. Calcifediol 68-88 parathyroid hormone Rattus norvegicus 6-25 3004922-1 1986 The in vivo effect of PTH on renal 24-hydroxylase activity of 25-hydroxyvitamin D3 (25OHD3) was examined in vitamin D-deficient thyroparathyroidectomized rats by a recently developed sensitive in vitro assay of 25OHD3-hydroxylases using rat kidney homogenates and by an in vivo assay measuring the accumulation of tritiated metabolites in plasma 5 h after injection of 25OH[3H]D3. Calcifediol 62-82 parathyroid hormone Rattus norvegicus 22-25 3840228-2 1985 We compared the effect of oral administration of 25-OH-D3 (50 micrograms per day for one month) on serum concentrations of calcium, phosphate, parathyroid hormone, 25-OH-D, and 1,25-(OH)2D in five healthy adults and in six patients with primary hyperparathyroidism. Calcifediol 49-57 parathyroid hormone Homo sapiens 143-162 3938042-2 1985 The results reported show that the decrease of estradiol levels are associated with a significant decrease in 25-OH-D3 serum levels, possibly as result of a lower concentration of vitamin D binding protein, which is extremely sensitive to changes in oestrogen levels. Calcifediol 110-118 GC vitamin D binding protein Homo sapiens 180-205 3002968-8 1986 Monocytes incubated with IFN-gamma developed 25-OH D3 1-hydroxylase activity, detected by conversion of tritiated 25-(OH) D3 to a more polar metabolite which coeluted with 1,25-(OH)2 D3 on straight and reverse-phase HPLC. Calcifediol 114-124 interferon gamma Homo sapiens 25-34 4094414-1 1985 The vitamin D-binding protein from human serum has been crystallized from polyethylene glycol as a complex with 25-hydroxyvitamin D3 and examined by X-ray diffraction photography. Calcifediol 112-132 GC vitamin D binding protein Homo sapiens 4-29 3876830-3 1985 When the plasma was labelled with a tracer concentration of [3H]calcidiol, it was apparent that holo- and apo-DBP did not co-chromatograph on chromatofocusing. Calcifediol 64-73 GC vitamin D binding protein Sus scrofa 110-113 3876830-4 1985 The separation of these two forms of DBP on chromatofocusing was verified by using purified apo-DBP mixed with either a tracer or a saturating concentration of calcidiol. Calcifediol 160-169 GC vitamin D binding protein Sus scrofa 37-40 6543324-4 1984 In our study, a 50% displacement of radiolabeled 25-hydroxyvitamin D3 ([3H]25OHD3) from its initial binding is achieved with 325 fmol/mL 25(R),26(OH)2D3 and 850-1000 fmol/mL 25(S),26(OH)2D3--a difference in potency of approximately 3-fold. Calcifediol 49-69 adaptor-related protein complex 2, alpha 2 subunit Mus musculus 134-139 2987615-6 1985 With regard to in vitro activity in displacing radiolabeled 25-hydroxyvitamin D3 from vitamin D binding protein and radiolabelled 1,25-dihydroxyvitamin D3 from a chick intestinal cytosol receptor, 3 beta-fluorovitamin D3 and 3 beta-deoxyvitamin D3 both showed very poor binding efficiencies when compared with vitamin D3. Calcifediol 60-80 GC vitamin D binding protein Gallus gallus 86-111 2981664-1 1985 In order to determine whether cAMP mediates the effects of PTH on the metabolism of 25-hydroxyvitamin D3 (25-OH-D3) on chick kidney cells in primary culture, the effect of forskolin on the production of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] and 24,25-dihydroxyvitamin D3 [24,25-(OH)2D3] was assessed. Calcifediol 84-104 parathyroid hormone Gallus gallus 59-62 2981664-4 1985 Similar results were observed when cultures were preincubated with nonradioactive 25-OH-D3 for 4 h in the presence of PTH and forskolin, followed by a 30-min incubation with radioactive substrate. Calcifediol 82-90 parathyroid hormone Gallus gallus 118-121 2981664-6 1985 At maximal concentrations of PTH (10 ng/ml) and forskolin (10 microM), the effects of the two on 25-OH-D3 metabolism were not additive. Calcifediol 97-105 parathyroid hormone Gallus gallus 29-32 2981664-10 1985 The results of these studies indicate that the effects of PTH on the metabolism of 25-OH-D3 by chick kidney cells are mediated by cAMP, since they can be enhanced and mimicked by forskolin, that they are exerted at the level of both 1- and 24-hydroxylase activity, and that they are not dependent on the calcium concentration of the medium. Calcifediol 83-91 parathyroid hormone Gallus gallus 58-61 6543324-4 1984 In our study, a 50% displacement of radiolabeled 25-hydroxyvitamin D3 ([3H]25OHD3) from its initial binding is achieved with 325 fmol/mL 25(R),26(OH)2D3 and 850-1000 fmol/mL 25(S),26(OH)2D3--a difference in potency of approximately 3-fold. Calcifediol 49-69 adaptor-related protein complex 2, alpha 2 subunit Mus musculus 171-176 6376069-6 1984 Supplementation with 25-hydroxyvitamin D3 for 2 weeks in another group of rabbits (n = 4) resulted in marked improvement in glucose-stimulated insulin release and glucose tolerance. Calcifediol 21-41 insulin Oryctolagus cuniculus 143-150 6541534-1 1984 We describe direct, nonchromatographic assays for 25-hydroxyvitamin D3 in which we use either rat vitamin D-binding protein or rabbit antibodies to 25-hydroxyvitamin D3-3-hemisuccinate-bovine serum albumin as binding protein. Calcifediol 50-70 GC, vitamin D binding protein Rattus norvegicus 98-123 6600222-7 1983 The data are consistent with the hypothesis that control the renal metabolism of 25-hydroxyvitamin D3 in Hyp mice is reset such tht 24-hydroxylase activity is inappropriate high for the prevailing serum phosphate over a wide range of concentrations. Calcifediol 81-101 phosphate regulating endopeptidase homolog, X-linked Mus musculus 105-108 6547147-5 1984 A significant correlation was found between the serum concentration of either albumin or vitamin D-binding protein and the serum concentrations of total calcium, 25-OHD3, 1,25-(OH2)D3, and PTH but not with ionized calcium or free 1,25-(OH2)D3 index. Calcifediol 162-169 albumin Homo sapiens 78-85 6547147-5 1984 A significant correlation was found between the serum concentration of either albumin or vitamin D-binding protein and the serum concentrations of total calcium, 25-OHD3, 1,25-(OH2)D3, and PTH but not with ionized calcium or free 1,25-(OH2)D3 index. Calcifediol 162-169 GC vitamin D binding protein Homo sapiens 89-114 6608994-0 1984 Metabolism of 25-hydroxyvitamin D3 in renal slices from the X-linked hypophosphatemic (Hyp) mouse: abnormal response to fall in serum calcium. Calcifediol 14-34 phosphate regulating endopeptidase homolog, X-linked Mus musculus 87-90 6608994-1 1984 The effect of the X-linked Hyp mutation on 25-hydroxyvitamin D3 (25-OH-D3) metabolism in mouse renal cortical slices was investigated. Calcifediol 43-63 phosphate regulating endopeptidase homolog, X-linked Mus musculus 27-30 6608994-1 1984 The effect of the X-linked Hyp mutation on 25-hydroxyvitamin D3 (25-OH-D3) metabolism in mouse renal cortical slices was investigated. Calcifediol 65-73 phosphate regulating endopeptidase homolog, X-linked Mus musculus 27-30 6610018-0 1984 Effects of hypophysectomy and growth hormone treatment on renal hydroxylation of 25-hydroxycholecalciferol in rats. Calcifediol 81-106 gonadotropin releasing hormone receptor Rattus norvegicus 30-44 6317364-1 1984 Renal production of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] from 25-hydroxyvitamin D3 (25OHD3) is increased by PTH. Calcifediol 65-85 parathyroid hormone Rattus norvegicus 111-114 6320659-0 1984 Effect of PTH and 1,25(OH)2D3 on renal 25(OH)D3 metabolism, adenylate cyclase, and protein kinase. Calcifediol 39-47 parathyroid hormone Rattus norvegicus 10-13 6320659-1 1984 The purpose of these studies was to characterize the action of PTH and 1,25(OH)2D3 on the renal metabolism of 25(OH)D3 to 1,25(OH)2D3 and 24,25(OH)2D3. Calcifediol 110-118 parathyroid hormone Rattus norvegicus 63-66 6320659-6 1984 1,25(OH)2D3 also blocked the effect of PTH (5.0 U/ml) on renal 25(OH)D3 metabolism. Calcifediol 63-71 parathyroid hormone Rattus norvegicus 39-42 6320659-8 1984 These studies demonstrate that PTH may act directly on the kidney to modulate renal 25(OH)D3 metabolism and that this action can be inhibited by 1,25(OH)2D3. Calcifediol 84-92 parathyroid hormone Rattus norvegicus 31-34 7023922-11 1981 The concentration of free 25-OHD3 and free 1,25-(OH)2D3 in the fetal circulation exceeds the maternal levels due to the differences in the DBP concentrations of the two bloodstreams. Calcifediol 26-33 D-box binding PAR bZIP transcription factor Homo sapiens 139-142 6300629-0 1982 The role of parathyroid hormone in the regulation of the metabolism of 25-hydroxyvitamin D3. Calcifediol 71-91 parathyroid hormone Homo sapiens 12-31 6297543-6 1983 This new vitamin D3 metabolite, however, had greater affinity than 25-hydroxyvitamin D3 to both the rat plasma vitamin D binding protein and the 1,25-dihydroxyvitamin D specific cytosol receptor. Calcifediol 67-87 GC, vitamin D binding protein Rattus norvegicus 111-136 6981502-1 1982 In young rats, PTH markedly stimulates the renal conversion of 25-hydroxyvitamin D3 (25OHD3) to 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], the biologically active form of vitamin D3. Calcifediol 63-83 parathyroid hormone Rattus norvegicus 15-18 6257493-0 1981 In vitro stimulation of 25-hydroxycholecalciferol 1 alpha-hydroxylation by parathyroid hormone in chick kidney slices: evidence for a role for adenosine 3",5"-monophosphate. Calcifediol 24-49 parathyroid hormone Gallus gallus 75-94 6257493-1 1981 We studied the effect of parathyroid hormone (PTH) on the in vitro conversion of 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol [1,25-(OH)2D3] by kidney slices from vitamin D-deficient chicks. Calcifediol 81-106 parathyroid hormone Gallus gallus 25-44 6893594-7 1980 The same affinity is found for 24,25-dihydroxyvitamin D3 but 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 have a 3- and 10-fold lower affinity, respectively. Calcifediol 61-81 dopamine receptor D3 Gallus gallus 54-56 6263245-5 1980 Furthermore, in the presence of 25-hydroxycholecalciferol, the rate of chemical modification of the amino groups in human vitamin D binding protein is decreased and the susceptibility of intact vitamin D binding protein to proteolytic degradation is reduced, suggesting that some surface sites in the vitamin D binding protein molecule are less accessible to external agents. Calcifediol 32-57 GC vitamin D binding protein Homo sapiens 122-147 6263245-5 1980 Furthermore, in the presence of 25-hydroxycholecalciferol, the rate of chemical modification of the amino groups in human vitamin D binding protein is decreased and the susceptibility of intact vitamin D binding protein to proteolytic degradation is reduced, suggesting that some surface sites in the vitamin D binding protein molecule are less accessible to external agents. Calcifediol 32-57 GC vitamin D binding protein Homo sapiens 194-219 6263245-4 1980 Spectrofluorimetric studies showed that 25-hydroxycholecalciferol causes a saturable enhancement of intrinsic fluorescence of human vitamin D binding protein and alters the pH profile of protein fluorescence, suggesting that there are alterations in the local environment of tryptophan residue(s) after ligand binding. Calcifediol 40-65 GC vitamin D binding protein Homo sapiens 132-157 6263245-5 1980 Furthermore, in the presence of 25-hydroxycholecalciferol, the rate of chemical modification of the amino groups in human vitamin D binding protein is decreased and the susceptibility of intact vitamin D binding protein to proteolytic degradation is reduced, suggesting that some surface sites in the vitamin D binding protein molecule are less accessible to external agents. Calcifediol 32-57 GC vitamin D binding protein Homo sapiens 194-219 6775702-1 1980 The vitamin D metabolite, 24,25-dihydroxyvitamin D-3, is made from 25-hydroxyvitamin D-3 by an enzyme (25-hydroxyvitamin D-3 24-hydroxylase) located in the renal mitochondria of vitamin D and calcium-replete chicks. Calcifediol 67-88 cytochrome P450 family 24 subfamily A member 1 Gallus gallus 103-139 6893597-1 1980 The approximate association constants of the plasma vitamin D binding globulin (Gc-globulin) for 25-hydroxycholecalciferol (25(OH)D3) and the plasma 25(OH)D3 binding capacities were measured in samples from 123 patients with a variety of disorders. Calcifediol 97-122 GC vitamin D binding protein Homo sapiens 80-91 90502-4 1979 Detailed quantitative studies were first carried out on the interaction of 25(OH)D3 with DBP in 21 different samples of serum, representing eight different Gc phenotypes. Calcifediol 75-83 D-box binding PAR bZIP transcription factor Homo sapiens 89-92 92374-3 1979 In addition the Gc-globulin levels correlate well with the ability of plasma to bind 25-hydroxycholecalciferol. Calcifediol 85-110 GC vitamin D binding protein Homo sapiens 16-27 109470-5 1979 Bovine parathyroid hormone stimulated the 1- and reduced the 24-hydroxylase in 6 h, but this only occurred in cultures either previously treated with 1,25(OH)2D3 and EGTA to lower Ca to 0.8 mM or in cultures grown in the presence of 25-hydroxyvitamin D3 (25(OH)D3). Calcifediol 233-253 parathyroid hormone Bos taurus 7-26 109470-5 1979 Bovine parathyroid hormone stimulated the 1- and reduced the 24-hydroxylase in 6 h, but this only occurred in cultures either previously treated with 1,25(OH)2D3 and EGTA to lower Ca to 0.8 mM or in cultures grown in the presence of 25-hydroxyvitamin D3 (25(OH)D3). Calcifediol 255-263 parathyroid hormone Bos taurus 7-26 6774968-5 1980 DBP1 and DBP2 both appeared to have one binding site for 25-hydroxyvitamin D3 per molecule of protein, with apparently similar association constants at 4 degrees C of 5--7 x 10(9) M-1. Calcifediol 57-77 DEAH-box helicase 16 Rattus norvegicus 9-13 114281-4 1979 Levels of calcium binding activity and content of CaBP did not correlate with serum immunoreactive parathormone levels, but were directly related to circulating 25-hydroxycholecalciferol (25-OHD) levels. Calcifediol 161-186 S100 calcium binding protein G Homo sapiens 50-54 744925-0 1978 Effect of growth hormone on the metabolism of 25-hydroxycholecalciferol in hypophysectomized rats on a diet without vitamin D and low in calcium. Calcifediol 46-71 gonadotropin releasing hormone receptor Rattus norvegicus 10-24 744925-8 1978 These results suggest that the decrease in the conversion of 25-(OH)D3 to 1,25-(OH)2D3 after hypophysectomy may be related to the lack of growth hormone. Calcifediol 61-70 gonadotropin releasing hormone receptor Rattus norvegicus 138-152 318387-5 1978 In the presence of a bovine adrenal NADPH-ferredoxin reductase, bovine adrenal ferredoxin and NADPH, the cytochrome P-450 supported the formation of 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Calcifediol 179-199 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 105-121 659599-0 1978 Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. Calcifediol 47-72 parathyroid hormone Canis lupus familiaris 14-33 659599-6 1978 25-Hydroxycholecalciferol, 25-(OH)D(3), in doses of 125-240 ng, caused complete suppression of PTH secretion. Calcifediol 0-25 parathyroid hormone Canis lupus familiaris 95-98 750606-2 1978 Administration of 50 micrograms/d of 25(OH)D3 for 8 weeks led to a return of the mineralization front to normal associated with a return of TmPO4/GFR to normal, an increase in serum phosphate and calcium concentrations, a fall in serum IPTH, and a rise in serum alkaline phosphatase activity. Calcifediol 37-45 Rap guanine nucleotide exchange factor 5 Homo sapiens 146-149 196836-1 1977 Teh stimulatory effect of parathyroid hormone (PTH) on renal 1alpha-hydroxylation of 25-hydroxyvitamin D3 (25-OH-D3) was studied in thyro-parathyroidectomized (TPTX), vitamin D-deficient rats into which bovine PTH, theophylline, cAMP or dibutyryl cAMP (dbcAMP) was constantly infused. Calcifediol 85-105 parathyroid hormone Rattus norvegicus 26-45 564862-2 1978 PTH potentiated CaBP synthesis in the presence of vitamin D3, 25-OH-D3, 1 alpha-OH-D3, DHT, and 1,25(OH)2D3. Calcifediol 62-70 parathyroid hormone Gallus gallus 0-3 196836-1 1977 Teh stimulatory effect of parathyroid hormone (PTH) on renal 1alpha-hydroxylation of 25-hydroxyvitamin D3 (25-OH-D3) was studied in thyro-parathyroidectomized (TPTX), vitamin D-deficient rats into which bovine PTH, theophylline, cAMP or dibutyryl cAMP (dbcAMP) was constantly infused. Calcifediol 107-115 parathyroid hormone Rattus norvegicus 26-45 301629-6 1977 By constrast, 5,6 trans-25 hydroxyvitamin D3 decreased PTH and caused a significant decrease in urine hydroxyproline. Calcifediol 14-44 parathyroid hormone Homo sapiens 55-58 867174-0 1977 Serum levels of 25-hydroxycholecalciferol as a diagnostic aid in vitamin D deficiency states. Calcifediol 16-41 activation induced cytidine deaminase Homo sapiens 58-61 821943-9 1976 Specific binding of vitamin D3,25-OH-D3, and 1,25-(OH)2D3 by human serum was completely neutralized after immunoprecipitation of the serum with the gamma globulin fraction of anti-Cal-BP antiserum, indicating a common transport protein for these sterols in human plasma. Calcifediol 31-39 calreticulin Rattus norvegicus 180-186 973599-1 1976 25-Hydroxycholecalciferol (25-HCC) levels were measured in 31 bedouin females and eight bedouin male tribesmen and compared with the levels in Jewish males and females in Beersheba. Calcifediol 0-25 HCC Homo sapiens 30-33 821943-13 1976 The Cal-BP content of human serum is approximately 10(-5) M, whereas the calcifidiol content is approximately 10(-7) M. Normally, the dominant moiety of human plasma Cal-BP is the apoprotein. Calcifediol 73-84 calreticulin Rattus norvegicus 166-172 33747191-9 2021 With the increase in 25-(OH)D3 concentration, the expression level of mTOR increased, the expression level of LC3B-II decreased and the apoptosis rate was significantly increased. Calcifediol 21-30 mechanistic target of rapamycin kinase Homo sapiens 70-74 956382-3 1976 DBP was labeled by the addition of a tracer amount of 3H-labeled 25-OH-D3 to the original plasma used for protein fractionation. Calcifediol 65-73 D-box binding PAR bZIP transcription factor Homo sapiens 0-3 956382-11 1976 Direct study of the binding capacity of the purified DBP for added 25-OH-D3 showed that the isolated DBP had a high affinity for 25-OH-D3, with an apparent maximum binding capacity of one molecule of 25-OH-D3 per molecule of protein. Calcifediol 67-75 D-box binding PAR bZIP transcription factor Homo sapiens 53-56 956382-11 1976 Direct study of the binding capacity of the purified DBP for added 25-OH-D3 showed that the isolated DBP had a high affinity for 25-OH-D3, with an apparent maximum binding capacity of one molecule of 25-OH-D3 per molecule of protein. Calcifediol 67-75 D-box binding PAR bZIP transcription factor Homo sapiens 101-104 956382-11 1976 Direct study of the binding capacity of the purified DBP for added 25-OH-D3 showed that the isolated DBP had a high affinity for 25-OH-D3, with an apparent maximum binding capacity of one molecule of 25-OH-D3 per molecule of protein. Calcifediol 129-137 D-box binding PAR bZIP transcription factor Homo sapiens 53-56 956382-11 1976 Direct study of the binding capacity of the purified DBP for added 25-OH-D3 showed that the isolated DBP had a high affinity for 25-OH-D3, with an apparent maximum binding capacity of one molecule of 25-OH-D3 per molecule of protein. Calcifediol 129-137 D-box binding PAR bZIP transcription factor Homo sapiens 101-104 956382-11 1976 Direct study of the binding capacity of the purified DBP for added 25-OH-D3 showed that the isolated DBP had a high affinity for 25-OH-D3, with an apparent maximum binding capacity of one molecule of 25-OH-D3 per molecule of protein. Calcifediol 129-137 D-box binding PAR bZIP transcription factor Homo sapiens 53-56 956382-11 1976 Direct study of the binding capacity of the purified DBP for added 25-OH-D3 showed that the isolated DBP had a high affinity for 25-OH-D3, with an apparent maximum binding capacity of one molecule of 25-OH-D3 per molecule of protein. Calcifediol 129-137 D-box binding PAR bZIP transcription factor Homo sapiens 101-104 4812447-16 1974 These results indicate that 25HCC enhances tubular reabsorption of phosphorus in rats, only in the presence of either endogenous or exogenous circulating PTH, but not in its absence and thus imply a PTH-dependent mechanism of 25HCC action on the kidney. Calcifediol 28-33 parathyroid hormone Rattus norvegicus 154-157 4812447-16 1974 These results indicate that 25HCC enhances tubular reabsorption of phosphorus in rats, only in the presence of either endogenous or exogenous circulating PTH, but not in its absence and thus imply a PTH-dependent mechanism of 25HCC action on the kidney. Calcifediol 28-33 parathyroid hormone Rattus norvegicus 199-202 4812447-16 1974 These results indicate that 25HCC enhances tubular reabsorption of phosphorus in rats, only in the presence of either endogenous or exogenous circulating PTH, but not in its absence and thus imply a PTH-dependent mechanism of 25HCC action on the kidney. Calcifediol 226-231 parathyroid hormone Rattus norvegicus 199-202 164197-0 1975 Early effect of 25-hydroxycholecalciferol (25-OH-D3) and 1,25-dihydroxycholecalciferol (1,25-(OH)2-D3) on the ability of parathyroid hormone (PTH) to elevate cyclic AMP of intact bone cells. Calcifediol 16-41 parathyroid hormone Homo sapiens 121-140 164197-0 1975 Early effect of 25-hydroxycholecalciferol (25-OH-D3) and 1,25-dihydroxycholecalciferol (1,25-(OH)2-D3) on the ability of parathyroid hormone (PTH) to elevate cyclic AMP of intact bone cells. Calcifediol 16-41 parathyroid hormone Homo sapiens 142-145 164197-0 1975 Early effect of 25-hydroxycholecalciferol (25-OH-D3) and 1,25-dihydroxycholecalciferol (1,25-(OH)2-D3) on the ability of parathyroid hormone (PTH) to elevate cyclic AMP of intact bone cells. Calcifediol 43-51 parathyroid hormone Homo sapiens 121-140 33747191-9 2021 With the increase in 25-(OH)D3 concentration, the expression level of mTOR increased, the expression level of LC3B-II decreased and the apoptosis rate was significantly increased. Calcifediol 21-30 microtubule associated protein 1 light chain 3 beta Homo sapiens 110-114 33865853-0 2021 Elucidation of metabolic pathways of 25-hydroxyvitamin D3 mediated by Cyp24a1 and Cyp3a using Cyp24a1 knockout rats generated by CRISPR/Cas9 system. Calcifediol 37-57 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 70-77 33783959-9 2021 There was significantly negative correlation (P < 0.001) between the levels of serum 25(OH)D3 and PTH. Calcifediol 85-93 parathyroid hormone Homo sapiens 98-101 33895867-5 2021 Vitamin D supplementation had an inconsistent effect on PTH concentrations and meta-analysis showed non- significant reduction (P = 0.08) whereas calcifediol, calcitriol and paricalcitol consistently reduced PTH. Calcifediol 146-157 parathyroid hormone Homo sapiens 208-211 33895867-12 2021 Calcifediol and analogues consistently suppressed PTH, but the increase in FGF23 with calcitriol analogues warrants caution. Calcifediol 0-11 parathyroid hormone Homo sapiens 50-53 33865853-2 2021 Plasma 25(OH)D3 concentrations in Cyp24a1 KO rats were approximately two-fold higher than in wild-type rats. Calcifediol 7-15 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 34-41 33865853-0 2021 Elucidation of metabolic pathways of 25-hydroxyvitamin D3 mediated by Cyp24a1 and Cyp3a using Cyp24a1 knockout rats generated by CRISPR/Cas9 system. Calcifediol 37-57 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 82-87 33865853-0 2021 Elucidation of metabolic pathways of 25-hydroxyvitamin D3 mediated by Cyp24a1 and Cyp3a using Cyp24a1 knockout rats generated by CRISPR/Cas9 system. Calcifediol 37-57 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 94-101 33147594-8 2021 DISCUSSION/CONCLUSION: The pilot study gives promising results that it is worthwhile to evaluate short-term sunlight exposure as a potentially effective approach in decreasing BP and PR in 25-hydroxyvitamin D3-insufficient prehypertensive patients in a larger trial with a control group. Calcifediol 189-209 transmembrane protein 37 Homo sapiens 183-185 33305962-4 2021 Higher levels of body mass index, and systolic blood pressure and lower level of 25 (OH)-D3 were detected in the presence of VDR ApaI. Calcifediol 81-91 vitamin D receptor Homo sapiens 125-128 33227068-9 2020 RESULTS: BRCA1 mut women had lower serum calcifediol levels compared to BRCA wt women (p = 0.003). Calcifediol 41-52 BRCA1 DNA repair associated Homo sapiens 9-14 33586001-8 2021 This review analyzes the interactions of PTH, P, Ca, FGF23, calcidiol, calcitriol and Klotho with the RANKL/RANKL/OPG system and the Wnt/beta-catenin, pathway and their implications in bone and cardiovascular disorders in CKD. Calcifediol 60-69 TNF superfamily member 11 Homo sapiens 102-107 33586001-8 2021 This review analyzes the interactions of PTH, P, Ca, FGF23, calcidiol, calcitriol and Klotho with the RANKL/RANKL/OPG system and the Wnt/beta-catenin, pathway and their implications in bone and cardiovascular disorders in CKD. Calcifediol 60-69 TNF superfamily member 11 Homo sapiens 108-113 33586001-8 2021 This review analyzes the interactions of PTH, P, Ca, FGF23, calcidiol, calcitriol and Klotho with the RANKL/RANKL/OPG system and the Wnt/beta-catenin, pathway and their implications in bone and cardiovascular disorders in CKD. Calcifediol 60-69 basic transcription factor 3 pseudogene 11 Homo sapiens 114-117 31705290-7 2020 Lower serum 25-hydroxyvitamin D level was associated with an increased risk of poor functional outcome (RR 1.86; 95% CI 1.16-2.98), all-cause mortality (RR 3.56; 95% CI 1.54-8.25), and recurrence of stroke (RR 5.49; 95% CI 2.69-11.23). Calcifediol 12-31 ribonucleotide reductase catalytic subunit M1 Homo sapiens 104-108 33471654-8 2020 Although endogenous 25(OH)D3 levels were reduced by IM D2, the total 25(OH)D levels increased by 5.0, 7.0, or 10.3 ng/mL in average after injection of 200,000 IU, 400,000 IU, or 600,000 IU D2. Calcifediol 20-28 WASP family member 2 Homo sapiens 52-57 33471654-11 2020 CONCLUSION: A single dose of 200,000 IU, 400,000 IU, or 600,000 IU IM D2 raises total 25-hydroxyvitamin D levels by 5.0, 7.0, or 10.3 ng/mL on average for at least 12 weeks and reduces iPTH and endogenous 25(OH)D3 levels without affecting levels of serum calcium, BTMs, DBP, and urinary calcium. Calcifediol 205-213 WASP family member 2 Homo sapiens 67-72 33142484-5 2020 On day 21, 25-OH-D3 increased serum concentrations of total antioxidant capacity (T-AOC), catalase (CAT), and glutathione peroxidase in broilers fed low Ca and P diet (Interaction, P < 0.05). Calcifediol 11-19 catalase Homo sapiens 90-98 33142484-5 2020 On day 21, 25-OH-D3 increased serum concentrations of total antioxidant capacity (T-AOC), catalase (CAT), and glutathione peroxidase in broilers fed low Ca and P diet (Interaction, P < 0.05). Calcifediol 11-19 catalase Homo sapiens 100-103 32932945-0 2020 25-Hydroxycholecalciferol Concentration Is Associated with Protein Loss and Serum Albumin Level during the Acute Phase of Burn Injury. Calcifediol 0-25 albumin Homo sapiens 82-89 33066266-7 2020 The highest increase in TNF-alpha transcripts was observed in HIV+ subjects with deficient 25(OH)D3 levels. Calcifediol 91-99 tumor necrosis factor Homo sapiens 24-33 32932945-10 2020 Our study showed that concentration of 25-hydroxycholecalciferol is strongly correlated with serum albumin level, even more than total burn surface area and burn degrees as expected. Calcifediol 39-64 albumin Homo sapiens 99-106 32344004-1 2020 Mutations in CYP2R1 and CYP27A1 involved in the conversion of Cholecalciferol into Calcidiol were associated with the impaired 25-hydroxylase activity therefore affecting the Vitamin D metabolism. Calcifediol 83-92 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 13-19 32344004-1 2020 Mutations in CYP2R1 and CYP27A1 involved in the conversion of Cholecalciferol into Calcidiol were associated with the impaired 25-hydroxylase activity therefore affecting the Vitamin D metabolism. Calcifediol 83-92 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 24-31 32616230-6 2020 Supplemental 25-OH-D3 relieved peripheral hypertension and prevented time-dependent increases of RVDP in Ad-hens through the renin-angiotensin system and circulating nitric oxide availability and by regulating vascular remodeling including elastin/collagen ratio and smooth muscle cell proliferation in the pulmonary artery for improved elasticity/stiffness (P < 0.05). Calcifediol 13-21 elastin Gallus gallus 240-247 32371216-6 2020 The expression of CYP27B1 was lower in subjects with 25(OH)D3 levels below 50 nmol/L (deficiency) than subjects with both insufficient and sufficient levels of 25(OH)D3. Calcifediol 53-61 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 18-25 32371216-6 2020 The expression of CYP27B1 was lower in subjects with 25(OH)D3 levels below 50 nmol/L (deficiency) than subjects with both insufficient and sufficient levels of 25(OH)D3. Calcifediol 160-168 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 18-25 31827258-0 2020 Low serum 25-hydroxyvitamin D levels may increase the detrimental effect of VDR variants on the risk of essential hypertension. Calcifediol 10-29 vitamin D receptor Homo sapiens 76-79 32616230-6 2020 Supplemental 25-OH-D3 relieved peripheral hypertension and prevented time-dependent increases of RVDP in Ad-hens through the renin-angiotensin system and circulating nitric oxide availability and by regulating vascular remodeling including elastin/collagen ratio and smooth muscle cell proliferation in the pulmonary artery for improved elasticity/stiffness (P < 0.05). Calcifediol 13-21 collagen type III alpha 1 chain Gallus gallus 248-256 32083542-7 2020 Serum vitamin D concentration (25(OH)D3) showed a protective effect on CIMT (OR= 0.94; CI= 0.89-0.99; p= 0.025). Calcifediol 31-39 CIMT Homo sapiens 71-75 32547638-11 2020 Conclusions: Serum 25(OH)D3 levels were inversely associated with the summary inflammatory z-score and in particular with IL6 in the years following CRC diagnosis. Calcifediol 19-27 interleukin 6 Homo sapiens 122-125 32231239-1 2020 Recent studies have suggested that vitamin D activities involve vitamin D receptor (VDR)-dependent and VDR-independent effects of 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 25-hydroxyvitamin D3 (25(OH)D3) and ligand-independent effects of the VDR. Calcifediol 178-198 vitamin D receptor Rattus norvegicus 84-87 31945466-0 2020 25(OH)D3 stimulates the expression of vitamin D target genes in renal tubular cells when Cyp27b1 is abrogated. Calcifediol 0-8 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 89-96 32359596-10 2020 Dietary 25-OH-D3 increased serum concentration of 25-OH-D3, carbonic anhydrase (CA), and calcitonin (CT) (P < 0.01) and reduced corticosterone, lipopolysaccharide and osteocalcin concentration (P <= 0.05). Calcifediol 8-16 calcitonin Gallus gallus 89-99 32359596-10 2020 Dietary 25-OH-D3 increased serum concentration of 25-OH-D3, carbonic anhydrase (CA), and calcitonin (CT) (P < 0.01) and reduced corticosterone, lipopolysaccharide and osteocalcin concentration (P <= 0.05). Calcifediol 8-16 bone gamma-carboxyglutamate protein Gallus gallus 167-178 31863554-2 2020 The aim of this work was to assess serum 25-hydroxyvitamin D (25(OH)VD) levels in steroid-resistant, steroid-sensitive patients with asthma and in healthy controls, and to investigate the association between the vitamin D receptor gene (VDR) FokI and ApaI polymorphisms and GC resistance in patients with asthma. Calcifediol 41-60 vitamin D receptor Homo sapiens 212-230 31982424-11 2020 Also, Vitamin D analogue significantly increased expression of Nrf2 and its downstream effectors (HO-1 and GSH), improved serum levels of total 25-hydroxyvitamin D and calcium, decreased neuro-inflammation and Amyloid beta load as well as hyperphosphorylation of MAPK-38, ERK1/2 and tau proteins were also observed. Calcifediol 144-163 NFE2 like bZIP transcription factor 2 Rattus norvegicus 63-67 31965076-8 2020 Deficiency of serum 25-hydroxyvitamin D in hypertensive subjects was significantly associated with CRP positivity, low levels of mean serum calcium, low levels of mean serum phosphorous, high levels of mean alkaline phosphatase (p < 0.0001), and abnormal alanine transaminase (ALT) (p = 0.0015) compared with the same parameters in the normotensive subjects. Calcifediol 20-39 C-reactive protein Homo sapiens 99-102 31837045-1 2020 BACKGROUND: The association between vitamin D-binding protein (VDBP) and 25-hydroxyvitamin D (25 (OH)D) with colorectal cancer (CRC) is still ambiguous. Calcifediol 73-92 GC vitamin D binding protein Homo sapiens 36-61 31837045-1 2020 BACKGROUND: The association between vitamin D-binding protein (VDBP) and 25-hydroxyvitamin D (25 (OH)D) with colorectal cancer (CRC) is still ambiguous. Calcifediol 73-92 GC vitamin D binding protein Homo sapiens 63-67 32359596-11 2020 The increase effect in PTH was more pronounced when 25-OH-D3 was supplemented to layers under high stocking density (interaction, P = 0.05). Calcifediol 52-60 parathyroid hormone Gallus gallus 23-26 31698477-9 2020 In multivariate analysis, aldosterone and 25-hydroxyvitamin D levels were significantly correlated with serum PTH levels. Calcifediol 42-61 parathyroid hormone Homo sapiens 110-113 32231239-5 2020 Administration of 25(OH)D3 reversed rickets symptoms in Cyp27b1-KO and Vdr (R270L) rats. Calcifediol 18-26 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 56-63 32231239-5 2020 Administration of 25(OH)D3 reversed rickets symptoms in Cyp27b1-KO and Vdr (R270L) rats. Calcifediol 18-26 vitamin D receptor Rattus norvegicus 71-74 32231239-7 2020 In contrast, the effects of 25(OH)D3 on Vdr (R270L) rats strongly suggested a direct action of 25(OH)D3 via VDR-genomic pathways. Calcifediol 28-36 vitamin D receptor Rattus norvegicus 40-43 32231239-7 2020 In contrast, the effects of 25(OH)D3 on Vdr (R270L) rats strongly suggested a direct action of 25(OH)D3 via VDR-genomic pathways. Calcifediol 95-103 vitamin D receptor Rattus norvegicus 40-43 32231239-7 2020 In contrast, the effects of 25(OH)D3 on Vdr (R270L) rats strongly suggested a direct action of 25(OH)D3 via VDR-genomic pathways. Calcifediol 95-103 vitamin D receptor Rattus norvegicus 108-111 32033065-11 2020 Our results revealed that 25(OH)D3 had a negative correlation with the intact parathyroid hormone (iPTH) when the serum 25(OH)D3 level <= 20 ng/mL (r = -0.21, p = 0.001). Calcifediol 26-34 parathyroid hormone Homo sapiens 78-97 32319119-2 2020 Vitamin D is converted to the relatively inactive metabolite, 25-hydroxyvitamin D3 [25(OH)D3 ], by CYP27A1 and CYP2R1 in the liver, then to 1,25(OH)2 D3 by a specific, mitochondrial enzyme, CYP27B1 (1alpha-hydroxylase) that is present primarily in the kidney. Calcifediol 62-82 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 99-106 32319119-2 2020 Vitamin D is converted to the relatively inactive metabolite, 25-hydroxyvitamin D3 [25(OH)D3 ], by CYP27A1 and CYP2R1 in the liver, then to 1,25(OH)2 D3 by a specific, mitochondrial enzyme, CYP27B1 (1alpha-hydroxylase) that is present primarily in the kidney. Calcifediol 62-82 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 111-117 31718198-1 2020 OBJECTIVE: to verify the association of serum concentrations of 25-hydroxyvitamin D and glycemic levels with the genetic variants rs1544410 and rs2228570 of the VDR gene in adolescents from the Northeast region of Brazil. Calcifediol 64-83 vitamin D receptor Homo sapiens 161-164 32033065-11 2020 Our results revealed that 25(OH)D3 had a negative correlation with the intact parathyroid hormone (iPTH) when the serum 25(OH)D3 level <= 20 ng/mL (r = -0.21, p = 0.001). Calcifediol 120-128 parathyroid hormone Homo sapiens 78-97 31373168-2 2019 This study aimed to identify the substrate of PTPN2 in mediating beneficial effects of 25-Hydroxyvitamin D3 (25(OH)2D3 ) on diabetic periodontitis. Calcifediol 87-109 protein tyrosine phosphatase, non-receptor type 2 Mus musculus 46-51 31700074-9 2019 A moderate negative correlation was observed between median serum 25-hydroxyvitamin D levels and BPPV patient numbers each month. Calcifediol 66-85 benign paroxysmal positional vertigo Homo sapiens 97-101 31723461-9 2019 Mean level of 25-hydroxyvitamin D was 40.99 ng/mL in the SCC group and 26.34 ng/mL in the control group (P < 0.05). Calcifediol 14-33 serpin family B member 3 Homo sapiens 57-60 31675257-1 2019 Introduction: Extended-release calcifediol (ERC) is an orally administered prohormone of active vitamin D (1,25-dihydroxyvitamin D [1,25D]) designed to safely and sufficiently increase serum total 25-hydroxyvitamin D (25D) to reduce elevated parathyroid hormone (PTH) in patients with non-dialysis-chronic kidney disease (ND-CKD). Calcifediol 31-42 parathyroid hormone Homo sapiens 242-261 31675257-1 2019 Introduction: Extended-release calcifediol (ERC) is an orally administered prohormone of active vitamin D (1,25-dihydroxyvitamin D [1,25D]) designed to safely and sufficiently increase serum total 25-hydroxyvitamin D (25D) to reduce elevated parathyroid hormone (PTH) in patients with non-dialysis-chronic kidney disease (ND-CKD). Calcifediol 31-42 parathyroid hormone Homo sapiens 263-266 25905352-0 2000 Approach to Hypercalcemia A reduction in serum calcium can stimulate parathyroid hormone (PTH) release which may then increase bone resorption, enhance renal calcium reabsorption, and stimulate renal conversion of 25-hydroxyvitamin D3, to the active moiety 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] which then will enhance intestinal calcium absorption. Calcifediol 214-234 parathyroid hormone Homo sapiens 69-88 25905352-0 2000 Approach to Hypercalcemia A reduction in serum calcium can stimulate parathyroid hormone (PTH) release which may then increase bone resorption, enhance renal calcium reabsorption, and stimulate renal conversion of 25-hydroxyvitamin D3, to the active moiety 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] which then will enhance intestinal calcium absorption. Calcifediol 214-234 parathyroid hormone Homo sapiens 90-93 31641537-1 2020 Megalin and cubilin are two receptors that mediate endocytosis of 25-hydroxyvitamin D (25(OH)D) for its final activation by hydroxylation. Calcifediol 66-85 LDL receptor related protein 2 Homo sapiens 0-7 31641537-1 2020 Megalin and cubilin are two receptors that mediate endocytosis of 25-hydroxyvitamin D (25(OH)D) for its final activation by hydroxylation. Calcifediol 66-85 cubilin Homo sapiens 12-19 31696838-13 2019 The CIMT was found to be related to increased age, smoking, and 25-hydroxyvitamin D in CKD patients. Calcifediol 64-83 CIMT Homo sapiens 4-8 31701079-0 2019 Calcifediol Decreases Interleukin-6 Secretion by Cultured Human Trophoblasts From GDM Pregnancies. Calcifediol 0-11 interleukin 6 Homo sapiens 22-35 31891001-2 2019 CYP24A1-mediated vitamin D clearance, calculated as the ratio of serum 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 (the vitamin D metabolic ratio, VDMR), is induced by 1,25-dihydroxyvitamin D and may assess tissue-level activity. Calcifediol 100-120 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 0-7 32542086-4 2020 The aim of this study was to evaluate the association among genetic variants of Klotho, namely rs1207568 and rs9536314, serum 25(OH)D3 levels, and multiple sclerosis (both risk and disease progression). Calcifediol 126-134 klotho Homo sapiens 80-86 31374914-8 2019 In ANOVA along concentration strata, lower calcidiol associated with higher parathyroid hormone only (p < 0.001). Calcifediol 43-52 parathyroid hormone Homo sapiens 76-95 30802957-10 2019 Cultured GEC expressed two 25-hydroxylases (CYP27A1 and CYP2R1), as well as 1-alpha hydroxylase, enabling conversion of vitamin D to both 25(OH)D3 and 1,25(OH)2 D3 . Calcifediol 138-146 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 56-62 31555688-3 2019 Herein we aimed to present novel evidence on the association of two VDBP polymorphisms (rs4588) and (rs7041) with CAD in patients after acute myocardial infarction and study possible correlations of these polymorphisms with 25-hydroxyvitamin D [25(OH)D] serum levels. Calcifediol 224-243 GC vitamin D binding protein Homo sapiens 68-72 30802957-10 2019 Cultured GEC expressed two 25-hydroxylases (CYP27A1 and CYP2R1), as well as 1-alpha hydroxylase, enabling conversion of vitamin D to both 25(OH)D3 and 1,25(OH)2 D3 . Calcifediol 138-146 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 44-51 31598576-7 2019 DBP then binds to cytoplasmic actin to provide an array of high-affinity binding sites for 25-hydroxyvitamin D [25(OH)D]. Calcifediol 91-110 D-box binding PAR bZIP transcription factor Homo sapiens 0-3 31086078-8 2019 The possibility that vitamin D3 and 25(OH)D3, being 3beta-hydroxysteroids, affect hepatitis C virus production by direct inhibition of the Hedgehog pathway in a vitamin D receptor-independent manner was ruled out. Calcifediol 36-44 vitamin D receptor Homo sapiens 161-179 31242663-13 2019 OPG values were significantly correlated with cardiac parameters LVEDV (r = 0.862, p < 0.001), LVEF (r = -0.832, p < 0.001), and c-f PWV(r = 0.833, p < 0.001), and also with 25-OH-D3 (r = -0.636, p < 0.001). Calcifediol 183-191 TNF receptor superfamily member 11b Homo sapiens 0-3 30893561-0 2019 Megalin mediates 25-hydroxyvitamin D3 actions in human mesenchymal stem cells. Calcifediol 17-37 LDL receptor related protein 2 Homo sapiens 0-7 30623714-10 2019 The findings of the present study suggested that vitamin D deficiency in the second trimester was inversely correlated with fasting and 1-h plasma glucose after 75 g glucose challenge test; also, low 25 OHD3 levels were associated with insulin resistance. Calcifediol 200-207 insulin Homo sapiens 236-243 30790351-8 2019 Using linear regression we determined a curve with 25(OH)D3/cholecalciferol versus normalized Cyp2R1 mRNA abundance with an R2 value of 0.85. Calcifediol 51-59 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 94-100 31086078-9 2019 Taken together, this study proposes a novel mode of action for the anti-hepatitis C virus activity of vitamin D3 that is mediated by 25(OH)D3 in a vitamin D receptor-independent mechanism. Calcifediol 133-141 vitamin D receptor Homo sapiens 147-165 31077177-1 2019 BACKGROUND: The present study aimed to study the relationship between serum 25 hydroxyvitamin D3(25(OH)D3) and insulin-like growth factor-1 (IGF-1) and thyroid nodules. Calcifediol 76-96 insulin like growth factor 1 Homo sapiens 111-139 31077177-1 2019 BACKGROUND: The present study aimed to study the relationship between serum 25 hydroxyvitamin D3(25(OH)D3) and insulin-like growth factor-1 (IGF-1) and thyroid nodules. Calcifediol 76-96 insulin like growth factor 1 Homo sapiens 141-146 31077177-1 2019 BACKGROUND: The present study aimed to study the relationship between serum 25 hydroxyvitamin D3(25(OH)D3) and insulin-like growth factor-1 (IGF-1) and thyroid nodules. Calcifediol 97-105 insulin like growth factor 1 Homo sapiens 111-139 31035488-6 2019 The association between calcidiol/paricalcitol treatment and elevated mortality remained significant after adjusting for age, sex, diabetes, C-reactive protein, and hemodialysis vintage. Calcifediol 24-33 C-reactive protein Homo sapiens 141-159 31077177-1 2019 BACKGROUND: The present study aimed to study the relationship between serum 25 hydroxyvitamin D3(25(OH)D3) and insulin-like growth factor-1 (IGF-1) and thyroid nodules. Calcifediol 97-105 insulin like growth factor 1 Homo sapiens 141-146 30729713-1 2019 AIM: Vitamin D3 or 25(OH)D3 may have a potential role in rheumatoid arthritis (RA) pathogenesis by inhibiting the expression of pro-inflammatory cytokines including interleukin-6 (IL-6). Calcifediol 19-27 interleukin 6 Homo sapiens 165-178 30729713-1 2019 AIM: Vitamin D3 or 25(OH)D3 may have a potential role in rheumatoid arthritis (RA) pathogenesis by inhibiting the expression of pro-inflammatory cytokines including interleukin-6 (IL-6). Calcifediol 19-27 interleukin 6 Homo sapiens 180-184 30421324-1 2019 In patients with neurofibromatosis type 1 (NF1), decreased bone mineral density (BMD) and low levels of 25-hydroxy vitamin D3 (25OHD) have been reported. Calcifediol 104-125 neurofibromin 1 Homo sapiens 17-41 31274343-4 2019 Increasing dietary 25(OH)D3 levels increased serum 25(OH)D3 concentrations linearly (p < 0.01), decreased the frequency of CD3+CD4+ and CD3+CD8+ T cells (p < 0.01), and the serum level of complement component 3 (p < 0.05). Calcifediol 19-27 CD3 epsilon subunit of T-cell receptor complex Sus scrofa 123-126 31274343-4 2019 Increasing dietary 25(OH)D3 levels increased serum 25(OH)D3 concentrations linearly (p < 0.01), decreased the frequency of CD3+CD4+ and CD3+CD8+ T cells (p < 0.01), and the serum level of complement component 3 (p < 0.05). Calcifediol 19-27 CD4 molecule Sus scrofa 127-130 31274343-4 2019 Increasing dietary 25(OH)D3 levels increased serum 25(OH)D3 concentrations linearly (p < 0.01), decreased the frequency of CD3+CD4+ and CD3+CD8+ T cells (p < 0.01), and the serum level of complement component 3 (p < 0.05). Calcifediol 19-27 CD3 epsilon subunit of T-cell receptor complex Sus scrofa 136-139 30421324-1 2019 In patients with neurofibromatosis type 1 (NF1), decreased bone mineral density (BMD) and low levels of 25-hydroxy vitamin D3 (25OHD) have been reported. Calcifediol 104-125 neurofibromin 1 Homo sapiens 43-46 30222077-3 2019 Both cholecalciferol (D3) and 25-hydroxycholecalciferol [25(OH)D3] apical effluxes were decreased by chemical inhibition of ABCB1 in Caco-2 cells and increased by ABCB1 overexpression in Griptites or Madin-Darby canine kidney type II cells. Calcifediol 30-55 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 30222077-3 2019 Both cholecalciferol (D3) and 25-hydroxycholecalciferol [25(OH)D3] apical effluxes were decreased by chemical inhibition of ABCB1 in Caco-2 cells and increased by ABCB1 overexpression in Griptites or Madin-Darby canine kidney type II cells. Calcifediol 30-55 ATP binding cassette subfamily B member 1 Homo sapiens 163-168 30031146-0 2019 Generation of 1,25-dihydroxyvitamin D3 in Cyp27b1 knockout mice by treatment with 25-hydroxyvitamin D3 rescued their rachitic phenotypes. Calcifediol 82-102 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 42-49 30031146-10 2019 Interestingly, the liver mitochondrial fraction prepared from Cyp27b1 KO mice converted 25(OH)D3 to 1,25(OH)2D3. Calcifediol 88-96 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 62-69 30359690-9 2019 Accordingly, VD-metabolites (25-hydroxyvitamin D3, calcitriol) significantly stimulated IL-1beta gene expression in cultured trophoblasts. Calcifediol 29-49 interleukin 1 beta Homo sapiens 88-96 30367940-1 2019 Three 23-hydroxylated vitamin D3 derivatives, which are metabolites of 25-hydroxyvitamin D3 produced by CYP24A1 and a related diastereomer, were efficiently synthesized. Calcifediol 71-91 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 104-111 30031146-1 2019 We have reported that 25-hydroxyvitamin D3 [25(OH)D3] binds to vitamin D receptor and exhibits several biological functions directly in vitro. Calcifediol 22-42 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 63-81 30031146-3 2019 Daily treatment with 25(OH)D3 at 250 mug kg-1 day-1 rescued rachitic phenotypes in the Cyp27b1 KO mice. Calcifediol 21-29 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 87-94 30031146-4 2019 Bone mineral density, female sexual cycles, and plasma levels of Ca, P, and PTH were all normalized following 25(OH)D3 administration. Calcifediol 110-118 parathyroid hormone Mus musculus 76-79 30031146-5 2019 An elevated Cyp24a1 mRNA expression was observed in the kidneys, and plasma concentrations of Cyp24a1-dependent metabolites of 25(OH)D3 were increased. Calcifediol 127-135 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 94-101 30031146-8 2019 The curative effect of 25(OH)D3 was considered to depend on the de novo synthesis of 1,25(OH)2D3 in the Cyp27b1 KO mice. Calcifediol 23-31 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 104-111 30028992-3 2018 The impact of bioactivation enzymes was shown upon the addition of ketoconazole (10 muM KTZ), a pan-CYP inhibitor, which reduced the apparent potency of 25(OH)D3 and increased the EC50 from 272 to 608 nM in HEK293 cells. Calcifediol 153-161 peptidylprolyl isomerase G Homo sapiens 100-103 31666475-7 2019 Pearson"s correlation was used to analyze the association between TNF-alpha, leptin and 25-hydroxyvitamin D (25(OH)D). Calcifediol 88-107 tumor necrosis factor Homo sapiens 66-75 31666475-7 2019 Pearson"s correlation was used to analyze the association between TNF-alpha, leptin and 25-hydroxyvitamin D (25(OH)D). Calcifediol 88-107 leptin Homo sapiens 77-83 30647532-2 2018 In this study, we aimed to evaluate the correlations between serum levels of 25-hydroxyvitamin D3 (25(OH)D3) and disease activity and predict active disease based on vitamin D status. Calcifediol 99-107 iodothyronine deiodinase 3 Homo sapiens 95-97 30400332-5 2018 Two key observations validate this important non-classical action of vitamin D: first, vitamin D receptor (VDR) is expressed by the majority of immune cells, including B and T lymphocytes, monocytes, macrophages, and dendritic cells; second, there is an active vitamin D metabolism by immune cells that is able to locally convert 25(OH)D3 into 1,25(OH)2D3, its active form. Calcifediol 330-338 vitamin D receptor Homo sapiens 87-105 30400332-5 2018 Two key observations validate this important non-classical action of vitamin D: first, vitamin D receptor (VDR) is expressed by the majority of immune cells, including B and T lymphocytes, monocytes, macrophages, and dendritic cells; second, there is an active vitamin D metabolism by immune cells that is able to locally convert 25(OH)D3 into 1,25(OH)2D3, its active form. Calcifediol 330-338 vitamin D receptor Homo sapiens 107-110 30015370-7 2018 Both serum 25(OH)D3 and total 25(OH)D were negatively correlated with alkaline phosphatase , PTH and percent body fat. Calcifediol 11-19 parathyroid hormone Homo sapiens 93-96 30314996-14 2018 Finally, the inhibitory effects induced by VDR overexpression could be reversed by the VDR inhibitor, calcifediol. Calcifediol 102-113 vitamin D receptor Homo sapiens 43-46 30314996-14 2018 Finally, the inhibitory effects induced by VDR overexpression could be reversed by the VDR inhibitor, calcifediol. Calcifediol 102-113 vitamin D receptor Homo sapiens 87-90 29788105-0 2018 Associations of Circulating 25-Hydroxyvitamin D3 Concentrations With Incident, Sporadic Colorectal Adenoma Risk According to Common Vitamin D-Binding Protein Isoforms. Calcifediol 28-48 GC vitamin D binding protein Homo sapiens 132-157 29788105-6 2018 Thus, the vitamin D-incident, sporadic colorectal adenoma association may differ by common DBP isoforms, and patients with the Gc2 isoform may particularly benefit from maintaining higher circulating 25(OH)D3 concentrations for adenoma prevention. Calcifediol 200-208 solute carrier family 25 member 18 Homo sapiens 127-130 30157946-1 2018 OBJECTIVES: Vitamin D binding protein (VDBP) is the main transporter of 25-hydroxyvitamin D3 (25-OHD) in the circulation. Calcifediol 72-92 GC vitamin D binding protein Homo sapiens 12-37 30157946-1 2018 OBJECTIVES: Vitamin D binding protein (VDBP) is the main transporter of 25-hydroxyvitamin D3 (25-OHD) in the circulation. Calcifediol 72-92 GC vitamin D binding protein Homo sapiens 39-43 29965969-7 2018 In this study, we found that adding 25-hydroxyvitamin D3 (25D3) during the IL-15 induced differentiation of monocytes into MPhi increased the expression of the antimicrobial peptide cathelicidin, including both CAMP mRNA and the encoded protein cathelicidin in a dose-dependent manner. Calcifediol 36-56 interleukin 15 Homo sapiens 75-80 30093913-1 2018 Background: The aim in this study was to investigate the effect of vitamin D (25(OH)D3) supplementation on heat shock protein 60 (HSP 60) and other inflammatory markers (IL-17, TNF-alpha, PAB) in patients with coronary heart disease (CHD). Calcifediol 78-86 heat shock protein family D (Hsp60) member 1 Homo sapiens 107-128 30093913-1 2018 Background: The aim in this study was to investigate the effect of vitamin D (25(OH)D3) supplementation on heat shock protein 60 (HSP 60) and other inflammatory markers (IL-17, TNF-alpha, PAB) in patients with coronary heart disease (CHD). Calcifediol 78-86 heat shock protein family D (Hsp60) member 1 Homo sapiens 130-136 29467214-2 2018 25-Hydroxyvitamin D3 (25OHD3), the most abundant circulating metabolite of vitamin D3, is further transformed to the biologically active metabolite 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) by CYP27B1 in the kidney and extrarenal tissues, and to nonactive metabolites by other cytochrome P450 enzymes. Calcifediol 0-20 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 201-208 29516520-0 2018 25-Hydroxyvitamin D3 -enhanced PTPN2 positively regulates periodontal inflammation through the JAK/STAT pathway in human oral keratinocytes and a mouse model of type 2 diabetes mellitus. Calcifediol 0-20 protein tyrosine phosphatase non-receptor type 2 Homo sapiens 31-36 30221147-8 2018 In a linear regression model adjusted for age, gender, and BMI, a significant inverse association of C-reactive protein (CRP) (p = 0.031) and faecal calprotectin (FC) (p = 0.025) with 25-OH-D3 levels was observed for CD patients. Calcifediol 184-192 C-reactive protein Homo sapiens 101-119 30221147-8 2018 In a linear regression model adjusted for age, gender, and BMI, a significant inverse association of C-reactive protein (CRP) (p = 0.031) and faecal calprotectin (FC) (p = 0.025) with 25-OH-D3 levels was observed for CD patients. Calcifediol 184-192 C-reactive protein Homo sapiens 121-124 29325125-11 2018 Addition of 12.5 mug/kg of 25-OH-D3 increased mRNA expression level of 1alpha-hydroxylase in kidneys and those of nVDR, mVDR, and NaPi-IIb in the duodenum of broilers compared with birds fed the diet without 25-OH-D3. Calcifediol 27-35 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 120-124 29520786-7 2018 RESULTS: In hGFs and hPDLCs, 25-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 induced hCAP-18/LL-37 expression, which was further increased by Porphyromonas gingivalis lipopolysaccharide. Calcifediol 29-50 cathelicidin antimicrobial peptide Homo sapiens 89-96 29743982-8 2018 Before training, a reverse correlation between IL-6 and total oxidative capacity (TOC) levels (p < 0.05) was found, while after training between IL-6 and calcidiol levels (p <= 0.001). Calcifediol 157-166 interleukin 6 Homo sapiens 148-152 29053944-0 2018 Investigation of the C-3-epi-25(OH)D3 of 25-hydroxyvitamin D3 in urban schoolchildren. Calcifediol 41-61 complement C3 Homo sapiens 21-24 29520786-7 2018 RESULTS: In hGFs and hPDLCs, 25-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 induced hCAP-18/LL-37 expression, which was further increased by Porphyromonas gingivalis lipopolysaccharide. Calcifediol 29-50 cathelicidin antimicrobial peptide Homo sapiens 97-102 29382742-6 2018 When male kidneys preferentially hydroxylate 25-hydroxyvitamin D3 using 24-hydroxylase rather than 25-hydroxyvitamin D3-1-alpha hydroxylase, DHT suppressed the Pgr-mediated 24-hydroxylase expression, and it is important to note that DHT increased the blood 25-hydroxyvitamin D3 levels. Calcifediol 45-65 progesterone receptor Mus musculus 160-163 29235391-1 2018 Objectives To investigate possible associations between 25-hydroxyvitamin D3 (25(OH)D3), oestradiol (E2) and IFN-gamma (IFNgamma) in female patients with inactive systemic lupus erythematosus (SLE). Calcifediol 56-76 interferon gamma Homo sapiens 120-128 29172936-1 2018 Objectives The aim of this report is to describe the identification of a novel vitamin D metabolite, a C-3, alpha-epimer of 25-hydroxycholecalciferol (3-epi-25(OH)D3), in serum and plasma extracts of cat blood and compare its abundance in cat, dog and rat serum to 25-hydroxycholecalciferol (25(OH)D3), a conventional marker of vitamin D status. Calcifediol 124-149 complement C3 Canis lupus familiaris 103-106 29172936-1 2018 Objectives The aim of this report is to describe the identification of a novel vitamin D metabolite, a C-3, alpha-epimer of 25-hydroxycholecalciferol (3-epi-25(OH)D3), in serum and plasma extracts of cat blood and compare its abundance in cat, dog and rat serum to 25-hydroxycholecalciferol (25(OH)D3), a conventional marker of vitamin D status. Calcifediol 265-290 complement C3 Canis lupus familiaris 103-106 29172936-1 2018 Objectives The aim of this report is to describe the identification of a novel vitamin D metabolite, a C-3, alpha-epimer of 25-hydroxycholecalciferol (3-epi-25(OH)D3), in serum and plasma extracts of cat blood and compare its abundance in cat, dog and rat serum to 25-hydroxycholecalciferol (25(OH)D3), a conventional marker of vitamin D status. Calcifediol 157-165 complement C3 Canis lupus familiaris 103-106 29962427-0 2018 Sex-Specific Association of Serum 25-Hydroxyvitamin D3 with Insulin Resistance in Chinese Han Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Calcifediol 34-54 insulin Homo sapiens 60-67 29089453-3 2017 Both cytotrophoblasts and syncytiotrophoblasts expressed genes for the vitamin D receptor, for LRP2 and CUBN that mediate internalization of calcidiol, for CYP27B1 that encodes the enzyme that converts calcidiol into active calcitriol, and for CYP24A1 that encodes the enzyme that modifies calcitriol and calcidiol to inactive calcitetrol. Calcifediol 141-150 cubilin Homo sapiens 104-108 29115640-7 2018 In HaCaT and ORS-KC, application of specific CYP450 inhibitors revealed that CYP27B1 was impaired by IMA and NIL leading to an intracellular accumulation of calcidiol. Calcifediol 157-166 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 77-84 28104493-2 2017 We demonstrated that skeletal muscle is able to internalise extracellular vitamin D binding protein, which then binds to actin in the cytoplasm, to provide high affinity binding sites which accumulate 25-hydroxyvitamin D3 (25(OH)D3) [1]. Calcifediol 201-221 vitamin D binding protein Mus musculus 74-99 28104493-7 2017 Pre-incubation of C2 myotubes or primary mouse muscle fibers with PTH (0.1 to 100 pM) for 3h resulted in a concentration-dependent decrease in 25(OH)D3 uptake after 4 or 16h. Calcifediol 143-151 parathyroid hormone Mus musculus 66-69 28104493-9 2017 In C2 myotubes, retention of 25(OH)D3 was decreased after addition of PTH (0.1 to 100pM) in a concentration-dependent manner by up to 80% (p<0.001) compared to non-PTH treated-C2 myotubes. Calcifediol 29-37 parathyroid hormone Mus musculus 70-73 28104493-9 2017 In C2 myotubes, retention of 25(OH)D3 was decreased after addition of PTH (0.1 to 100pM) in a concentration-dependent manner by up to 80% (p<0.001) compared to non-PTH treated-C2 myotubes. Calcifediol 29-37 parathyroid hormone Mus musculus 167-170 28104493-10 2017 These data show that muscle uptake and retention of 25(OH)D3 are modulated by PTH, a physiological regulator of mineral homeostasis, but the cell culture model may not be a comprehensive reflection of vitamin D homeostatic mechanisms in whole animals. Calcifediol 52-60 parathyroid hormone Mus musculus 78-81 28589636-0 2017 25-Hydroxyvitamin D3 and its C-3 epimer are elevated in the skin and serum of Skh-1 mice supplemented with dietary vitamin D3. Calcifediol 0-20 complement component 3 Mus musculus 29-32 27639478-6 2017 Ethanol intake decreased renal Cyp27b1 while increased tumoral CYP24A1 gene expression.Treatment with 25-hydroxyvitamin D3 significantly stimulated CYP27B1 in tumors of non-alcohol-drinking mice, while increased both renal and tumoral CYP24A1. Calcifediol 102-122 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 31-38 27639478-6 2017 Ethanol intake decreased renal Cyp27b1 while increased tumoral CYP24A1 gene expression.Treatment with 25-hydroxyvitamin D3 significantly stimulated CYP27B1 in tumors of non-alcohol-drinking mice, while increased both renal and tumoral CYP24A1. Calcifediol 102-122 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 63-70 27639478-6 2017 Ethanol intake decreased renal Cyp27b1 while increased tumoral CYP24A1 gene expression.Treatment with 25-hydroxyvitamin D3 significantly stimulated CYP27B1 in tumors of non-alcohol-drinking mice, while increased both renal and tumoral CYP24A1. Calcifediol 102-122 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 148-155 27639478-6 2017 Ethanol intake decreased renal Cyp27b1 while increased tumoral CYP24A1 gene expression.Treatment with 25-hydroxyvitamin D3 significantly stimulated CYP27B1 in tumors of non-alcohol-drinking mice, while increased both renal and tumoral CYP24A1. Calcifediol 102-122 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 235-242 27639478-7 2017 Coadministration of ethanol and 25-hydroxyvitamin D3 reduced in 60% renal 25-hydroxyvitamin D3-dependent Cyp24a1 upregulation (P<0.05). Calcifediol 32-52 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 105-112 27639478-7 2017 Coadministration of ethanol and 25-hydroxyvitamin D3 reduced in 60% renal 25-hydroxyvitamin D3-dependent Cyp24a1 upregulation (P<0.05). Calcifediol 74-94 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 105-112 28548312-9 2017 Lastly, in patients who received calcifediol (25-OH-D3 ), we documented normal 24-hydroxylase activity (CYP24A1). Calcifediol 33-44 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 104-111 28259644-8 2017 Serum 25(OH) D3 concentrations were inversely associated with hs-CRP and leptin concentrations after adjusted the BMI only in the PreDM group (P<0.05). Calcifediol 6-15 leptin Homo sapiens 73-79 28092021-3 2017 These are mediated by the presence of vitamin D receptor (VDR) and thanks to the presence of the 1-alpha-hydroxylase, the protein that converts the 25-hydroxyvitamin (calcidiol) to the active form 1,25-dihydroxyvitamin (calcitriol). Calcifediol 167-176 vitamin D receptor Homo sapiens 38-56 28092021-3 2017 These are mediated by the presence of vitamin D receptor (VDR) and thanks to the presence of the 1-alpha-hydroxylase, the protein that converts the 25-hydroxyvitamin (calcidiol) to the active form 1,25-dihydroxyvitamin (calcitriol). Calcifediol 167-176 vitamin D receptor Homo sapiens 58-61 28304097-2 2017 A rapid liquid-chromatography tandem mass spectrometry (LC-MS/MS)-based blood test enabling measurement of the 25-OH-D3 :24,25-(OH)2 D3 ratio (R) can identify IIH patients on the basis of reduced C24-hydroxylation of 25-OH-D3 by CYP24A1 in vivo. Calcifediol 111-119 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 229-236 28259644-9 2017 At the multivariate analysis, hs-CRP and leptin were the major determinant of 25(OH) D3 concentration (beta=-0.174 and beta=-0.171, respectively). Calcifediol 78-87 leptin Homo sapiens 41-47 28178628-1 2017 Previous publications widely reported that 25-hydroxyvitamin D-1-alpha-hydroxylase (CYP27B1) regulated the metabolism of 25-hydroxyvitamin D3, which has a close association between altered activity of vitamin D and vascular calcification has been reported in various human diseases, including chronic kidney disease, osteoporosis and atherosclerosis. Calcifediol 121-141 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 84-91 28116494-3 2017 In this study, we developed a novel procedure for measuring the kinetic and equilibrium constants of human-DBP with vitamin D3 and three metabolites: 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], 25-hydroxyvitamin D3 (25OHD3) and 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] by surface plasmon resonance (SPR). Calcifediol 190-210 D-box binding PAR bZIP transcription factor Homo sapiens 107-110 28116494-3 2017 In this study, we developed a novel procedure for measuring the kinetic and equilibrium constants of human-DBP with vitamin D3 and three metabolites: 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], 25-hydroxyvitamin D3 (25OHD3) and 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] by surface plasmon resonance (SPR). Calcifediol 212-218 D-box binding PAR bZIP transcription factor Homo sapiens 107-110 27079155-4 2017 The results showed that, maternal CX+25-OH-D3 supplementation increased the shank pigmentation for 7-days post hatch in ducklings under a NRC vitamin regimen, and for 14-days post hatch in ducklings under a HIGH vitamin regimen. Calcifediol 37-45 nuclear receptor coactivator 6 Homo sapiens 138-141 27079155-5 2017 Growth performance, antioxidant status and serum phosphorus of ducklings under a NRC vitamin regimen were increased by maternal CX+25-OH-D3 supplementation; however, these positive effects were not observed in ducklings under a HIGH vitamin regimen. Calcifediol 131-139 nuclear receptor coactivator 6 Homo sapiens 81-84 27079155-8 2017 Data suggest that maternal CX+25-OH-D3 supplementation is important for starter ducklings under a NRC vitamin regimen, but not HIGH vitamin regimen. Calcifediol 30-38 nuclear receptor coactivator 6 Homo sapiens 98-101 28612564-1 2017 OBJECTIVES: To investigate the relationship between serum 25-hydroxyvitamin D3 [25(OH)D3 ] concentration and glucose metabolism. Calcifediol 80-88 iodothyronine deiodinase 3 Homo sapiens 76-78 28287628-7 2017 There was a negative correlation between calcidiol and PTH levels (P<0.01). Calcifediol 41-50 parathyroid hormone Homo sapiens 55-58 28222027-5 2017 As co-expression, it increased the CD38+HLA-DR- and decreased CD38-HLA-DR+ subpopulations in both CD4+ and CD8+ T-cells, and decreased CD4+CD38-HLA-DR- and CD8+ CD38+HLA-DR+; whereas both calcidiol concentrations decreased the proliferation of CD38-HLA-DR- and CD38-HLA-DR+ subpopulations. Calcifediol 188-197 CD8a molecule Homo sapiens 144-159 28222027-7 2017 In contrast, there was a positive but non-significant correlation between serum calcidiol levels and the expression of CD38 and HLA-DR in CD4+ and CD8+ T-cells. Calcifediol 80-89 CD38 molecule Homo sapiens 119-123 28222027-7 2017 In contrast, there was a positive but non-significant correlation between serum calcidiol levels and the expression of CD38 and HLA-DR in CD4+ and CD8+ T-cells. Calcifediol 80-89 CD4 molecule Homo sapiens 138-141 28222027-7 2017 In contrast, there was a positive but non-significant correlation between serum calcidiol levels and the expression of CD38 and HLA-DR in CD4+ and CD8+ T-cells. Calcifediol 80-89 CD8a molecule Homo sapiens 147-150 28302199-6 2017 RESULTS: The 25-(OH)D3 level in the HSP and HSPN groups was significantly lower than that in the healthy control group (P<0.05), and the 25-(OH)D3 level in the HSPN group was significantly lower than that in the HSP group (P<0.05). Calcifediol 13-22 heat shock protein 90 alpha family class A member 1 Homo sapiens 44-48 28302199-6 2017 RESULTS: The 25-(OH)D3 level in the HSP and HSPN groups was significantly lower than that in the healthy control group (P<0.05), and the 25-(OH)D3 level in the HSPN group was significantly lower than that in the HSP group (P<0.05). Calcifediol 140-149 heat shock protein 90 alpha family class A member 1 Homo sapiens 163-167 28243241-3 2017 In addition, the expression of TIM-3 on T and NK cells of six HCs after calcidiol and calcitriol (active VitD) treatments was evaluated by flow cytometry. Calcifediol 72-81 hepatitis A virus cellular receptor 2 Homo sapiens 31-36 28243241-4 2017 Calcidiol increased the mRNA expression of HAVCR2 (TIM-3; Th1-cells inhibitor) in HCs and HESNs. Calcifediol 0-9 hepatitis A virus cellular receptor 2 Homo sapiens 43-49 28243241-4 2017 Calcidiol increased the mRNA expression of HAVCR2 (TIM-3; Th1-cells inhibitor) in HCs and HESNs. Calcifediol 0-9 hepatitis A virus cellular receptor 2 Homo sapiens 51-56 27881592-0 2017 The C-3alpha Epimer of 25-Hydroxycholecalciferol from Endogenous and Exogenous Sources Supports Normal Growth and Bone Mineral Density in Weanling Rats. Calcifediol 23-48 complement C3 Homo sapiens 4-12 27881592-1 2017 BACKGROUND: The C-3alpha epimer of 25-hydroxycholecalciferol [3-epi-25(OH)D3] is elevated in infants. Calcifediol 35-60 complement C3 Homo sapiens 16-24 28012697-4 2017 The expression of LL-37 can be regulated by various endogenous factors including the active form of vitamin D (25(OH)D3). Calcifediol 111-119 cathelicidin antimicrobial peptide Homo sapiens 18-23 26386496-15 2016 CONCLUSION: The present study indicates that improvement of serum 25-hydroxyvitamin D3 levels is associated with substantial decrease in recurrence of BPPV. Calcifediol 66-86 benign paroxysmal positional vertigo Homo sapiens 151-155 27174720-9 2016 Incubation with 25-hydroxyvitamin D3 significantly decreased the concentrations of RV antigen and non-structural protein 4 (NSP4), and up-regulated the mRNA expression of Beclin 1 and PR-39 in the RV-infected IPEC-J2 cells. Calcifediol 16-36 beclin 1 Sus scrofa 171-179 27174720-9 2016 Incubation with 25-hydroxyvitamin D3 significantly decreased the concentrations of RV antigen and non-structural protein 4 (NSP4), and up-regulated the mRNA expression of Beclin 1 and PR-39 in the RV-infected IPEC-J2 cells. Calcifediol 16-36 antibacterial protein PR-39 Sus scrofa 184-189 27174720-12 2016 Furthermore, 25-hydroxyvitamin D3 decreased the p62 mRNA expression and increased porcine cathelicidins (PMAP23, PG1-5 and PR-39) mRNA expression in the RV-infected cells. Calcifediol 13-33 antibacterial peptide PMAP-23 Sus scrofa 105-111 27174720-12 2016 Furthermore, 25-hydroxyvitamin D3 decreased the p62 mRNA expression and increased porcine cathelicidins (PMAP23, PG1-5 and PR-39) mRNA expression in the RV-infected cells. Calcifediol 13-33 protegrin-1 Sus scrofa 113-118 27174720-12 2016 Furthermore, 25-hydroxyvitamin D3 decreased the p62 mRNA expression and increased porcine cathelicidins (PMAP23, PG1-5 and PR-39) mRNA expression in the RV-infected cells. Calcifediol 13-33 antibacterial protein PR-39 Sus scrofa 123-128 27399352-1 2016 CONTEXT: CYP27B1 converts 25-hydroxyvitamin D3 to active 1,25-dihydroxyvitamin D3, playing a vital role in calcium homeostasis and bone growth. Calcifediol 26-46 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 9-16 27399352-8 2016 MAIN OUTCOME: The main outcomes of the study were novel mutations leading to a severe loss of CYP27B1 activities for metabolism of 25-hydroxyvitamin D3. Calcifediol 131-151 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 94-101 26319202-0 2016 Influence of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on expression of P-glycoprotein and cytochrome P450 3A in sheep. Calcifediol 13-33 multidrug resistance protein 1 Ovis aries 80-94 27785371-3 2016 Finding that resorbing osteoclasts in human bone express vitamin D receptor (VDR), we examined their response to different concentrations of 25-hydroxy vitamin D3 [25(OH)D3] (100 or 500 nmol L-1) and 1,25-dihydroxy vitamin D3 [1,25(OH)2D3] (0.1 or 0.5 nmol L-1) metabolites in cell cultures. Calcifediol 141-162 vitamin D receptor Homo sapiens 77-80 27364341-1 2016 Pseudovitamin D deficiency is the consequence of a genetic defect in the CYP27B1 gene resulting in diminished or absent conversion of 25-hydroxyvitamin D3 (25-(OH)D3) into 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) and leads to growth retardation and rickets, usually in the first 2 years of life. Calcifediol 134-154 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 73-80 27364341-1 2016 Pseudovitamin D deficiency is the consequence of a genetic defect in the CYP27B1 gene resulting in diminished or absent conversion of 25-hydroxyvitamin D3 (25-(OH)D3) into 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) and leads to growth retardation and rickets, usually in the first 2 years of life. Calcifediol 156-165 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 73-80 26298279-10 2016 In multivariate analysis, eGFR and calcidiol levels were the main independent determinants of serum PTH. Calcifediol 35-44 parathyroid hormone Homo sapiens 100-103 27403416-4 2016 The active form of vitamin D, 1,25-dihydroxyvitamin D (calcitriol), is biosynthesised in the kidney through the hydroxylation of 25-hydroxycholecalciferol by the CYP27B1 enzyme. Calcifediol 129-154 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 162-169 27001276-0 2016 Circulating adiponectin concentrations are increased by dietary resistant starch and correlate with serum 25-hydroxycholecalciferol concentrations and kidney function in Zucker diabetic fatty rats. Calcifediol 106-131 adiponectin, C1Q and collagen domain containing Rattus norvegicus 12-23 27001276-6 2016 Adiponectin concentrations strongly correlated with serum 25-hydroxycholecalciferol (r = 0.815; P < .001) and urinary creatinine concentrations (r = 0.818; P < .001) and inversely correlated with proteinuria (r = -0.583; P = .02). Calcifediol 58-83 adiponectin, C1Q and collagen domain containing Rattus norvegicus 0-11 27066262-9 2016 There is a correlation (p < 0.01) between calcidiol and parathyroid hormone (r = -0.336). Calcifediol 45-54 parathyroid hormone Homo sapiens 59-78 27042275-1 2016 AIMS/INTRODUCTION: To evaluate serum 25-hydroxyvitamin D3 (25(OH)D3) in newly diagnosed type 2 diabetes patients and to explore the associations of 25(OH)D3 with insulin resistance and beta-cell function. Calcifediol 59-67 iodothyronine deiodinase 3 Homo sapiens 55-57 26260969-11 2016 CONCLUSIONS: Polymorphisms associated with lower DBP level attenuated the association between low serum 25(OH)D3 level and food allergy, consistent with greater vitamin D bioavailability in those with a lower DBP level. Calcifediol 104-112 D-box binding PAR bZIP transcription factor Homo sapiens 49-52 26260969-11 2016 CONCLUSIONS: Polymorphisms associated with lower DBP level attenuated the association between low serum 25(OH)D3 level and food allergy, consistent with greater vitamin D bioavailability in those with a lower DBP level. Calcifediol 104-112 D-box binding PAR bZIP transcription factor Homo sapiens 209-212 26654942-0 2016 Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo. Calcifediol 13-33 vitamin D receptor Homo sapiens 44-62 26654942-0 2016 Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo. Calcifediol 13-33 epidermal growth factor receptor Homo sapiens 101-105 26654942-6 2016 To study anti-proliferative activity and signaling, EGFR mutant lung cancer cells were treated with the circulating metabolite of vitamin D, 25-hydroxyvitamin D3 (25D3). Calcifediol 141-161 epidermal growth factor receptor Homo sapiens 52-56 26893158-6 2016 We show that 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 inhibited p38MAPK phosphorylation and that these effects were not mediated by changes in the expression of MAPK phosphatase-1 (MKP-1). Calcifediol 13-33 dual specificity phosphatase 1 Homo sapiens 190-195 26359508-0 2016 Dietary calcium intake influences the relationship between serum 25-hydroxyvitamin D3 (25OHD) concentration and parathyroid hormone (PTH) concentration. Calcifediol 65-85 parathyroid hormone Homo sapiens 112-131 26359508-1 2016 OBJECTIVES: To investigate whether dietary calcium intake will modify the relationship between serum 25-hydroxyvitamin D3 (25OHD) with intact serum parathyroid hormone (PTH) concentrations in apparently healthy Indian adolescents. Calcifediol 101-121 parathyroid hormone Homo sapiens 148-167 26385608-3 2016 25-Hydroxyvitamin D3 (25D3), a precursor of 1,25D3, and elocalcitol, an analog of 1,25D3, caused ectodomain shedding of TNFR1 within 30 min, whereas 1,25-dihydroxyvitamin D2 (1,25D2) and paricalcitol, a derivative of 1,25D2, did not. Calcifediol 0-20 TNF receptor superfamily member 1A Homo sapiens 120-125 26255277-5 2015 Treatment of lipopolysaccharide (LPS)-stimulated monocytes with 0-100 ng/mL 25-hydroxyvitamin D3 also increased BNBD3, BNBD4, BNBD7, and BNBD10 in a dose-dependent manner. Calcifediol 76-96 beta-defensin 3 Bos taurus 112-117 26288355-5 2015 Intervention with a single dose of 25-hydroxyvitamin D3 (25(OH)D) is capable of suppressing macrophage-mediated iNOS production resulting in mitigation of local skin destruction, enhanced tissue repair, protection from marrow depletion, and rescue from severe precipitous wasting. Calcifediol 35-55 nitric oxide synthase 2, inducible Mus musculus 112-116 26176830-7 2015 Excess 25(OH)D3 upregulated both M1 marker (TNF-alpha) and M2 marker (TGF-beta1) levels of kidney-infiltrating macrophages. Calcifediol 7-15 tumor necrosis factor Mus musculus 44-53 26176830-7 2015 Excess 25(OH)D3 upregulated both M1 marker (TNF-alpha) and M2 marker (TGF-beta1) levels of kidney-infiltrating macrophages. Calcifediol 7-15 transforming growth factor, beta 1 Mus musculus 70-79 26827959-9 2016 Finally, our recent studies using the same cell line demonstrate that 25(OH)D3 can act as a VDR agonist to induce gene transactivation. Calcifediol 70-78 vitamin D receptor Homo sapiens 92-95 26441239-3 2015 CYP24A1 is a cytochrome P450 enzyme that is involved in the side chain oxidation and destruction of both 1,25(OH)2D3 and 25-hydroxyvitamin D3 (25-OH-D3). Calcifediol 121-141 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 0-7 26255277-5 2015 Treatment of lipopolysaccharide (LPS)-stimulated monocytes with 0-100 ng/mL 25-hydroxyvitamin D3 also increased BNBD3, BNBD4, BNBD7, and BNBD10 in a dose-dependent manner. Calcifediol 76-96 beta-defensin 4 Bos taurus 119-124 26255277-5 2015 Treatment of lipopolysaccharide (LPS)-stimulated monocytes with 0-100 ng/mL 25-hydroxyvitamin D3 also increased BNBD3, BNBD4, BNBD7, and BNBD10 in a dose-dependent manner. Calcifediol 76-96 beta-defensin 7 Bos taurus 126-131 26255277-5 2015 Treatment of lipopolysaccharide (LPS)-stimulated monocytes with 0-100 ng/mL 25-hydroxyvitamin D3 also increased BNBD3, BNBD4, BNBD7, and BNBD10 in a dose-dependent manner. Calcifediol 76-96 beta-defensin 10 Bos taurus 137-143 26501255-1 2015 Vitamin D3 shows tumoristatic and anticancer effects by acting through the vitamin D receptor (VDR), while hydroxylation of 25-hydroxyvitamin D3 at position 1alpha by CYP27B1 is an essential step in its activation. Calcifediol 124-144 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 167-174 26184408-3 2015 The discovery that almost all tissues and cells in the body express the VDR and that several tissues possess the enzymatic capability to convert 25-hydroxyvitamin D (25(OH)-D3; cholecalciferol) to the active form, suggests that vitamin D fulfills various extra-osseous functions (Bouillon et al., Endocr Rev 29(6):726-776, 2008; Holick, N Engl J Med 357(3):266-281, 2007). Calcifediol 166-175 vitamin D receptor Homo sapiens 72-75 25773720-1 2015 PURPOSE: This study seeks to develop fiber membranes for local sustained delivery of 25-hydroxyvitamin D3 to induce the expression and secretion of LL-37 at or near the surgical site, which provides a novel therapeutic approach to minimize the risk of infections. Calcifediol 85-105 cathelicidin antimicrobial peptide Homo sapiens 148-153 25773720-10 2015 Human keratinocytes and monocytes express significantly higher levels of hCAP18/LL-37 after incubation with plasma treated and 25-hydroxyvitamin D3 loaded PCL fibers than the cells incubated with around ten times amount of free drug. Calcifediol 127-147 cathelicidin antimicrobial peptide Homo sapiens 73-79 25773720-10 2015 Human keratinocytes and monocytes express significantly higher levels of hCAP18/LL-37 after incubation with plasma treated and 25-hydroxyvitamin D3 loaded PCL fibers than the cells incubated with around ten times amount of free drug. Calcifediol 127-147 cathelicidin antimicrobial peptide Homo sapiens 80-85 25639477-6 2015 Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082. Calcifediol 23-31 interleukin 1 beta Homo sapiens 40-48 25639477-6 2015 Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082. Calcifediol 23-31 GLI family zinc finger 2 Homo sapiens 62-67 25639477-6 2015 Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082. Calcifediol 23-31 caspase 1 Homo sapiens 130-139 25639477-6 2015 Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082. Calcifediol 23-31 NLR family pyrin domain containing 3 Homo sapiens 163-168 25875760-3 2015 In this study, we performed a more focused selection of further 12 VDR target genes and demonstrated that changes of their mRNA expression in PBMCs of VitDmet subjects significantly correlate with alterations of 25-hydroxyvitamin D3 serum levels. Calcifediol 212-232 vitamin D receptor Homo sapiens 67-70 25788584-0 2015 25-Hydroxycholecalciferol Enhances Male Broiler Breast Meat Yield through the mTOR Pathway. Calcifediol 0-25 mechanistic target of rapamycin Gallus gallus 78-82 25501638-1 2015 CYP27B1 hydroxylates 25-hydroxyvitamin D3 in position C1alpha into biologically active 1,25-dihydroxyvitamin D3, calcitriol. Calcifediol 21-41 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-7 25446887-14 2015 Taken together, these studies indicate that rapid increases in 25-hydroxyvitamin D3 trigger CYP24A1 and FGF23 induction, limiting effective exposure to calcitriol and iPTH reduction in SHPT. Calcifediol 63-83 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 92-99 25446887-14 2015 Taken together, these studies indicate that rapid increases in 25-hydroxyvitamin D3 trigger CYP24A1 and FGF23 induction, limiting effective exposure to calcitriol and iPTH reduction in SHPT. Calcifediol 63-83 fibroblast growth factor 23 Homo sapiens 104-109 25738588-2 2015 OBJECTIVE: Characterize the temporal relationship between 25-hydroxyvitamin D3 levels [25(OH)D3] and intact iPTH for several seasons, by gender and latitude in the U.S. and relate 25-hydrovitamin D2 [25(OH)D2] levels with PTH levels and total 25(OH)D levels. Calcifediol 58-78 parathyroid hormone Homo sapiens 109-112 25092518-2 2015 The resulting intracrine conversion of precursor 25-hydroxyvitamin D3 (25OHD) to active 1,25-dihydroxyvitamin D (1,25(OH)2D) can stimulate expression of antibacterial cathelicidin (CAMP). Calcifediol 49-69 cathelicidin antimicrobial peptide Homo sapiens 181-185 25194637-2 2015 There remains an unidentified enzyme responsible for 25% of the 25-hydroxylation of vitamin D3, while 75% of serum 25-hydroxyvitamin D3 (25-OH-D3) arises from CYP2R1. Calcifediol 115-135 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 159-165 25194637-2 2015 There remains an unidentified enzyme responsible for 25% of the 25-hydroxylation of vitamin D3, while 75% of serum 25-hydroxyvitamin D3 (25-OH-D3) arises from CYP2R1. Calcifediol 137-145 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 159-165 25501638-1 2015 CYP27B1 hydroxylates 25-hydroxyvitamin D3 in position C1alpha into biologically active 1,25-dihydroxyvitamin D3, calcitriol. Calcifediol 21-41 endogenous retrovirus group K member 1 Homo sapiens 54-61 24309068-2 2014 Our previous dietary studies demonstrated that an adequate serum 25-hydroxyvitamin D3 (25D) of 80nmol/L or more reduces bone RANKL expression, osteoclastogenesis and maintains the optimal levels of trabecular bone volume (BV/TV%) in young rats. Calcifediol 65-85 TNF superfamily member 11 Rattus norvegicus 125-130 25897656-0 2015 Effect of 25-hydroxyvitamin D3 on rotavirus replication and gene expressions of RIG-I signalling molecule in porcine rotavirus-infected IPEC-J2 cells. Calcifediol 10-30 DExD/H-box helicase 58 Sus scrofa 80-85 25897656-1 2015 The study evaluated whether a 25-hydroxyvitamin D3 (25D3) supplementation decreases the replication of rotavirus by the retinoic acid-inducible gene I (RIG-I) signalling pathway in a porcine small intestinal epithelial cell line (IPEC-J2). Calcifediol 30-50 DExD/H-box helicase 58 Sus scrofa 152-157 25329305-5 2014 We showed that primary human osteoblasts responded to both 25(OH)D3 and 1,25(OH)2D3 by reducing their proliferation and enhancing their differentiation by the increase of alkaline phosphatase, osteocalcin and osteopontin expression. Calcifediol 59-67 bone gamma-carboxyglutamate protein Homo sapiens 193-204 25329305-5 2014 We showed that primary human osteoblasts responded to both 25(OH)D3 and 1,25(OH)2D3 by reducing their proliferation and enhancing their differentiation by the increase of alkaline phosphatase, osteocalcin and osteopontin expression. Calcifediol 59-67 secreted phosphoprotein 1 Homo sapiens 209-220 24655660-2 2014 The primary aim of this study was to investigate the relationship between plasma levels of 25-hydroxyvitamin D3 and suggested in vivo markers of CYP3A activity in healthy volunteers from Sweden and Korea. Calcifediol 91-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 145-150 24655660-4 2014 In addition, we studied the modulating effects of three vitamin D receptor promoter polymorphisms on the association between 25-hydroxyvitamin D3 and CYP3A enzyme activity in Swedish subjects. Calcifediol 125-145 vitamin D receptor Homo sapiens 56-74 24655660-4 2014 In addition, we studied the modulating effects of three vitamin D receptor promoter polymorphisms on the association between 25-hydroxyvitamin D3 and CYP3A enzyme activity in Swedish subjects. Calcifediol 125-145 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 150-155 24655660-5 2014 The plasma levels of 25-hydroxyvitamin D3 were not significantly associated with CYP3A phenotypes in any of the three studies, but after accounting for the vitamin D receptor polymorphism rs4516035, there was a significant positive association between 25-hydroxyvitamin D3 and CYP3A activity (p = 0.004). Calcifediol 252-272 vitamin D receptor Homo sapiens 156-174 24655660-5 2014 The plasma levels of 25-hydroxyvitamin D3 were not significantly associated with CYP3A phenotypes in any of the three studies, but after accounting for the vitamin D receptor polymorphism rs4516035, there was a significant positive association between 25-hydroxyvitamin D3 and CYP3A activity (p = 0.004). Calcifediol 252-272 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 277-282 24655660-8 2014 In conclusion, our results suggest that the overall influence on the CYP3A activity by 25-hydroxyvitamin D3 is of marginal importance. Calcifediol 87-107 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-74 25352759-7 2014 When BV2 cells were transfected with 1-alpha-hydroxylase siRNA or VDR siRNA, the inhibitory effect of 25-hydroxyvitamin D3 on activated BV2 cells was suppressed. Calcifediol 102-122 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 66-69 25128460-5 2014 The effect of [25(OH)D3]-treated dendritic cells (DCs) on CD4(+) T cell response was determined by ELISA and flow cytometry. Calcifediol 15-23 CD4 molecule Homo sapiens 58-61 25128460-9 2014 [25(OH)D3]-treated DCs significantly inhibited IL-17 production [P=0.002] and decreased the percentage of CD4(+)IL-17(+) [P=0.007] in young asthmatics. Calcifediol 1-9 interleukin 17A Homo sapiens 47-52 25128460-9 2014 [25(OH)D3]-treated DCs significantly inhibited IL-17 production [P=0.002] and decreased the percentage of CD4(+)IL-17(+) [P=0.007] in young asthmatics. Calcifediol 1-9 CD4 molecule Homo sapiens 106-109 25128460-9 2014 [25(OH)D3]-treated DCs significantly inhibited IL-17 production [P=0.002] and decreased the percentage of CD4(+)IL-17(+) [P=0.007] in young asthmatics. Calcifediol 1-9 interleukin 17A Homo sapiens 112-117 25236584-0 2014 Vitamin D3 metabolite calcidiol primes human dendritic cells to promote the development of immunomodulatory IL-10-producing T cells. Calcifediol 22-31 interleukin 10 Homo sapiens 108-113 25236584-8 2014 However, like calcitriol, calcidiol not only exerted an inhibitory effect on DC maturation and cytokine production, and primed DCs to promote the development of suppressive IL-10-producing Treg cells. Calcifediol 26-35 interleukin 10 Homo sapiens 173-178 25236584-9 2014 Strikingly, in contrast to the population of IL-10-producing Treg cells induced by calcitriol-primed DCs, the IL-10-producing Treg cells induced by calcidiol-primed DCs exhibited sustained IFN-gamma production in face of their suppressive capacity. Calcifediol 148-157 interleukin 10 Homo sapiens 110-115 25236584-9 2014 Strikingly, in contrast to the population of IL-10-producing Treg cells induced by calcitriol-primed DCs, the IL-10-producing Treg cells induced by calcidiol-primed DCs exhibited sustained IFN-gamma production in face of their suppressive capacity. Calcifediol 148-157 interferon gamma Homo sapiens 189-198 24184871-5 2014 Adding 25(OH)D3 to monocytes cultured in vitamin D-deficient serum or media decreased monocyte adhesion to fibronectin and migration stimulated by monocyte chemotactic protein 1 (MCP-1). Calcifediol 7-15 fibronectin 1 Homo sapiens 107-118 24184871-5 2014 Adding 25(OH)D3 to monocytes cultured in vitamin D-deficient serum or media decreased monocyte adhesion to fibronectin and migration stimulated by monocyte chemotactic protein 1 (MCP-1). Calcifediol 7-15 C-C motif chemokine ligand 2 Homo sapiens 147-177 24184871-5 2014 Adding 25(OH)D3 to monocytes cultured in vitamin D-deficient serum or media decreased monocyte adhesion to fibronectin and migration stimulated by monocyte chemotactic protein 1 (MCP-1). Calcifediol 7-15 C-C motif chemokine ligand 2 Homo sapiens 179-184 25230725-5 2014 RESULTS: We found that activated T cells express CYP27B1 and have the capacity to produce sufficient 1,25(OH)2D3 to affect vitamin D-responsive genes when cultured with physiological concentrations of 25(OH)D3 in serum-free medium. Calcifediol 201-209 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 49-56 25352759-8 2014 25-Hydroxyvitamin D3 also inhibited the increased phosphorylation of p38 seen in LPS-activated BV2 cells, and this inhibition was blocked by VDR siRNA. Calcifediol 0-20 mitogen-activated protein kinase 14 Mus musculus 69-72 25352759-8 2014 25-Hydroxyvitamin D3 also inhibited the increased phosphorylation of p38 seen in LPS-activated BV2 cells, and this inhibition was blocked by VDR siRNA. Calcifediol 0-20 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 141-144 25352759-10 2014 This study also shows that the inhibitory effect of 25-hydroxyvitamin D3 on NO production might be exerted by inhibiting LPS-induced phosphorylation of p38 through the mediation of VDR signaling. Calcifediol 52-72 mitogen-activated protein kinase 14 Mus musculus 152-155 25352759-10 2014 This study also shows that the inhibitory effect of 25-hydroxyvitamin D3 on NO production might be exerted by inhibiting LPS-induced phosphorylation of p38 through the mediation of VDR signaling. Calcifediol 52-72 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 181-184 25230725-10 2014 However, DBP sequesters 25(OH)D3 and inhibits the production of 1,25(OH)2D3 in T cells. Calcifediol 24-32 D-box binding PAR bZIP transcription factor Homo sapiens 9-12